Document and Entity Information
Document and Entity Information - USD ($) | 12 Months Ended | ||
Jun. 30, 2020 | Jul. 31, 2020 | Dec. 31, 2019 | |
Cover [Abstract] | |||
Document Type | 10-K | ||
Document Annual Report | true | ||
Document Period End Date | Jun. 30, 2020 | ||
Document Transition Report | false | ||
Entity File Number | 1-11373 | ||
Entity Registrant Name | Cardinal Health, Inc. | ||
Entity Incorporation, State or Country Code | OH | ||
Entity Tax Identification Number | 31-0958666 | ||
Entity Address, Address Line One | 7000 Cardinal Place | ||
Entity Address, City or Town | Dublin | ||
Entity Address, State or Province | OH | ||
Entity Address, Postal Zip Code | 43017 | ||
City Area Code | (614) | ||
Local Phone Number | 757-5000 | ||
Title of 12(b) Security | Common shares (without par value) | ||
Trading Symbol | CAH | ||
Security Exchange Name | NYSE | ||
Entity Well-Known Seasoned Issuer | Yes | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Large Accelerated Filer | ||
Entity Small Business | false | ||
Entity Emerging Growth Company | false | ||
Entity Shell Company | false | ||
Entity Public Float | $ 14,729,138,108 | ||
Entity Common Stock, Shares Outstanding | 292,444,079 | ||
Amendment Flag | false | ||
Document Fiscal Year Focus | 2020 | ||
Document Fiscal Period Focus | FY | ||
Entity Central Index Key | 0000721371 | ||
Current Fiscal Year End Date | --06-30 | ||
Documents Incorporated by Reference | Documents Incorporated by Reference: Portions of the registrant’s Definitive Proxy Statement to be filed for its 2020 Annual Meeting of Shareholders are incorporated by reference into the sections of this Form 10-K addressing the requirements of Part III of Form 10-K. |
Consolidated Statements of Earn
Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions | 12 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | |
Income Statement [Abstract] | |||
Revenue | $ 152,922 | $ 145,534 | $ 136,809 |
Cost of products sold | 146,054 | 138,700 | 129,628 |
Gross margin | 6,868 | 6,834 | 7,181 |
Operating expenses: | |||
Distribution, selling, general and administrative expenses | 4,572 | 4,480 | 4,596 |
Restructuring and employee severance | 122 | 125 | 176 |
Amortization and other acquisition-related costs | 524 | 621 | 707 |
Impairments and (gain)/loss on disposal of assets, net | 7 | (488) | 1,417 |
Litigation (recoveries)/charges, net | 5,741 | 36 | 159 |
Operating earnings/(loss) | (4,098) | 2,060 | 126 |
Other (income)/expense, net | (1) | 15 | 23 |
Interest expense, net | 238 | 294 | 329 |
Loss on early extinguishment of debt | 16 | 0 | 2 |
Gain on Sale of Investments | (579) | 0 | 0 |
Earnings/(loss) before income taxes | (3,772) | 1,751 | (228) |
Provision for/(benefit from) income taxes | (79) | 386 | (487) |
Net earnings | (3,693) | 1,365 | 259 |
Less: Net earnings attributable to noncontrolling interests | (3) | (2) | (3) |
Net earnings/(loss) attributable to Cardinal Health, Inc. | $ (3,696) | $ 1,363 | $ 256 |
Earnings/(loss) per common share attributable to Cardinal Health, Inc. | |||
Earnings Per Share, Basic | $ (12.61) | $ 4.55 | $ 0.82 |
Earnings Per Share, Diluted | $ (12.61) | $ 4.53 | $ 0.81 |
Weighted-average number of common shares outstanding: | |||
Basic (in shares) | 293 | 300 | 313 |
Diluted (in shares) | 293 | 301 | 315 |
Consolidated Statements of Comp
Consolidated Statements of Comprehensive Income - USD ($) $ in Millions | 12 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | |
Statement of Comprehensive Income [Abstract] | |||
Net earnings | $ (3,693) | $ 1,365 | $ 259 |
Other comprehensive income/(loss): | |||
Foreign currency translation adjustments and other | 3 | 18 | 58 |
Amounts reclassified to earnings | 0 | 0 | (23) |
Net unrealized gain/(loss) on derivative instruments, net of tax | (28) | (5) | (2) |
Total other comprehensive income/(loss), net of tax | (25) | 13 | 33 |
Total comprehensive income/(loss) | (3,718) | 1,378 | 292 |
Net Income (Loss) Attributable to Noncontrolling Interest | 3 | 2 | 3 |
Total comprehensive income attributable to Cardinal Health, Inc. | $ (3,721) | $ 1,376 | $ 289 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Millions | Jun. 30, 2020 | Jun. 30, 2019 |
Current assets: | ||
Cash and equivalents | $ 2,771 | $ 2,531 |
Trade receivables, net | 8,264 | 8,448 |
Inventories, net | 13,198 | 12,822 |
Prepaid expenses and other | 1,707 | 1,946 |
Total current assets | 25,940 | 25,747 |
Property and equipment, net | 2,366 | 2,356 |
Goodwill and other intangibles, net | 11,275 | 11,808 |
Other assets | 1,185 | 1,052 |
Total assets | 40,766 | 40,963 |
Current liabilities: | ||
Accounts payable | 21,374 | 21,535 |
Current portion of long-term obligations and other short-term borrowings | 10 | 452 |
Other accrued liabilities | 2,231 | 2,122 |
Total current liabilities | 23,615 | 24,109 |
Long-term obligations, less current portion | 6,765 | 7,579 |
Deferred income taxes and other liabilities | 8,594 | 2,945 |
Preferred shares, without par value: | ||
Authorized—500 thousand shares, Issued—none | 0 | 0 |
Common shares, without par value: | ||
Authorized—755 million shares, Issued—327 million shares at June 30, 2020 and 2019, respectively | 2,789 | 2,763 |
Retained earnings | 1,170 | 5,434 |
Common shares in treasury, at cost: 34 million shares and 28 million shares at June 30, 2020 and 2019, respectively | (2,066) | (1,790) |
Accumulated other comprehensive loss | (104) | (79) |
Total Cardinal Health, Inc. shareholders' equity | 1,789 | 6,328 |
Noncontrolling interests | 3 | 2 |
Total shareholders’ equity | 1,792 | 6,330 |
Total liabilities and shareholders’ equity | $ 40,766 | $ 40,963 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - shares | Jun. 30, 2020 | Jun. 30, 2019 |
Statement of Financial Position [Abstract] | ||
Preferred shares, authorized | 500,000 | 500,000 |
Preferred shares, issued | 0 | 0 |
Common shares, authorized | 755,000,000 | 755,000,000 |
Common shares, issued | 327,000,000 | 327,000,000 |
Common shares in treasury | 34,000,000 | 28,000,000 |
Consolidated Statements of Shar
Consolidated Statements of Shareholders' Equity - USD ($) shares in Millions, $ in Millions | Total | Common Shares | Retained Earnings | Treasury Shares | Accumulated Other Comprehensive Loss | Noncontrolling Interests |
Net Income (Loss) Attributable to Parent | $ 256 | $ 256 | ||||
Balance at beginning of period (in shares) at Jun. 30, 2017 | 327 | |||||
Balance at beginning of period at Jun. 30, 2017 | 6,828 | $ 2,697 | 4,967 | $ (125) | $ 20 | |
Treasury, balance at beginning of period (in shares) at Jun. 30, 2017 | (11) | |||||
Treasury, balance at beginning of period at Jun. 30, 2017 | $ (731) | |||||
Increase (Decrease) in Shareholders' Equity | ||||||
Net earnings | 259 | (1) | ||||
Net Earnings Including Portion Attributable to Noncontrolling Interest Excluding Redeemable Noncontrolling Interest | 255 | |||||
Other comprehensive income, net of tax | 33 | 33 | ||||
Purchase of noncontrolling interests | (19) | (19) | ||||
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture | 90 | $ 33 | $ 57 | |||
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture | 1 | |||||
Treasury shares acquired (in shares) | (8.4) | |||||
Share repurchase program activity | (550) | $ (550) | ||||
Dividends declared | (584) | (584) | ||||
Other | 6 | 6 | 0 | |||
Balance at end of period (in shares) at Jun. 30, 2018 | 327 | |||||
Balance at end of period at Jun. 30, 2018 | 6,059 | $ 2,730 | 4,645 | (92) | 0 | |
Treasury, balance at end of period (in shares) at Jun. 30, 2018 | (18) | |||||
Treasury, balance at end of period at Jun. 30, 2018 | $ (1,224) | |||||
Balance at beginning of period (in shares) at Jun. 30, 2017 | 327 | |||||
Balance at beginning of period at Jun. 30, 2017 | $ 6,828 | $ 2,697 | 4,967 | (125) | 20 | |
Treasury, balance at beginning of period (in shares) at Jun. 30, 2017 | (11) | |||||
Treasury, balance at beginning of period at Jun. 30, 2017 | $ (731) | |||||
Increase (Decrease) in Shareholders' Equity | ||||||
Share repurchase program activity | $ (1,500) | |||||
Balance at end of period (in shares) at Jun. 30, 2020 | 327 | 327 | ||||
Balance at end of period at Jun. 30, 2020 | $ 1,792 | $ 2,789 | 1,170 | (104) | 3 | |
Treasury, balance at end of period (in shares) at Jun. 30, 2020 | (34) | (35) | ||||
Treasury, balance at end of period at Jun. 30, 2020 | $ (2,066) | $ (2,066) | ||||
Net Income (Loss) Attributable to Parent | 1,363 | |||||
Balance at beginning of period (in shares) at Jun. 30, 2018 | 327 | |||||
Balance at beginning of period at Jun. 30, 2018 | 6,059 | $ 2,730 | 4,645 | (92) | 0 | |
Treasury, balance at beginning of period (in shares) at Jun. 30, 2018 | (18) | |||||
Treasury, balance at beginning of period at Jun. 30, 2018 | $ (1,224) | |||||
Increase (Decrease) in Shareholders' Equity | ||||||
Net earnings | 1,365 | 2 | ||||
Other comprehensive income, net of tax | 13 | 13 | ||||
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture | 67 | $ 33 | $ 34 | |||
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture | 1 | |||||
Treasury shares acquired (in shares) | (11) | |||||
Share repurchase program activity | (600) | $ (600) | ||||
Dividends declared | (575) | (575) | ||||
Other | $ (1) | 1 | ||||
Balance at end of period (in shares) at Jun. 30, 2019 | 327 | 327 | ||||
Balance at end of period at Jun. 30, 2019 | $ 6,330 | $ 2,763 | 5,434 | (79) | 2 | |
Treasury, balance at end of period (in shares) at Jun. 30, 2019 | (28) | (28) | ||||
Treasury, balance at end of period at Jun. 30, 2019 | $ (1,790) | $ (1,790) | ||||
Net Income (Loss) Attributable to Parent | (3,696) | |||||
Increase (Decrease) in Shareholders' Equity | ||||||
Net earnings | (3,693) | 3 | ||||
Other comprehensive income, net of tax | (25) | (25) | ||||
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture | 100 | $ 26 | $ 74 | |||
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture | 0 | |||||
Treasury shares acquired (in shares) | (7.3) | |||||
Share repurchase program activity | (350) | $ (350) | ||||
Dividends declared | (570) | (570) | ||||
Other | $ 0 | (2) | 2 | |||
Balance at end of period (in shares) at Jun. 30, 2020 | 327 | 327 | ||||
Balance at end of period at Jun. 30, 2020 | $ 1,792 | $ 2,789 | $ 1,170 | $ (104) | $ 3 | |
Treasury, balance at end of period (in shares) at Jun. 30, 2020 | (34) | (35) | ||||
Treasury, balance at end of period at Jun. 30, 2020 | $ (2,066) | $ (2,066) |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) $ in Millions | 12 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | |
Cash flows from operating activities: | |||
Net earnings | $ (3,693) | $ 1,365 | $ 259 |
Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities: | |||
Depreciation and amortization | 913 | 1,000 | 1,032 |
Loss on Sale of Investments | 0 | 3 | 6 |
Gain on Sale of Investments | (579) | 0 | 0 |
Impairments and (gain)/loss on disposal of assets, net | 7 | (488) | 1,417 |
Loss on early extinguishment of debt | 16 | 0 | 2 |
Share-based compensation | 90 | 82 | 85 |
Provision for/(benefit from) deferred income taxes | (961) | (83) | (1,012) |
Provision for bad debts | 106 | 88 | 74 |
Change in fair value of contingent consideration obligation | 0 | 0 | (2) |
Change in operating assets and liabilities, net of effects from acquisitions and divestitures: | |||
Decrease/(increase) in trade receivables | 82 | (751) | (871) |
Increase in inventories | (409) | (551) | (1,211) |
Increase/(decrease) in accounts payable | (162) | 1,864 | 2,574 |
Other accrued liabilities and operating items, net | 6,550 | 193 | 415 |
Net cash provided by operating activities | 1,960 | 2,722 | 2,768 |
Cash flows from investing activities: | |||
Acquisition of subsidiaries, net of cash acquired | 0 | (82) | (6,142) |
Additions to property and equipment | (375) | (328) | (384) |
Purchase of other investments | (20) | (18) | (9) |
Proceeds from sale of investments and available-for-sale securities | 886 | 3 | 65 |
Proceeds from divestitures, net of cash sold, and disposal of property and equipment | 2 | 763 | 862 |
Net cash provided by/(used in) investing activities | 493 | 338 | (5,608) |
Cash flows from financing activities: | |||
Payment of contingent consideration obligation | 0 | 0 | (35) |
Net change in short-term borrowings | (2) | 0 | (50) |
Payments to Acquire Businesses and Interest in Affiliates | 0 | 0 | 106 |
Reduction of long-term obligations | (1,399) | (1,102) | (954) |
Proceeds from interest rate swap terminations | 112 | 0 | 0 |
Proceeds from long-term obligations, net of issuance costs | 0 | 0 | 3 |
Net tax proceeds/(withholding) from share-based compensation | 8 | (14) | (3) |
Dividends on common shares | (569) | (577) | (581) |
Purchase of treasury shares | (350) | (600) | (550) |
Net cash used in financing activities | (2,200) | (2,293) | (2,276) |
Effect of exchange rates changes on cash and equivalents | (13) | 1 | 4 |
Cash reclassified to assets held for sale | 0 | 0 | (4) |
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | 240 | 768 | (5,116) |
Cash and equivalents at beginning of period | 2,531 | 1,763 | 6,879 |
Cash and equivalents at end of period | 2,771 | 2,531 | 1,763 |
Supplemental Information: | |||
Cash payments for interest | 226 | 285 | 320 |
Cash payments for income taxes | $ 368 | $ 311 | $ 425 |
Basis of Presentation and Summa
Basis of Presentation and Summary of Significant Accounting Policies | 12 Months Ended |
Jun. 30, 2020 | |
Accounting Policies [Abstract] | |
Basis of Presentation and Summary of Significant Accounting Policies | 1. Basis of Presentation and Summary of Significant Accounting Policies Cardinal Health, Inc. is a globally integrated healthcare services and products company providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices. We provide medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. References to “we”, “our” and similar pronouns in these consolidated financial statements are to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context otherwise requires. Our fiscal year ends on June 30. References to fiscal 2020 , 2019 and 2018 in these consolidated financial statements are to the fiscal years ended June 30, 2020 , 2019 and 2018 , respectively. Basis of Presentation Our consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively. Use of Estimates Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of financial statements in accordance with GAAP requires us to make estimates, judgments and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Estimates, judgments and assumptions are used in the accounting and disclosure related to, among other items, allowance for doubtful accounts, inventory valuation and reserves, goodwill and other intangible asset impairment, loss contingencies (including product liability and self-insurance accruals), and income taxes. Actual amounts could ultimately differ from these estimated amounts. The outbreak of the novel strain of coronavirus (“COVID-19”) has severely impacted, and continues to severely impact the U.S. and global economies, and beginning in the third quarter of fiscal 2020, our businesses have been impacted in a variety of ways. We cannot estimate the length or severity of the COVID-19 pandemic or the related U.S. and global economic consequences on our business and operations, including whether and when historic economic and operating conditions will resume or the extent to which the disruption may impact our business, financial position, results of operations or cash flow. Our e stimates, judgments and assumptions related to COVID-19 could ultimately differ over time . Cash Equivalents We consider liquid investments purchased with an initial maturity of three months or less to be cash equivalents. The carrying value of cash equivalents approximates fair value. Receivables and Allowance for Doubtful Accounts Trade receivables are presented net of an allowance for doubtful accounts of $206 million and $193 million at June 30, 2020 and 2019 , respectively. An account is considered past due on the first day after its due date. In accordance with contract terms, we generally have the ability to charge customers service fees or higher prices if an account is considered past due. We regularly monitor past due accounts and establish appropriate reserves to cover potential losses, which are based primarily on historical collection rates and the credit worthiness of the customer. We write off any amounts deemed uncollectible against the established allowance for doubtful accounts. We provide financing to various customers. Such financing arrangements range from 1 year to 5 years at interest rates that are generally subject to fluctuation. Interest income on these arrangements is recognized as it is earned. The financings may be collateralized, guaranteed by third parties or unsecured. Finance notes, net and related accrued interest were $104 million (current portion $12 million ) and $103 million (current portion $12 million ) at June 30, 2020 and 2019 , respectively, and are included in other assets (current portion is included in prepaid expenses and other) in the consolidated balance sheets. Finance notes receivable allowance for doubtful accounts were $27 million and $14 million at June 30, 2020 and 2019 , respectively. We estimate an allowance for these financing receivables based on historical collection rates and the credit worthiness of the customer. We write off any amounts deemed uncollectible against the established allowance for doubtful accounts. Concentrations of Credit Risk We maintain cash depository accounts with major banks, and we invest in high quality, short-term liquid instruments, and in marketable securities. Our short-term liquid instruments mature within three months and we have not historically incurred any related losses. Our trade receivables and finance notes and related accrued interest are exposed to a concentration of credit risk with certain large customers and with customers in the retail and healthcare sectors. Credit risk can be affected by changes in reimbursement and other economic pressures impacting the healthcare industry. With respect to customers in the retail and healthcare sectors, such credit risk is limited due to supporting collateral and the diversity of the customer base, including its wide geographic dispersion. We perform regular credit evaluations of our customers’ financial conditions and maintain reserves for losses through the established allowance for doubtful accounts. Historically, such losses have been within our expectations. Refer to the "Receivables and Allowance for Doubtful Accounts" section within this Note for additional information on the accounting treatment of reserves for allowance for doubtful accounts. Major Customers CVS Health Corporation ("CVS") and OptumRx, are our only customers that individually account for at least 10 percent of revenue and gross trade receivables. These customers are primarily serviced through our Pharmaceutical segment. The following table summarizes historical percent of revenue and gross trade receivables from CVS and OptumRx: Percent of Revenue Percent of Gross Trade Receivables at June 30 2020 2019 2018 2020 2019 CVS 26 % 26 % 25 % 26 % 24 % OptumRx 14 % 13 % 11 % 6 % 4 % We have entered into agreements with group purchasing organizations (“GPOs”) which act as purchasing agents that negotiate vendor contracts on behalf of their members. Vizient, Inc. and Premier, Inc. are our two largest GPO member relationships in terms of revenue. Sales to members of these two GPOs collectively accounted for 16 percent , 22 percent and 22 percent of revenue for fiscal 2020 , 2019 and 2018 , respectively. Our trade receivable balances are with individual members of the GPO, and therefore no significant concentration of credit risk exists with these types of arrangements. Inventories A substantial portion of our inventories ( 56 percent at both June 30, 2020 and 2019 ) are valued at the lower of cost, using the last-in, first-out ("LIFO") method, or market. These inventories are included within the core pharmaceutical distribution facilities of our Pharmaceutical segment (“distribution facilities”) and are primarily merchandise inventories. The LIFO method presumes that the most recent inventory purchases are the first items sold, so LIFO helps us better match current costs and revenue. We believe that the average cost method of inventory valuation provides a reasonable approximation of the current cost of replacing inventory within the distribution facilities. As such, the LIFO reserve is the difference between (a) inventory at the lower of LIFO cost or market and (b) inventory at replacement cost determined using the average cost method of inventory valuation. At June 30, 2020 and 2019 , respectively, inventories valued at LIFO cost were $411 million and $230 million higher than the average cost value. We do not record inventories in excess of replacement cost. As such, we did not write-up the value of our inventory from average cost to LIFO cost at June 30, 2020 or 2019 . Our remaining inventory that is not valued at the lower of LIFO cost or market is stated at the lower of cost, using the first-in, first-out method, or net realizable value. Net realizable value is defined as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Inventories presented in the consolidated balance sheets are net of reserves for excess and obsolete inventory which were $155 million and $171 million at June 30, 2020 and 2019 , respectively. We reserve for inventory obsolescence using estimates based on historical experience, historical and projected sales trends, specific categories of inventory, age and expiration dates of on-hand inventory and manufacturer return policies. Cash Discounts Manufacturer cash discounts are recorded as a component of inventory cost and recognized as a reduction of cost of products sold as inventory is sold. Property and Equipment Property and equipment are carried at cost less accumulated depreciation. Property and equipment held for sale are recorded at the lower of cost or fair value less cost to sell. When certain events or changes in operating conditions occur, an impairment assessment may be performed on the recoverability of the carrying amounts. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, including finance lease assets which are depreciated over the terms of their respective leases. We generally use the following range of useful lives for our property and equipment categories: buildings and improvements— 3 to 39 years ; machinery and equipment— 3 to 20 years ; and furniture and fixtures— 3 to 7 years . We recorded depreciation and amortization expense of $405 million , $455 million and $446 million for fiscal 2020 , 2019 and 2018 , respectively. The following table presents the components of property and equipment, net at June 30: (in millions) 2020 2019 Land, building and improvements $ 2,185 $ 1,992 Machinery and equipment 3,008 3,038 Furniture and fixtures 138 138 Total property and equipment, at cost 5,331 5,168 Accumulated depreciation and amortization (2,965 ) (2,812 ) Property and equipment, net $ 2,366 $ 2,356 Repairs and maintenance expenditures are expensed as incurred. Interest on long-term projects is capitalized using a rate that approximates the weighted-average interest rate on long-term obligations, which was 3 percent at June 30, 2020 . The amount of capitalized interest was immaterial for all periods presented. Goodwill and Other Intangible Assets Purchased goodwill and intangible assets with indefinite lives are not amortized, but instead are tested for impairment annually or when indicators of impairment exist. Purchased goodwill is tested for impairment at least annually. Qualitative factors are first assessed to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount. There is an option to bypass the qualitative assessment for any reporting unit in any period and proceed directly to performing the quantitative goodwill impairment test. We have elected to bypass the qualitative assessment for our annual goodwill impairment test in the current year. The quantitative goodwill impairment test involves a comparison of the estimated fair value of the reporting unit to the respective carrying amount. Goodwill impairment testing involves judgment, including the identification of reporting units, qualitative evaluation of events and circumstances to determine if it is more likely than not that an impairment exists, and, if necessary, the estimation of the fair value of the applicable reporting unit. We have two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. These operating segments are comprised of divisions (components), for which discrete financial information is available. Components are aggregated into reporting units for purposes of goodwill impairment testing to the extent that they share similar economic characteristics. Our reporting units are: Pharmaceutical operating segment (excluding our Nuclear and Precision Health Solutions division); Nuclear and Precision Health Solutions division; Medical operating segment (excluding our Cardinal Health at-Home Solutions division) (“Medical Unit”); and Cardinal Health at-Home Solutions division. Our Nuclear and Precision Health Solutions division was formerly referred to as our Nuclear Pharmacy Services division and our Cardinal Health at-Home Solutions division was formerly referred to as our Cardinal Health at Home division. Fair value can be determined using market, income or cost-based approaches. Our determination of estimated fair value of the reporting units is based on a combination of the income-based and market-based approaches. Under the income-based approach, we use a discounted cash flow model in which cash flows anticipated over several future periods, plus a terminal value at the end of that time horizon, are discounted to their present value using an appropriate risk-adjusted rate of return. We use our internal forecasts to estimate future cash flows, which we believe are consistent with those of a market participant, and include an estimate of long-term growth rates based on our most recent views of the long-term outlook for each reporting unit. Actual results may differ materially from those used in our forecasts. We use discount rates that are commensurate with the risks and uncertainty inherent in the respective reporting units and in our internally-developed forecasts. Discount rates used in our reporting unit valuations ranged from 8.5 percent to 10.5 percent . Under the market-based guideline public company method, we determine fair value by comparing our reporting units to similar businesses or guideline companies whose securities are actively traded in public markets. We also use the guideline transaction method to determine fair value based on pricing multiples derived from the sale of companies that are similar to our reporting units. To further confirm fair value, we compare the aggregate fair value of our reporting units to our total market capitalization. Estimating the fair value of reporting units requires the use of estimates and significant judgments that are based on a number of factors including forecasted operating results. The use of alternate estimates and assumptions or changes in the industry or peer groups could materially affect the determination of fair value for each reporting unit and potentially result in goodwill impairment. We performed annual impairment testing in fiscal 2020 , 2019 and 2018 and with the exception of our Medical Unit in fiscal 2018 , concluded that there were no impairments of goodwill as the estimated fair value of each reporting unit exceeded its carrying value. In conjunction with the preparation of our consolidated financial statements for fiscal 2018, we completed our annual quantitative goodwill impairment test, which we perform annually in the fourth quarter. Using a combination of income and market-based approaches (using a discount rate of 8.5 percent ), the carrying value exceeded the fair value and resulted in an impairment charge of $1.4 billion related to our Medical Unit, which is included in impairments and loss on disposal of assets in our consolidated statements of earnings/(loss). Our fair value estimates utilize significant unobservable inputs and thus represent Level 3 fair value measurements. The impairment was primarily driven by inventory and cost challenges within our Cordis business which furthered in the fourth quarter of fiscal 2018 . This impairment charge did not impact our liquidity, cash flows from operations, or compliance with debt covenants. There was no tax benefit related to the goodwill impairment charge. The impairment test for indefinite-lived intangibles other than goodwill (primarily IPR&D) involves first assessing qualitative factors to determine if it is more likely than not that the fair value of the indefinite-lived intangible asset is less than its carrying amount. If so, then a quantitative test is performed to compare the estimated fair value of the indefinite-lived intangible asset to the respective asset's carrying amount. Our qualitative evaluation requires the use of estimates and significant judgments and considers the weight of evidence and significance of all identified events and circumstances and most relevant drivers of fair value, both positive and negative, in determining whether it is more likely than not that the fair value of the indefinite-lived intangible asset is less than its carrying amount. Intangible assets with finite lives, primarily customer relationships; trademarks, trade names and patents; and developed technology, are amortized using a combination of straight-line and accelerated methods based on the expected cash flows from the asset over their estimated useful lives. We review intangible assets with finite lives for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable. Determining whether an impairment loss occurred requires a comparison of the carrying amount to the sum of the future forecasted undiscounted cash flows expected to be generated by the asset group. Actual results may differ materially from those used in our forecasts. Assets Held for Sale We classify assets and liabilities (the “disposal group”) as held for sale when management commits to a plan to sell the disposal group in its present condition and at a price that is reasonable in relation to its current fair value. We also consider whether an active program to locate a buyer has been initiated and if it is probable that the sale will occur within one year without significant changes to the plan to sell. Upon classification of the disposal group as held for sale, we test the assets for impairment and cease related depreciation and amortization. Investments Investments in non-marketable equity securities are accounted for under the fair value, equity or net asset value method of accounting and are included in other assets in the consolidated balance sheets. For equity securities without a readily determinable fair value, we use the fair value measurement alternative and measure the securities at cost less impairment, if any, including adjustments for observable price changes in orderly transactions for an identical or similar investment of the same issuer. For investments in which we can exercise significant influence but do not control, we use the equity method of accounting. Our share of the earnings and losses are recorded in other (income)/expense, net in the consolidated statements of earnings/(loss). We monitor our investments for impairment by considering factors such as the operating performance of the investment and current economic and market conditions. Vendor Reserves In the ordinary course of business, our vendors may dispute deductions taken against payments otherwise due to them or assert other disputes. These disputes are researched and resolved based upon the findings of the research performed. At any given time, there are outstanding items in various stages of research and resolution. In determining appropriate reserves for areas of exposure with our vendors, we assess historical experience and current outstanding claims. We have established various levels of reserves based on the type of claim and status of review. Though the claim types are relatively consistent, we periodically refine our methodology by updating the reserve estimate percentages to reflect actual historical experience. The ultimate outcome of certain claims may be different than our original estimate and may require an adjustment. Adjustments to vendor reserves are included in cost of products sold. In addition, the reserve balance will fluctuate due to variations of outstanding claims from period-to-period, timing of settlements and specific vendor issues, such as bankruptcies. Vendor reserves were $77 million and $53 million at June 30, 2020 and 2019 , respectively, excluding third-party returns. See Third-Party Returns section within this Note for a description of third-party returns. Distribution Services Agreement and Other Vendor Fees Our Pharmaceutical segment recognizes fees received from distribution services agreements and other fees received from vendors related to the purchase or distribution of the vendors’ inventory when those fees have been earned and we are entitled to payment. Since the benefit provided to a vendor is related to the purchase and distribution of the vendor’s inventory, we recognize the fees as a reduction in the carrying value of the inventory that generated the fees, and as such, a reduction of cost of products sold in our consolidated statements of earnings/(loss) when the inventory is sold. Loss Contingencies and Self-Insurance We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. In connection with the opioid litigation as described further in the Note 7 , we recorded a pre-tax charge of $5.63 billion ( $5.14 billion after tax) during fiscal 2020. Definitive terms of a settlement under the Settlement Framework continue to be negotiated, and there is no assurance that the necessary parties will agree to a definitive settlement agreement or that the contingencies to any agreement will be satisfied. We develop and periodically update reserve estimates for the Cordis inferior vena cava ("Cordis IVC") claims, including those received to date and expected to be received in the future and related costs. To project future Cordis IVC claim costs, we use a methodology based largely on recent experience, including claim filing rates, estimated indemnity severity by claim type, sales data, implant and injury to report lag patterns and estimated defense costs. We also self-insure for employee healthcare, general liability, certain product liability matters, auto liability, property and workers' compensation. Self-insurance accruals include an estimate for expected settlements or pending claims, defense costs, administrative fees, claim adjustment costs and an estimate for claims incurred but not reported. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies and other liabilities is highly subjective and requires judgments about future events. We regularly review contingencies and our self-insurance accruals to determine whether our accruals and related disclosures are adequate. Any adjustments for changes in reserves are recorded in the period in which the change in estimate occurs. The amount of ultimate loss may differ materially from these estimates. We recognize these estimated loss contingencies, income from favorable resolution of litigation and certain defense costs in litigation (recoveries)/charges in our consolidated statements of earnings/(loss). See Note 7 for additional information regarding loss contingencies and product liability lawsuits. Guarantees In the ordinary course of business, we agree to indemnify certain other parties under acquisition and disposition agreements, customer agreements, intellectual property licensing agreements, and other agreements. Such indemnification obligations vary in scope and, when defined, in duration. In many cases, a maximum obligation is not explicitly stated, and therefore the overall maximum amount of the liability under such indemnification obligations cannot be reasonably estimated. Where appropriate, such indemnification obligations are recorded as a liability. Historically, we have not, individually or in the aggregate, made payments under these indemnification obligations in any material amounts. In certain circumstances, we believe that existing insurance arrangements, subject to the general deduction and exclusion provisions, would cover portions of the liability that may arise from these indemnification obligations. In addition, we believe that the likelihood of a material liability being triggered under these indemnification obligations is not probable. From time to time we enter into agreements that obligate us to make fixed payments upon the occurrence of certain events. Such obligations primarily relate to obligations arising under acquisition transactions, where we have agreed to make payments based upon the achievement of certain financial performance measures by the acquired business. Generally, the obligation is capped at an explicit amount. There were no material obligations at June 30, 2020 . Income Taxes We account for income taxes using the asset and liability method. Deferred tax assets and liabilities are measured using enacted tax rates in the respective jurisdictions in which we operate . We assess the realizability of deferred tax assets on a quarterly basis and provide a valuation allowance for deferred tax assets when it is more likely than not that at least a portion of the deferred tax assets will not be realized. The realizability of deferred tax assets depends on our ability to generate sufficient taxable income within the carryback or carryforward periods provided for in the tax law for each applicable tax jurisdiction and also considers all available positive and negative evidence. Deferred taxes for non-U.S. liabilities are not provided on the unremitted earnings of subsidiaries outside of the United States when it is expected that these earnings are indefinitely reinvested. We operate in a complex multinational tax environment and are subject to tax treaty arrangements and transfer pricing guidelines for intercompany transactions that are subject to interpretation. Uncertainty in a tax position may arise as tax laws are subject to interpretation. Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination of the technical merits of the position, including resolutions of any related appeals or litigation processes. The amount recognized is measured as the largest amoun t of tax benefit that is greater than 50 percent likely of being realized upon settlement. For tax benefits that do not qualify for recognition, we recognize a liability for unrecognized tax benefits. See Note 8 for additional information regarding income taxes. Other Accrued Liabilities Other accrued liabilities represent various current obligations, including certain accrued operating expenses and taxes payable. Noncontrolling Interests Noncontrolling interests represent the portion of net earnings, comprehensive income and net assets that is not attributable to Cardinal Health, Inc. Share-Based Compensation Share-based compensation provided to employees is recognized in the consolidated statements of earnings/(loss) based on the grant date fair value of the awards. The fair value of restricted share units and performance share units is determined by the grant date market price of our common shares. The fair value of stock options is determined on the grant date using a lattice valuation model. The compensation expense associated with nonvested performance share units is dependent on our periodic assessment of the probability of the targets being achieved and our estimate, which may vary over time, of the number of shares that ultimately will be issued. The compensation expense recognized for share-based awards is net of estimated forfeitures and is recognized ratably over the service period of the awards. All income tax effects of share-based awards are recognized in the consolidated statements of earnings/(loss) as awards vest or are settled. We classify share-based compensation expense in distribution, selling, general and administrative ("SG&A") expenses to correspond with the same line item as the majority of the cash compensation paid to employees. If awards are modified in connection with a restructuring activity, the incremental share-based compensation expense is classified in restructuring and employee severance. See Note 14 for additional information regarding share-based compensation. Dividends We paid cash dividends per common share of $1.92 , $1.91 and $1.85 in fiscal 2020 , 2019 and 2018 , respectively. Revenue Recognition We recognize revenue in an amount that reflects the consideration to which we expect to be entitled in exchange for the transfer of goods or services to customers. Revenue in both segments is primarily related to the distribution of pharmaceutical and medical products, which include both manufactured and sourced products, and we recognize at a point in time when title transfers to customers and we have no further obligation to provide services related to such merchandise. Service revenues are recognized over the period that services are provided to the customer. Revenues derived from services are not material for either segment for all periods presented. We are generally the principal in a transaction, therefore our revenue is primarily recorded on a gross basis. When we are a principal in a transaction, we have determined that we control the ability to direct the use of the product or service prior to transfer to a customer, are primarily responsible for fulfilling the promise to provide the product or service to our customer, have discretion in establishing prices, and ultimately control the transfer of the product or services provided to the customer. Sales Returns and Allowances Revenue is recorded net of sales returns and allowances. Revenues are measured based on the amount of consideration that we expect to receive, reduced by estimates for return allowances, discounts, rebates and other variable consideration. Sales returns are recorded based on estimates using historical data. Our customer return policies generally require that the product be physically returned, subject to restocking fees. We only allow customers to return products for credit in a condition suitable to be added back to inventory and resold at full value (“merchantable product”) or returned to vendors for credit. Product returns are generally consistent throughout the year and typically are not specific to any particular product or customer. We accrue for estimated sales returns and allowances at the time of sale based upon historical customer return trends, margin rates and processing costs. Our accrual for sales returns is reflected as a reduction of revenue and cost of products sold for the sales price and cost, respectively. At both June 30, 2020 and 2019 , the accrual for estimated sales returns and allowances was $495 million and $479 million , the impact of which is reflected in trade receivables, net and inventories, net in the consolidated balance sheets. Sales returns and allowances were $2.3 billion , $2.2 billion and $2.4 billion , for fiscal 2020 , 2019 and 2018 , respectively, and the net impact on net earnings/(loss) in the consolidated statements of earnings/(loss) was immaterial in fiscal 2020 , 2019 and 2018 . Third-Party Returns We generally do not accept non-merchantable pharmaceutical product returns from our customers, so many of our customers return non-merchantable pharmaceutical products to the manufacturer through third parties. Since our customers generally do not have a direct relationship with manufacturers, our vendors pass the value of such returns to us (usually in the form of an accounts payable deduction). We, in turn, pass the value received to our customer. In certain instances, we pass the estimated value of the return to our customer prior to our receipt of the value from the vendor. Although we believe we have satisfactory protections, we could be subject to claims from customers or vendors if our administration of this overall process was deficient in some respect or our contractual terms with vendors are in conflict with our contractual terms with our customers. We have maintained reserves for some of these situations based on their nature and our historical experience with their resolution. Shipping and Handling Shipping and handling costs are primarily included in SG&A expenses in our consolidated statements of earnings/(loss) and include all delivery expenses as well as all costs to prepare the product for shipment to the end customer. Shipping and handling |
Leases
Leases | 12 Months Ended |
Jun. 30, 2020 | |
Leases [Abstract] | |
Leases | 5. Leases Our operating leases are primarily for corporate offices, distribution facilities, vehicles, and equipment. We determine if an arrangement is a lease at its inception by evaluating whether the arrangement conveys the right to use an identified asset and whether we obtain substantially all of the economic benefits from and have the ability to direct the use of the asset. Our lease agreements generally do not contain any material residual value guarantees or material restrictive covenants. Beginning July 1, 2019, operating lease right-of-use assets and corresponding operating lease liabilities are recognized in our consolidated balance sheet at lease commencement date based on the present value of lease payments over the lease term. Operating lease expense for operating lease assets is recognized on a straight-line basis over the lease term. As most of our leases do not provide an implicit rate, we use our collateralized incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. We use the implicit rate if it is readily determinable. Our lease agreements contain lease components and non-lease components. For all asset classes, we have elected to account for both of these components as a single lease component. We also, from time to time, sublease portions of our real estate property, resulting in sublease income. Sublease income and the related assets and cash flows are not material to the consolidated financial statements at or for the fiscal year ended June 30, 2020 . We also have elected to apply a practical expedient for short-term leases whereby we do not recognize a lease liability and right-of-use asset for leases with a term of less than 12 months. Short-term lease expense recognized in fiscal 2020 was not material. In addition, upon adoption of the new lease standard, we elected the package of three practical expedients permitted under the transition guidance, which include the carry forward of our leases without reassessing 1) whether any contracts are leases or contain leases, 2) lease classification and 3) initial direct costs. Our leases have remaining lease terms from less than 1 year up to approximately 22 years . Our lease terms may include options to extend or terminate the lease when it is reasonably certain and there is a significant economic incentive to exercise that option. The following table summarizes the components of lease cost: (in millions) 2020 Operating lease cost $ 134 Finance lease cost 13 Variable lease cost 17 Total lease cost $ 164 Variable lease cost primarily includes payments for property taxes, maintenance and insurance. Our rental expense relating to operating leases was $153 million and $172 million in fiscal 2019 and 2018 , respectively. The following table summarizes supplemental balance sheet information related to leases at June 30: (in millions) 2020 Operating Leases Operating lease right-of-use assets $ 426 Current portion of operating lease liabilities 104 Long-term operating lease liabilities 341 Total operating lease liabilities 445 Finance Leases Finance lease right-of-use assets 33 Current portion of finance lease liabilities 9 Long-term finance lease liabilities 25 Total finance lease liabilities $ 34 Operating leases are included in other assets, other accrued liabilities, and deferred income taxes and other liabilities in our consolidated balance sheet. Finance leases are included in property and equipment, net, current portion of long-term obligations and other short-term borrowings, and long-term obligations, less current portion in our consolidated balance sheet. The following tables summarizes supplemental cash flow information related to leases: (in millions) 2020 Cash paid for lease liabilities: Operating cash flows paid for operating leases $ 125 Financing cash flows paid for finance leases 7 Non-cash right-of-use assets obtained in exchange for lease obligations: New operating leases 150 New finance leases 40 Amended lease standard adoption impact as of July 1, 2019 (1) 400 (1) Includes the effect of $22 million from reclassifying deferred rent as an offset to the lease right-of-use asset in accordance with the transition guidance. Our operating leases had a weighted-average remaining lease term of 6.4 years and a weighted-average discount rate of 2.9 percent . Our finance leases had a weighted-average remaining lease term of 4.3 years and a weighted-average discount rate of 2.4 percent . Future lease payments under non-cancellable leases as of June 30, 2020 were as follows: (in millions) Operating Leases Finance Leases Total 2021 $ 117 $ 10 $ 127 2022 96 9 105 2023 72 9 81 2024 51 4 55 2025 44 2 46 Thereafter 123 2 125 Total future lease payments 503 36 539 Less: leases not yet commenced (1) 4 — 4 Less: imputed interest 54 2 56 Total lease liabilities $ 445 $ 34 $ 479 (1) As of June 30, 2020 , we had certain leases that were executed but did not have control of the underlying assets; therefore, the lease liabilities and right-of-use assets are not recorded in the consolidated balance sheet. The future minimum rental payments for operating leases having initial or remaining non-cancelable lease terms in excess of one year at June 30, 2019 for fiscal 2020 through 2024 and thereafter were as follows: $126 million , $100 million , $76 million , $54 million , $33 million and $94 million . |
Restructuring and Employee Seve
Restructuring and Employee Severance | 12 Months Ended |
Jun. 30, 2020 | |
Restructuring Charges [Abstract] | |
Restructuring and Employee Severance | 3. Restructuring and Employee Severance The following tables summarize restructuring and employee severance costs: (in millions) 2020 2019 2018 Employee-related costs $ 66 $ 95 $ 34 Facility exit and other costs 56 30 142 Total restructuring and employee severance $ 122 $ 125 $ 176 Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of product distribution and lease contract termination costs, lease costs associated with vacant facilities, accelerated depreciation, equipment relocation costs, project consulting fees, vendor transition fees, costs associated with restructuring our delivery of information technology infrastructure services and certain other divestiture-related costs. In fiscal 2020 and 2019 , restructuring costs are primarily related to implementation of certain enterprise-wide cost-savings measures. In fiscal 2018 , we entered into an agreement to transition the distribution of our Medical segment's surgeon gloves in certain international markets from a third-party distribution arrangement to a direct distribution model. The costs associated with this restructuring included $125 million , on a pre-tax basis, in contract termination costs that were paid during fiscal 2018 . These costs are reflected in restructuring and employee severance in the consolidated statements of earnings/(loss) during the fiscal year ended 2018. The following table summarizes activity related to liabilities associated with restructuring and employee severance: (in millions) Employee- Related Costs Facility Exit and Other Costs Total Balance at June 30, 2018 $ 24 $ 4 $ 28 Additions 84 8 92 Payments and other adjustments (44 ) (4 ) (48 ) Balance at June 30, 2019 64 8 72 Additions 85 24 109 Payments and other adjustments (81 ) (4 ) (85 ) Balance at June 30, 2020 $ 68 $ 28 $ 96 |
Goodwill and Other Intangible A
Goodwill and Other Intangible Assets | 12 Months Ended |
Jun. 30, 2020 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Goodwill and Other Intangible Assets | 4. Goodwill and Other Intangible Assets Goodwill The following table summarizes the changes in the carrying amount of goodwill by segment and in total: (in millions) Pharmaceutical (1) Medical (2) Total Balance at June 30, 2018 $ 2,621 $ 5,695 $ 8,316 Goodwill acquired, net of purchase price adjustments 45 7 52 Foreign currency translation adjustments and other (3 ) 13 10 Balance at June 30, 2019 2,663 5,715 8,378 Goodwill acquired, net of purchase price adjustments (5 ) — (5 ) Foreign currency translation adjustments and other (1 ) (15 ) (16 ) Balance at June 30, 2020 $ 2,657 $ 5,700 $ 8,357 (1) At June 30, 2020 and 2019 , the Pharmaceutical segment accumulated goodwill impairment loss was $829 million . (2) At June 30, 2020 and 2019 , the Medical segment accumulated goodwill impairment loss was $1.4 billion . Other Intangible Assets The following tables summarize other intangible assets by class at June 30: 2020 (in millions) Gross Intangible Accumulated Amortization Net Intangible Weighted- Average Remaining Amortization Period (Years) Indefinite-life intangibles: IPR&D, trademarks and other $ 23 $ — $ 23 N/A Total indefinite-life intangibles 23 — 23 N/A Definite-life intangibles: Customer relationships 3,554 1,828 1,726 13 Trademarks, trade names and patents 673 341 332 13 Developed technology and other 1,604 767 837 11 Total definite-life intangibles 5,831 2,936 2,895 12 Total other intangible assets $ 5,854 $ 2,936 $ 2,918 N/A 2019 (in millions) Gross Intangible Accumulated Amortization Net Intangible Indefinite-life intangibles: IPR&D, trademarks and other $ 22 $ — $ 22 Total indefinite-life intangibles 22 — 22 Definite-life intangibles: Customer relationships 3,562 1,517 2,045 Trademarks, trade names and patents 672 295 377 Developed technology and other 1,602 616 986 Total definite-life intangibles 5,836 2,428 3,408 Total other intangible assets $ 5,858 $ 2,428 $ 3,430 Total amortization of intangible assets was $512 million , $531 million and $574 million for fiscal 2020 , 2019 and 2018 , respectively. The estimated annual amortization for intangible assets for fiscal 2021 through 2025 is as follows: $442 million , $408 million , $358 million , $329 million and $277 million |
Investments
Investments | 12 Months Ended |
Jun. 30, 2020 | |
Investments [Abstract] | |
Investments | <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:13pt;"><font style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;">. Investments</font><font style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;"> </font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;">In August 2018, we sold our </font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;">98 percent</font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> equity interest in naviHealth Holdings, LLC ("naviHealth") to investor entities controlled by Clayton, Dubilier &amp; Rice in exchange for cash proceeds of </font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;">$737 million</font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> (after adjusting for certain fees and expenses) and a </font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;">40 percent</font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> equity interest in a partnership that owns </font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;">100 percent</font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> of the equity interest of naviHealth. We also have certain call rights to reacquire naviHealth. We have accounted for this investment using the equity method of accounting and on a one-month reporting lag.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;">During the fiscal year ended </font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;">June&#160;30, 2019</font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, we recognized a pre-tax gain of </font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;">$508 million</font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> related to this divestiture in impairments and (gain)/loss on disposal of assets in our consolidated statements of earnings/(loss). The carrying value of this investment was </font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;">$334 million</font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> as of </font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;">June&#160;30, 2019</font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;">In May 2020, we sold our </font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;">40 percent</font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> equity interest in a partnership that owns </font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;">100 percent</font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> of the equity interest of naviHealth in exchange for cash proceeds of [] and recognized a gain of [] related to this disposal in gain on sale of naviHealth stock in our consolidated statements of earnings/(loss). During the three and twelve months ended </font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;">June&#160;30, 2020</font><font style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, our proportionate share of naviHealth&#8217;s net loss, which was recorded in other (income)/ expense, net in the consolidated statements of earnings/(loss), was immaterial.</font></div></div> |
Long-Term Obligations and Other
Long-Term Obligations and Other Short-Term Borrowings | 12 Months Ended |
Jun. 30, 2020 | |
Debt Disclosure [Abstract] | |
Long-Term Obligations and Other Short-Term Borrowings | 6. Long-Term Obligations and Other Short-Term Borrowings The following table summarizes long-term obligations and other short-term borrowings at June 30: (in millions) (1) 2020 2019 2.4% Notes due 2019 $ — $ 450 4.625% Notes due 2020 — 508 2.616% Notes due 2022 834 1,079 3.2% Notes due 2022 236 247 Floating Rate Notes due 2022 321 340 3.2% Notes due 2023 576 551 3.079% Notes due 2024 809 781 3.5% Notes due 2024 413 402 3.75% Notes due 2025 529 494 3.41% Notes due 2027 1,215 1,318 4.6% Notes due 2043 340 346 4.5% Notes due 2044 342 342 4.9% Notes due 2045 441 445 4.368% Notes due 2047 560 594 7.0% Debentures due 2026 124 124 Other Obligations 35 10 Total 6,775 8,031 Less: current portion of long-term obligations and other short-term borrowings 10 452 Long-term obligations, less current portion $ 6,765 $ 7,579 (1) Maturities are presented on a calendar year basis. Maturities of existing long-term obligations and other short-term borrowings for fiscal 2021 through 2025 and thereafter are as follows: $10 million , $1.4 billion , $585 million , $814 million , $414 million and $3.6 billion . Long-Term Debt All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. The 7.0% Debentures represent unsecured obligations of Allegiance Corporation (a wholly-owned subsidiary), which Cardinal Health, Inc. has guaranteed. None of these obligations are subject to a sinking fund and the Allegiance obligations are not redeemable prior to maturity. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $21.4 billion . In June 2020, we redeemed $500 million aggregate principle amount of 4.625% Notes due December 2020 at a redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes. In connection with the redemption, we recorded a $7 million loss on early extinguishment of debt. During fiscal 2020, we also early repurchased $247 million of the 2.616% Notes due 2022, $11 million of the 3.2% Notes due 2022, $20 million of the Floating Rate Notes due 2022, $104 million of the 3.41% Notes due 2027, $6 million of the 4.6% Notes due 2043, $5 million of the 4.9% Notes due 2045, and $35 million of the 4.368% Notes due 2047. In connection with the early debt repurchases, we recognized a $9 million loss on early extinguishment of debt. In November 2019, we repaid the full principal of the 2.4% Notes due 2019 at maturity for $450 million . The redemption and repurchases were paid for with available cash and other short-term borrowings. In fiscal 2019, we repurchased $67 million of the 2.616% Notes due 2022, $1 million of the 3.2% Notes due 2022, 8 million of the Floating Rate Notes due 2022, and $24 million of the 3.41% Notes due 2027 for a total of $100 million . The repurchases were paid for with available cash. The loss on early extinguishment of debt in connection with these early repurchases was immaterial. We also paid off the $1.0 billion 1.948% Notes due 2019 as they became due with available cash. In June 2018, we repaid the full principal of the 1.95% Notes due 2018 at maturity for $550 million . If we undergo a change of control, as defined in the notes, and if the notes receive specified ratings below investment grade by each of Standard & Poors Ratings Services, Moody’s Investors Services and Fitch Ratings, any holder of the notes, excluding the debentures, can require with respect to the notes owned by such holder, or we can offer, to repurchase the notes at 101% of the principal amount plus accrued and unpaid interest. Other Financing Arrangements In addition to cash and equivalents and operating cash flow, other sources of liquidity include a $2.0 billion commercial paper program backed by a $2.0 billion revolving credit facility. We also have a $1.0 billion committed receivables sales facility. In September 2019, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (“CHF”) through September 30, 2022. CHF was organized for the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its creditors. Our revolving credit and committed receivables sales facilities require us to maintain, as of the end of every fiscal quarter through December 2020, a consolidated net leverage ratio of no more than 4.00-to-1. The maximum permitted ratio will reduce to 3.75-to-1 in March 2021 and as of the end of every quarter thereafter . As of June 30, 2020 , we were in compliance with this financial covenant. At June 30, 2020 and 2019 , we had no amounts outstanding under the revolving credit facility; however, availability was reduced by outstanding letters of credit of $1 million and $24 million at June 30, 2020 and 2019 , respectively. Under our committed receivables sales facility program, we had a maximum amount outstanding of $700 million and an average daily amount outstanding of $12 million during fiscal 2020 . We also had no amounts outstanding under the committed receivables sales facility program; however, availability was reduced by outstanding standby letters of credit of $29 million and $30 million at June 30, 2020 and 2019 , respectively. Under our commercial paper program we had a maximum amount outstanding of $1.7 billion and an average daily amount outstanding of $183 million during fiscal 2020 . We had no amounts outstanding under the commercial paper program as of June 30, 2020 and 2019 . We also maintain other short-term credit facilities and an unsecured line of credit that allowed for borrowings up to $6 million and $9 million at June 30, 2020 and 2019 , respectively. The $35 million and $10 million balance of other obligations at June 30, 2020 and 2019 , respectively, consisted of short-term borrowings and finance leases. |
Income Taxes
Income Taxes | 12 Months Ended |
Jun. 30, 2020 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | 8. Income Taxes Earnings/(Loss) before Income Taxes and Provision for/(Benefit From) Income Taxes The following table summarizes earnings/(loss) before income taxes: (in millions) 2020 2019 2018 U.S. operations $ (4,056 ) $ 1,478 $ 391 Non-U.S. operations 284 273 (619 ) Earnings/(loss) before income taxes $ (3,772 ) $ 1,751 $ (228 ) The following table summarizes the components of provision for/(benefit from) income taxes: (in millions) 2020 2019 2018 Current: Federal $ 659 $ 295 $ 341 State and local 154 89 41 Non-U.S. 69 85 143 Total current $ 882 $ 469 $ 525 Deferred: Federal $ (822 ) $ (28 ) $ (1,003 ) State and local (127 ) (37 ) 16 Non-U.S. (12 ) (18 ) (25 ) Total deferred (961 ) (83 ) (1,012 ) Provision for/(benefit from) income taxes $ (79 ) $ 386 $ (487 ) Effective Tax Rate The following table presents a reconciliation of the provision based on the federal statutory income tax rate to our effective income tax rate: 2020 (1) 2019 (2) 2018 (1) Provision at Federal statutory rate 21.0 % 21.0 % 28.1 % State and local income taxes, net of federal benefit 2.5 0.9 (16.0 ) Tax effect of foreign operations — (0.7 ) (48.4 ) Nondeductible/nontaxable items (0.1 ) 2.5 (10.2 ) Goodwill impairment — — (124.7 ) Tax Act 0.1 (0.8 ) 410.9 Change in valuation allowances 1.5 4.5 (76.9 ) Foreign tax credits 0.5 (1.0 ) 27.3 China tax related to divestiture — — (25.8 ) Legal entity reorganization — (3.6 ) 71.4 Opioid litigation (23.2 ) — — Other (0.2 ) (0.7 ) (21.9 ) Effective income tax rate 2.1 % 22.1 % 213.8 % (1) The effective income tax rate for fiscal 2020 and 2018 represents an income tax benefit tax rate. (2) The effective income tax rate for fiscal 2019 represents an income tax expense tax rate. The income tax benefit rate was 2.1% and 213.8% in fiscal 2020 and fiscal 2018 compared to an income tax expense rate of 22.1% in fiscal 2019 . Fluctuations in the effective tax rates are primarily due to the impact of opioid litigation in fiscal 2020 and the impact of the U.S. Tax Cuts and Jobs Act ("Tax Act") in fiscal 2018, both described further below, as well as the Medical Unit goodwill impairment in fiscal 2018, as described in Note 1 . There were also changes in valuation allowances related to capital losses, credit carryforwards and net operating loss carryforwards in U.S. federal, U.S. state and international jurisdictions. In connection with the $5.63 billion pre-tax charge for the opioid litigation, we recorded a tax benefit of $488 million in fiscal 2020 , which is net of unrecognized tax benefits of $469 million , reflecting our current assessment of the estimated future deductibility of the amount that may be paid. We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the tax law; however, these estimates require significant judgment since the definitive settlement terms and documentation, including provisions related to deductibility, under the Settlement Framework have not been negotiated and the U.S. tax law governing deductibility was changed by the Tax Act. Further, it is possible that the tax authorities could challenge our interpretation of the currently enacted tax law or the estimates and assumptions used to assess the future deductibility of these benefits. The actual amount of the tax benefit related to uncertain tax positions may differ materially from these estimates. See Note 7 for more information regarding these matters. Our effective tax rate has benefits from negotiated lower than statutory tax rates in select foreign jurisdictions which individually are not material to our effective tax rate but in aggregate have a favorable tax impact of approximately $17 million during fiscal 2020. On December 22, 2017, the United States enacted the Tax Act. The Tax Act made broad and comp lex changes to the U.S. tax code that affected fiscal 2018 and incrementally affected our fiscal year 2019 financial results in several ways. First, the U.S. statutory tax rate in fiscal 2019 was reduced to 21.0% . Second, the Tax Act established new tax provisions that affected us beginning July 1, 2018 including, (1) eliminating the U.S. manufacturing deduction; (2) establishing new limitations on deductible interest expense and certain executive compensation; (3) eliminating the corporate alternative minimum tax; (4) creating the base erosion anti-abuse tax; (5) creating a new provision designed to tax global intangible low-tax income (“GILTI”) and allow for a deduction related to foreign derived intangible income ("FDII"); (6) generally eliminating U.S. federal income taxes on dividends from foreign subsidiaries; and (7) changing rules related to uses and limitations of net operating loss carryforwards created in tax years beginning after December 31, 2017. Regarding the new GILTI tax rules, we elected to treat taxes due on future GILTI inclusions in U.S. taxable income as a current period expense when incurred. As of June 30, 2020 , foreign earnings of approximately $800 million are considered indefinitely reinvested for working capital and other offshore investment needs. The computation of tax required if those earnings are repatriated is not practicable. For amounts not considered indefinitely reinvested, we have recorded an immaterial amount of income tax expense in our financial statements in fiscal 2020. Deferred Income Taxes Deferred income taxes arise from temporary differences between financial reporting and tax reporting bases of assets and liabilities and operating loss and tax credit carryforwards for tax purposes. The following table presents the components of the deferred income tax assets and liabilities at June 30: (in millions) 2020 2019 Deferred income tax assets: Receivable basis difference $ 39 $ 35 Accrued liabilities 607 133 Share-based compensation 38 39 Loss and tax credit carryforwards 589 621 Deferred tax assets related to uncertain tax positions 52 30 Other 87 6 Total deferred income tax assets 1,412 864 Valuation allowance for deferred income tax assets (470 ) (542 ) Net deferred income tax assets $ 942 $ 322 Deferred income tax liabilities: Inventory basis differences $ (1,083 ) $ (1,056 ) Property-related (327 ) (171 ) Goodwill and other intangibles (751 ) (808 ) Total deferred income tax liabilities $ (2,161 ) $ (2,035 ) Net deferred income tax liability $ (1,219 ) $ (1,713 ) Deferred income tax assets and liabilities in the preceding table, after netting by taxing jurisdiction and for uncertain tax positions, are in the following captions in the consolidated balance sheets at June 30: (in millions) 2020 2019 Noncurrent deferred income tax asset (1) $ 39 $ 36 Noncurrent deferred income tax liability (2) (1,258 ) (1,749 ) Net deferred income tax liability $ (1,219 ) $ (1,713 ) (1) Included in other assets in the consolidated balance sheets. (2) Included in deferred income taxes and other liabilities in the consolidated balance sheets. At June 30, 2020 we had gross federal, state and international loss and credit carryforwards of $123 million , $2.4 billion and $2.2 billion , respectively, the tax effect of which is an aggregate deferred tax asset of $589 million . Substantially all of these carryforwards are available for at least three years. Approximately $461 million of the valuation allowance at June 30, 2020 applies to certain federal, state and international loss carryforwards that, in our opinion, are more likely than not to expire unutilized. However, to the extent that tax benefits related to these carryforwards are realized in the future, the reduction in the valuation allowance would reduce income tax expense. Unrecognized Tax Benefits We had $998 million , $456 million and $423 million of unrecognized tax benefits at June 30, 2020 , 2019 and 2018 , respectively. The June 30, 2020 , 2019 and 2018 balances include $753 million , $303 million and $262 million , respectively, of unrecognized tax benefits that, if recognized, would have an impact on the effective tax rate. The remaining unrecognized tax benefits relate to tax positions for which ultimate deductibility is highly certain but for which there is uncertainty as to the timing of such deductibility. Recognition of these tax benefits would not affect our effective tax rate. We include the full amount of unrecognized tax benefits in deferred income taxes and other liabilities in the consolidated balance sheets. The following table presents a reconciliation of the beginning and ending amounts of unrecognized tax benefits: (in millions) 2020 2019 2018 Balance at beginning of fiscal year $ 456 $ 423 $ 417 Additions for tax positions of the current year 500 24 15 Additions for tax positions of prior years (1) 78 39 141 Reductions for tax positions of prior years (27 ) (5 ) (40 ) Settlements with tax authorities (1) (6 ) (25 ) (99 ) Expiration of the statute of limitations (1) (3 ) — (11 ) Balance at end of fiscal year $ 998 $ 456 $ 423 (1) Included in fiscal 2018 additions for tax positions of prior years is $110 million related to exposures acquired as part of the Patient Recovery Business for which we are fully indemnified. Also for fiscal 2018 are settlements of $81 million related to the Patient Recovery Business as well as $11 million of statute expirations. It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is a net decrease of $0 million to $370 million , exclusive of penalties and interest. We recognize accrued interest and penalties related to unrecognized tax benefits in the provision for income taxes. At June 30, 2020 , 2019 and 2018 , we had $146 million , $122 million and $110 million , respectively, accrued for the payment of interest and penalties. These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the consolidated balance sheets. During fiscal 2020 , 2019 , and 2018 we recognized $16 million , $8 million , and $8 million of expense for interest and penalties in income tax expense, respectively. Other Tax Matters We file income tax returns in the U.S. federal jurisdiction, various U.S. state and local jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2008 through the current fiscal year. We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), which has been acquired by Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $176 million and $165 million at June 30, 2020 and 2019 , respectively, and is included in other assets in the consolidated balance sheets. As a result of the acquisition of the Patient Recovery Business, Medtronic plc is obligated to indemnify us for certain tax exposures and transaction taxes related to periods prior to the acquisition under the purchase agreement. The indemnification receivable was $19 million and $22 million at June 30, 2020 and 2019 , respectively, and is included in other assets in the consolidated balance sheets. |
Commitments, Contingent Liabili
Commitments, Contingent Liabilities and Litigation | 12 Months Ended |
Jun. 30, 2020 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments, Contingent Liabilities and Litigation | h Corporation ("CVS Health") Red Oak Sourcing, LLC ("Red Oak Sourcing") is a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term through June 2024. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. Due to the achievement of predetermined milestones, we are required to make quarterly payments of $45.6 million to CVS Health for the initial term. Contingencies New York Opioid Stewardship Act In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $100 million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017. In December 2018, the U.S. District Court for the Southern District of New York ruled that the OSA is unconstitutional and enjoined its enforcement (the "Ruling"). In January 2019, the State filed notice of its intent to appeal the Ruling. In April 2019, the State, among other things, amended the OSA so that the assessment would only cover opioid sales in 2017 and 2018, subject to the State's pending appeal of the Ruling. We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. At June 30, 2020, we have no amounts accrued for the OSA because we do not believe it is probable that a liability has been incurred. Legal Proceedings We become involved from time to time in disputes, litigation and regulatory matters. From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits. From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions. We may be named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government . We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates. We recognize income from the favorable outcome of litigation when we receive the associated cash or assets. We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges in our consolidated statements of earnings/(loss). Opioid Lawsuits and Investigations Pharmaceutical wholesale distributors, including us, have been named as defendants in over 3,000 lawsuits relating to the distribution of prescription opioid pain medications. The lawsuits seek equitable relief and monetary damages based on a variety of legal theories including various common law claims, such as public nuisance, negligence and unjust enrichment as well as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organizations Act and various other statutes. These lawsuits also name pharmaceutical manufacturers, retail pharmacy chains and other entities as defendants. States & Political Subdivisions Approximately 2,800 of these lawsuits have been filed by counties, municipalities, cities and political subdivisions in various federal, state, and other courts. The vast majority of these lawsuits were filed in U.S. federal court and have been transferred for consolidated pre-trial proceedings in a Multi-District Litigation proceeding in the U.S. District Court for the Northern District of Ohio (the “MDL”). In January 2020, the complaints of Cabell County and City of Huntington, West Virginia were remanded from the MDL to U.S. District Court in West Virginia. A trial date has been set for October 2020. In addition, the complaints of San Francisco, California and the Cherokee Nation have been remanded to their original district courts. In addition, 25 state attorneys general have filed lawsuits against distributors, including us, in various state courts. A trial in New York for cases brought by the New York Attorney General and Nassau and Suffolk counties was scheduled to begin in March 2020, but was deferred due to the COVID-19 pandemic. A trial is scheduled to begin in Madison County, Ohio, in October 2020 for the case brought by the Ohio Attorney General. A state court trial in a case brought by certain West Virginia political subdivisions is scheduled for March 2021. Additionally, we have received requests, civil investigative demands, subpoenas or requests for information from additional state attorneys general offices and governmental authorities. In October 2019, we agreed in principle to a global settlement framework with a leadership group of state attorneys general that is designed to resolve all pending and future opioid lawsuits and claims by states and political subdivisions (the "Settlement Framework"). This Settlement Framework is subject to contingencies and uncertainties as to final terms, but is the basis for our negotiation of definitive terms and documentation. The Settlement Framework includes (1) a cash component , pursuant to which we would pay up to $5.56 billion over eighteen years , (2) development and participation in a program for distribution of opioid abuse treatment medications for a period of ten years, and (3) to-be specified industry-wide changes to controlled substance anti-diversion programs. Definitive terms for a settlement pursuant to the Settlement Framework continue to be negotiated, and there is no assurance that the necessary parties will agree to a definitive settlement agreement or that the contingencies to any agreement will be satisfied. In connection with these matters, we have $5.56 billion accrued at June 30, 2020, included in deferred income taxes and other liabilities in the consolidated balance sheets, which represents the cash component. We are unable to estimate the range of possible loss associated with these matters. We are unable to reasonably estimate the liability or cost associated with the other components of the Settlement Framework, the potential distribution of treatment medications and any incremental costs for changes to our controlled substance anti-diversion program that we may agree to. In the fiscal year ended June 30, 2020, we along with two other national distributors entered into a $215 million settlement with two Ohio counties, Cuyahoga and Summit, to resolve all claims in the first bellwether trial in the MDL, which had been set for trial for October 2019. In connection with this settlement, we incurred $66 million within litigation (recoveries)/charges, net during the fiscal year ended June 30, 2020. In connection with these matters (including the settlement with two Ohio counties), we recorded a total pre-tax charge of $5.63 billion ( $5.14 billion after tax) during the fiscal year ended June 30, 2020 in litigation (recoveries)/charges, net, in the consolidated statement of earnings/(loss) for the cash component. Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual. We continue to strongly dispute the allegations made in these lawsuits and reaching an agreement in principle on a global settlement framework is not an admission of liability or wrongdoing. Private Plaintiffs The Settlement Framework does not address claims by private plaintiffs, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals. Private plaintiffs had brought approximately 400 lawsuits as of July 28, 2020. Of these, 106 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs relating to the distribution of controlled substances. We are vigorously defending ourselves in these matters. Department of Justice Investigations We have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). The subpoenas seek documents relating to our anti-diversion policies, procedures and program, and our distribution of certain controlled substances. We are cooperating with these requests. Product Liability Lawsuits As of July 28, 2020, we are named as a defendant in 334 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 4,280 plaintiffs that allege personal injuries associated with the use of Cordis OptEase and TrapEase inferior vena cava (IVC) filter products. Another 31 lawsuits involving similar claims by approximately 36 plaintiffs are pending in other jurisdictions. These lawsuits seek a variety of remedies, including unspecified monetary damages. We continue to vigorously defend ourselves in these lawsuits and have begun to engage in preliminary resolution discussions with plaintiffs. At June 30, 2020, we had a total of $468 million , net of estimated insurance recoveries, accrued for losses and legal defense costs related to the Cordis IVC filter lawsuits which are presented on a gross basis in the consolidated balance sheets. We believe there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, we have accrued the minimum amount in the range. We estimate the high end of the range to be approximately $919 million , net of estimated insurance recoveries. Shareholder Securities Litigation In August 2019, the Louisiana Sheriffs' Pension & Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. The complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934 by making misrepresentations and omissions related to the integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. In June 2020, the court appointed 1199 SEIU Health Care Employees Pension Fund as lead plaintiff. We believe that the claims asserted in this complaint are without merit and intend to vigorously defend against them. Surgical Gown Recalls In January 2020, we issued a voluntary recall for 9.1 million AAMI Level 3 surgical gowns and two voluntary field actions (a recall of some packs and a corrective action allowing overlabeling of other packs) for 2.9 million Presource Procedure Packs containing affected gowns (together, the "Recalls"). These Recalls were necessary because we discovered in December 2019 that one of our FDA-registered suppliers in China had shifted production of some gowns to unapproved sites with uncontrolled manufacturing environments. Because of this, we could not assure sterility of the gowns. In connection with these Recalls, in the fiscal year ended June 30, 2020, we recorded total charges of $85 million , of which $48 million is within cost of products sold and $37 million is within SG&A in the consolidated statements of earnings/(loss). This charge represents our best estimate of costs for the Recalls and includes inventory write-off costs and certain remediation and supply disruption costs, such as costs to replace recalled products. Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. Other Civil Litigation Generic Pharmaceutical Pricing Antitrust Litigation In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. We have filed a motion to dismiss the complaints and we intend to vigorously defend ourselves in this matter. Active Pharmaceutical Ingredient Impurity Litigation Many participants in the pharmaceutical supply chain, including active pharmaceutical ingredient ("API") manufacturers, finished dose manufacturers, repackagers (including us), distributors (including us), and retailers have been named as defendants in lawsuits arising out of recalls of certain medications due to alleged impurities in the active pharmaceutical ingredients or finished product. In February 2019, a Multidistrict Litigation was created in the U.S. District Court for the District of New Jersey (the “Sartan MDL”) alleging API impurities in certain generic blood pressure medications. We were recently named as a defendant in a Multidistrict Litigation alleging API impurities in Zantac and its generic form, ranitidine. We intend to vigorously defend ourselves in these matters. Antitrust Litigation Proceeds We received and recognized income resulting from settlements of lawsuits in which we were a class member or plaintiff of $16 million , $94 million and $22 million during fiscal 2020 , 2019 , and 2018 |
Fair Value Measurements
Fair Value Measurements | 12 Months Ended |
Jun. 30, 2020 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | 9. Fair Value Measurements The following tables present the fair values for assets and (liabilities) measured on a recurring basis at June 30: 2020 (in millions) Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 721 $ — $ — $ 721 Other investments (1) 114 — — 114 Forward contracts (2) — 53 — 53 2019 (in millions) Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 297 $ — $ — $ 297 Other investments (1) 118 — — 118 Forward contracts (2) — 53 — 53 (1) The other investments balance includes investments in mutual funds, which are used to offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high-quality fixed income debt securities. The fair value of these investments is determined using quoted market prices. (2) |
Financial Instruments
Financial Instruments | 12 Months Ended |
Jun. 30, 2020 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Financial Instruments | 10. Financial Instruments We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements. Interest Rate Risk Management We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities along with both fixed-rate and variable-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs. Currency Exchange Risk Management We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses. Commodity Price Risk Management We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases. The following table summarizes the fair value of our assets and liabilities related to derivatives designated as hedging instruments and the respective line items in which they were recorded in the consolidated balance sheets at June 30: (in millions) 2020 2019 Assets: Pay-floating interest rate swaps (1) $ 27 $ 46 Cross-currency swap (1) 47 12 Foreign currency contracts (2) — 6 Total assets $ 74 $ 64 Liabilities: Pay-floating interest rate swaps (3) $ — $ 6 Foreign currency contracts (4) 4 2 Forward interest rate swaps (3) 16 — Commodity contracts (4) 1 3 Total liabilities $ 21 $ 11 (1) Included in other assets in the consolidated balance sheets. (2) Included in prepaid expenses and other in the consolidated balance sheets. (3) Included in deferred income taxes and other liabilities in the consolidated balance sheets. (4) Included in other accrued liabilities in the consolidated balance sheets. Fair Value Hedges We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the consolidated statements of earnings/(loss). D uring fiscal 2020 and 2019 , there was no gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt. In May 2020 , we unwound certain interest rate swap contracts. In connection with the unwind of these contracts, we received cash proceeds of $112 million . The related gain will be recognized in interest expense, net in our statement of earnings/(loss) over the remaining term of the related debt agreements, which ranged from 48 months to 63 months at June 30, 2020 . In connection with the debt repayment as described in Note 6 , two pay-floating interest rate swaps with notional amounts of $200 million matured in the second quarter of fiscal 2020 . During fiscal 2019 , we terminated notional amounts of $163 million of pay-floating interest rate swaps in connection with the debt repurchases in fiscal 2019 described in Note 6 . These swaps were previously designated as fair value hedges. During fiscal 2018 we entered into pay-floating interest rate swaps with total notional amounts of $1.1 billion . These swaps have been designated as fair value hedges of our fixed rate debt and are included in deferred income taxes and other liabilities in the consolidated balance sheets. During fiscal 2018 , $550 million of pay-floating interest rate swaps matured. The following tables summarize the outstanding interest rate swaps designated as fair value hedges at June 30: 2020 (in millions) Notional Amount Maturity Date Pay-floating interest rate swaps $ 550 Mar 2023 2019 (in millions) Notional Amount Maturity Date Pay-floating interest rate swaps $ 2,150 Nov 2019 - Sep 2025 The following table summarizes the gain/(loss) recognized in earnings for interest rate swaps designated as fair value hedges: (in millions) 2020 2019 2018 Pay-floating interest rate swaps (1) $ 106 $ 9 $ 11 Fixed-rate debt (1) (106 ) (9 ) (11 ) (1) Included in interest expense, net in the consolidated statements of earnings/(loss). Cash Flow Hedges We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings. During fiscal 2020 , we entered into forward interest rate swaps with a total notional amount of $200 million to hedge probable, but not firmly committed, future transactions associated with our debt. All gains and losses currently included within accumulated other comprehensive loss associated with our cash flow hedges that are expected to be reclassified into net earnings within the next 12 months are immaterial. We enter into foreign currency contracts to protect the value of anticipated foreign currency revenues and expenses. At June 30, 2020 and 2019 , we held contracts to hedge probable, but not firmly committed, revenue and expenses. The principal currencies hedged are the Canadian dollar, Mexican peso, euro, Thai baht, Chinese renminbi, Japanese yen, Australian dollar, and British pound. We enter into commodity contracts to manage the price risk associated with forecasted purchases of certain commodities used in our Medical segment. The following tables summarize the outstanding cash flow hedges at June 30: 2020 (in millions) Notional Amount Maturity Date Forward interest rate swaps $ 200 Jun 2022 Foreign currency contracts 328 Jul 2020 - Jun 2021 Commodity contracts 16 Jul 2020 - Jun 2021 2019 (in millions) Notional Amount Maturity Date Foreign currency contracts $ 381 Jul 2019 - Jun 2020 Commodity contracts 20 Jul 2019 - Jun 2020 The following table summarizes the pre-tax gain/(loss) included in OCI for derivative instruments designated as cash flow hedges: (in millions) 2020 2019 2018 Forward interest rate swaps $ (16 ) $ — $ — Commodity contracts 1 (5 ) 3 Foreign currency contracts (8 ) 5 (1 ) The following table summarizes the pre-tax gain/(loss) reclassified from AOCI into earnings for derivative instruments designated as cash flow hedges: (in millions) 2020 2019 2018 Foreign currency contracts (1) $ 7 $ 2 $ 1 Foreign currency contracts (2) 1 — — Foreign currency contracts (3) — 1 (2 ) Forward interest rate swaps (4) 2 2 2 Commodity contracts (3) (5 ) — — (1) Included in revenue in the consolidated statements of earnings/(loss). (2) Included in cost of products sold in the consolidated statements of earnings/(loss). (3) Included in SG&A expenses in the consolidated statements of earnings/(loss). (4) Included in interest expense, net in the consolidated statements of earnings/(loss). Net Investment Hedges We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments. In August 2019, we entered into a ¥64 billion ( $600 million ) cross-currency swap maturing in 2022 . In September 2018 , we entered into a €200 million ( $233 million ) cross-currency swap maturing in 2023 . Cross-currency swaps designated as net investment hedges are marked-to-market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings. Pre-tax gain from net investment hedges recorded in other foreign currency translation was $35 million and $12 million during fiscal 2020 and 2019 , respectively. Gain recognized in interest expense, net in the consolidated statements of earnings/(loss) for the portion of the net investment hedges excluded from the assessment of hedge effectiveness was $17 million and $5 million during fiscal 2020 and 2019 , respectively. Economic (Non-Designated) Hedges We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. The principal currency managed through foreign currency contracts is the euro, Canadian dollar, British pound, Japanese yen, and Chinese renminbi. The following tables summarize the outstanding economic (non-designated) derivative instruments at June 30: 2020 (in millions) Notional Amount Maturity Date Foreign currency contracts $ 325 July 2020 2019 (in millions) Notional Amount Maturity Date Foreign currency contracts $ 488 Jul 2019 The following table summarizes the gain/(loss) recognized in earnings for economic (non-designated) derivative instruments: (in millions) 2020 2019 2018 Foreign currency contracts (1) $ (11 ) $ (13 ) $ (5 ) (1) Included in other income, net in the consolidated statements of earnings/(loss). Fair Value of Financial Instruments The carrying amounts of cash and equivalents, trade receivables, net, accounts payable, and other accrued liabilities at June 30, 2020 and 2019 approximate fair value due to their short-term maturities. The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at June 30: (in millions) 2020 2019 Estimated fair value $ 7,273 $ 8,065 Carrying amount 6,775 8,031 The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement. The following table is a summary of the fair value gain/(loss) of our derivative instruments based upon the estimated amount that we would receive (or pay), considering counter-party credit risk, to terminate the contracts at June 30: 2020 2019 (in millions) Notional Fair Value Notional Fair Value Pay-floating interest rate swaps $ 550 $ 27 $ 2,150 $ 40 Foreign currency contracts 653 (4 ) 869 4 Forward interest rate swaps 200 (16 ) — — Cross-currency swap 833 47 233 12 Commodity contracts 16 (1 ) 20 (3 ) |
Shareholders' Equity
Shareholders' Equity | 12 Months Ended |
Jun. 30, 2020 | |
Equity [Abstract] | |
Shareholders' Equity | 11. Shareholders' Equity At June 30, 2020 and 2019 , authorized capital shares consisted of the following: 750 million Class A common shares, without par value; 5 million Class B common shares, without par value; and 500 thousand non-voting preferred shares, without par value. The Class A common shares and Class B common shares are collectively referred to below as “common shares”. Holders of common shares are entitled to share equally in any dividends declared by the Board of Directors and to participate equally in all distributions of assets upon liquidation. Generally, the holders of Class A common shares are entitled to one vote per share, and the holders of Class B common shares are entitled to one-fifth of one vote per share on proposals presented to shareholders for vote. Under certain circumstances, the holders of Class B common shares are entitled to vote as a separate class. Only Class A common shares were outstanding at June 30, 2020 and 2019 . We repurchased $1.5 billion of our common shares, in the aggregate, through share repurchase programs during fiscal 2020 , 2019 and 2018 , as described below. We funded the repurchases with available cash and short term borrowings. The common shares repurchased are held in treasury to be used for general corporate purposes. During fiscal 2020 , we repurchased 7.3 million common shares having an aggregate cost of $350 million . The average price paid per common share was $48.00 . These repurchases were made under an accelerated share repurchase ("ASR") program, which began on August 20, 2019 and was completed on December 4, 2019 . During fiscal 2019 , we repurchased 11.5 million common shares having an aggregate cost of $600 million . The average price paid per common share was $52.32 . These repurchases were made under ASR program, which began on August 16, 2018 and was completed on October 25, 2018 . During fiscal 2018 , we repurchased 8.4 million common shares having an aggregate cost of $550 million . The average price paid per common share was $65.30 . These repurchases include $300 million purchased under an ASR program, which began on February 14, 2018 and was completed on March 21, 2018 . We repurchased 4.3 million shares under the ASR at an average price paid per share of $69.26 . Accumulated Other Comprehensive Loss The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total: (in millions) Foreign Currency Translation Adjustments and other Unrealized Gain/(Loss) on Derivatives, net of tax Accumulated Other Comprehensive Loss Balance at June 30, 2018 $ (113 ) $ 21 $ (92 ) Other comprehensive income/(loss), net before reclassifications 18 — 18 Amounts reclassified to earnings — (5 ) (5 ) Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax of $1 million 18 (5 ) 13 Balance at June 30, 2019 (95 ) 16 (79 ) Other comprehensive loss, before reclassifications 3 (23 ) (20 ) Amounts reclassified to earnings — (5 ) (5 ) Total comprehensive income/(loss) attributable to Cardinal Health, Inc., net of tax of $4 million 3 (28 ) (25 ) Balance at June 30, 2020 $ (92 ) $ (12 ) $ (104 ) |
Earnings Per Share Attributable
Earnings Per Share Attributable to Cardinal Health, Inc. | 12 Months Ended |
Jun. 30, 2020 | |
Earnings Per Share [Abstract] | |
Earnings Per Share Attributable to Cardinal Health, Inc. | 12. Earnings/(Loss) Per Share Attributable to Cardinal Health, Inc. The following table reconciles the computation of basic and diluted earnings per share attributable to Cardinal Health, Inc.: (in millions, except per share amounts) 2020 2019 2018 Net earnings/(loss) $ (3,693 ) $ 1,365 $ 259 Net earnings attributable to noncontrolling interest (3 ) (2 ) (3 ) Net earnings/(loss) attributable to Cardinal Health, Inc. $ (3,696 ) $ 1,363 $ 256 Weighted-average common shares–basic 293 300 313 Effect of dilutive securities: Employee stock options, restricted share units, and performance share units — 1 2 Weighted-average common shares–diluted 293 301 315 Basic earnings/(loss) per common share attributable to Cardinal Health, Inc.: $ (12.61 ) $ 4.55 $ 0.82 Diluted earnings/(loss) per common share attributable to Cardinal Health, Inc.: (12.61 ) 4.53 0.81 The potentially dilutive employee stock options, restricted share units and performance share units that were anti-dilutive for fiscal 2020 , 2019 and 2018 were 6 million , 7 million and 6 million , respectively. During fiscal 2020 , there were 2 million potentially dilutive employee stock options, restricted share units and performance share units not included in the computation of diluted loss per common share attributable to Cardinal Health, Inc. because their effect would be anti-dilutive as a result of the net loss for the fiscal year. |
Segment Information
Segment Information | 12 Months Ended |
Jun. 30, 2020 | |
Segment Reporting [Abstract] | |
Segment Information | 13. Segment Information Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities. Revenue Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates pharmacies, including pharmacies in community health centers, nuclear pharmacies and radiopharmaceutical manufacturing facilities; provides pharmacy management services to hospitals as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers; and repackages generic pharmaceuticals and over-the-counter healthcare products. Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of medical, surgical and laboratory products known as national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division. The following table presents revenue for each reportable segment and Corporate: (in millions) 2020 2019 2018 Pharmaceutical $ 137,495 $ 129,917 $ 121,241 Medical 15,444 15,633 15,581 Total segment revenue 152,939 145,550 136,822 Corporate (1) (17 ) (16 ) (13 ) Total revenue $ 152,922 $ 145,534 $ 136,809 (1) Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments. The following tables present revenue for each reportable segment and disaggregated revenue within our two reportable segments and Corporate: (in millions) 2020 2019 Pharmaceutical Distribution and Specialty Solutions (1) (2) $ 136,693 $ 129,067 Nuclear and Precision Health Solutions 802 850 Pharmaceutical segment revenue 137,495 129,917 Medical distribution and products (3) 13,429 13,833 Cardinal Health at-Home Solutions 2,015 1,800 Medical segment revenue 15,444 15,633 Total segment revenue 152,939 145,550 Corporate (4) (17 ) (16 ) Total revenue $ 152,922 $ 145,534 (1) Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services" (2) Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division. (3) Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division (4) Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments. The following table presents revenue by geographic area: (in millions) 2020 2019 2018 United States $ 148,707 $ 141,479 $ 132,539 International 4,232 4,071 4,283 Total segment revenue 152,939 145,550 136,822 Corporate (1) (17 ) (16 ) (13 ) Total revenue $ 152,922 $ 145,534 $ 136,809 (1) Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments. Segment Profit We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general, and administrative ("SG&A") expenses. Segment SG&A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology, legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit. We do not allocate the following items to our segments: last-in first-out, or ("LIFO"), inventory charges/(credits); surgical gown recall costs; state opioid assessment related to prior fiscal years; restructuring and employee severance; amortization and other acquisition-related costs; impairments and (gain)/loss on disposal of assets; litigation (recoveries)/charges, net; other (income)/expense, net; interest expense, net; loss on early extinguishment of debt; gain on sale of equity interest in naviHealth and provision for/(benefit from) income taxes. In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $69 million , $55 million and $43 million for fiscal 2020 , 2019 and 2018 , respectively. In connection with the opioid litigation as discussed further in Note 7 , we recognized a pre-tax charge of $5.63 billion during fiscal 2020 which was retained at Corporate. In connection with the surgical gown recall as discussed further in Note 7 , we recognized a pre-tax charge of $85 million during fiscal 2020 which was retained at Corporate. In connection with the naviHealth divestiture discussed in Note 2 , we recognized a pre-tax gain of $508 million during fiscal 2019 which was retained at Corporate. In connection with the sale of our remaining equity interest in a partnership that owned naviHealth as discussed in Note 2 , we recognized a $579 million pre-tax gain ( $493 million after tax) during fiscal 2020 , which is included in gain on sale of equity interest naviHealth in the consolidated statements of earnings/(loss) and did not impact segment profit or operating earnings . The following tables present segment profit by reportable segment and Corporate: (in millions) 2020 2019 2018 Pharmaceutical $ 1,753 $ 1,834 $ 1,992 Medical 663 576 662 Total segment profit 2,416 2,410 2,654 Corporate (6,514 ) (350 ) (2,528 ) Total operating earnings $ (4,098 ) $ 2,060 $ 126 The following tables present depreciation and amortization and additions to property and equipment by reportable segment and Corporate: (in millions) 2020 2019 2018 Pharmaceutical $ 135 $ 147 $ 156 Medical 243 288 278 Corporate 535 565 598 Total depreciation and amortization $ 913 $ 1,000 $ 1,032 (in millions) 2020 2019 2018 Pharmaceutical $ 47 $ 35 $ 58 Medical 86 74 127 Corporate 242 219 199 Total additions to property and equipment $ 375 $ 328 $ 384 The following table presents total assets for each reportable segment and Corporate at June 30: (in millions) 2020 2019 2018 Pharmaceutical $ 22,398 $ 22,446 $ 21,421 Medical 14,691 15,284 16,066 Corporate 3,677 3,233 2,464 Total assets $ 40,766 $ 40,963 $ 39,951 The following tables present property and equipment, net by geographic area: (in millions) 2020 2019 2018 United States $ 1,880 $ 1,846 $ 1,950 International 486 510 537 Property and equipment, net $ 2,366 $ 2,356 $ 2,487 |
Share-Based Compensation
Share-Based Compensation | 12 Months Ended |
Jun. 30, 2020 | |
Share-based Payment Arrangement [Abstract] | |
Share-Based Compensation | 14. Share-Based Compensation We maintain stock incentive plans (collectively, the “Plans”) for the benefit of certain of our officers, directors and employees. At June 30, 2020 , 12 million shares remain available for future grants under the Amended Cardinal Health, Inc. 2011 Long-Term Incentive Plan ("2011 LTIP"). Under the 2011 LTIP's fungible share counting provisions, stock options are counted against the plan as one share for every share issued ; awards other than stock options are counted against the plan as two and one-half shares for every share issued . This means that only 5 million shares could be issued under awards other than stock options while 12 million shares could be issued under stock options. Shares are issued out of treasury shares when stock options are exercised and when restricted share units and performance share units vest. The following table provides total share-based compensation expense by type of award: (in millions) 2020 2019 2018 Restricted share unit expense $ 70 $ 63 $ 73 Employee stock option expense 3 10 22 Performance share unit expense 17 9 (10 ) Total share-based compensation expense $ 90 $ 82 $ 85 The total tax benefit related to share-based compensation was $16 million , $16 million and $23 million for fiscal 2020 , 2019 and 2018 , respectively. Restricted Share Units Restricted share units granted under the Plans generally vest in equal annual installments over three years . Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards. The following table summarizes all transactions related to restricted share units under the Plans: (in millions, except per share amounts) Restricted Share Units Weighted-Average Grant Date Fair Value per Share Nonvested at June 30, 2018 2 $ 71.58 Granted 2 50.13 Vested (1 ) 74.52 Canceled and forfeited (1 ) 62.32 Nonvested at June 30, 2019 2 51.65 Granted 2 42.71 Vested (1 ) 60.21 Canceled and forfeited — — Nonvested at June 30, 2020 3 $ 45.92 The following table provides additional data related to restricted share unit activity: (in millions) 2020 2019 2018 Total compensation cost, net of estimated forfeitures, related to nonvested restricted share and share unit awards not yet recognized, pre-tax $ 77 $ 75 $ 78 Weighted-average period in years over which restricted share and share unit cost is expected to be recognized (in years) 2 2 2 Total fair value of shares vested during the year $ 57 $ 68 $ 65 Stock Options Employee stock options granted under the Plans generally vest in equal annual installments over three years and are exercisable for a period up to ten years from the grant date. All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date. The following table summarizes all stock option transactions under the Plans: (in millions, except per share amounts) Stock Options Weighted-Average Exercise Price per Common Share Outstanding at June 30, 2018 7 $ 64.50 Granted — — Exercised — — Canceled and forfeited (1 ) 72.54 Outstanding at June 30, 2019 6 63.78 Granted — — Exercised (1 ) 42.36 Canceled and forfeited — — Outstanding at June 30, 2020 5 $ 65.15 Exercisable at June 30, 2020 5 $ 65.25 The following table provides additional detail related to stock options: (in millions, except per share amounts) 2020 2019 2018 Aggregate intrinsic value of outstanding options at period end $ 12 $ 10 $ 13 Aggregate intrinsic value of exercisable options at period end 12 10 13 Aggregate intrinsic value of exercised options 8 1 14 Net proceeds/(withholding) from share-based compensation 26 3 (3 ) Excess tax benefits from share based compensation 6 7 10 Total compensation cost, net of estimated forfeitures, related to unvested stock options not yet recognized, pre-tax 1 5 17 Total fair value of shares vested during the year 8 20 19 Weighted-average grant date fair value per stock option $ 8.26 $ 8.34 $ 13.50 (in years) 2020 2019 2018 Weighted-average remaining contractual life of outstanding options 5 5 7 Weighted-average remaining contractual life of exercisable options 5 5 5 Weighted-average period over which stock option compensation cost is expected to be recognized 1 1 2 Until the end of fiscal 2018, stock options were granted to our officers and certain employees. The fair values were estimated on the grant date using a lattice valuation model. We believe the lattice model provides reasonable estimates because it has the ability to take into account individual exercise patterns based on changes in our stock price and other variables, and it provides for a range of input assumptions, which are disclosed in the table below. The risk-free rate is based on the U.S. Treasury yield curve at the time of the grant. We analyzed historical data to estimate option exercise behaviors and employee terminations to be used within the lattice model. The expected life of the options granted was calculated from the option valuation model and represents the length of time in years that the options granted are expected to be outstanding. Expected volatilities are based on implied volatility from traded options on our common shares and historical volatility over a period of time commensurate with the contractual term of the option grant (up to ten years ). There were no stock options granted to employees during fiscal year 2020 or 2019 . The following table provides the range of assumptions used to estimate the fair value of stock options: 2018 Risk-free interest rate 2.1% Expected volatility 25% Dividend yield 2.7% - 2.8% Expected life in years 7 Performance Share Units Performance share units generally vest over a three -year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 240 percent of the target award amount. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards. The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts): (in millions, except per share amounts) Performance Share Units Weighted-Average Grant Date Fair Value per Share Nonvested at June 30, 2018 0.4 $ 66.13 Granted 0.6 50.96 Vested — — Canceled and forfeited (0.1 ) 52.20 Nonvested at June 30, 2019 0.9 51.45 Granted 0.7 44.03 Vested (0.1 ) 48.40 Canceled and forfeited (0.2 ) 50.92 Nonvested at June 30, 2020 1.3 $ 54.24 The following table provides additional data related to performance share unit activity: (in millions) 2020 2019 2018 Total compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized, pre-tax $ 29 $ 12 $ 1 Weighted-average period over which performance share unit cost is expected to be recognized (in years) 2 2 2 Total fair value of shares vested during the year $ 5 $ — $ 14 Employee Retirement Savings Plans Substantially all of our domestic non-union employees are eligible to be enrolled in our company-sponsored contributory retirement savings plans, which include features under Section 401(k) of the Internal Revenue Code of 1986, and provide for matching and discretionary contributions by us. The total expense for our employee retirement savings plans was $66 million , $99 million and $129 million for fiscal 2020 , 2019 and 2018 , respectively. |
Selected Quarterly Financial Da
Selected Quarterly Financial Data (Unaudited) | 12 Months Ended |
Jun. 30, 2020 | |
Quarterly Financial Information Disclosure [Abstract] | |
Selected Quarterly Financial Data (Unaudited) | 15. Selected Quarterly Financial Data (Unaudited) The following is selected quarterly financial data for fiscal 2020 and 2019 . The sum of the quarters may not equal year-to-date due to rounding. (in millions, except per common share amounts) First Second Third Fourth Fiscal 2020 Revenue $ 37,341 $ 39,735 $ 39,157 $ 36,689 Gross margin 1,679 1,714 1,885 1,590 Distribution, selling, general and administrative expenses 1,107 1,163 1,165 1,137 Net earnings/(loss) (4,921 ) 220 351 657 Less: Net earnings attributable to noncontrolling interests (1 ) — (1 ) (1 ) Net earnings/(loss) attributable to Cardinal Health, Inc. (4,922 ) 220 350 656 Net earnings/(loss) attributable to Cardinal Health, Inc. per common share: Basic $ (16.65 ) $ 0.75 $ 1.20 $ 2.25 Diluted (16.65 ) 0.75 1.19 2.23 (1) Includes a $5.63 billion pre-tax charge for the opioid litigation ( $5.14 billion after tax). (2) Includes a $579 million pre-tax gain ( $493 million after tax) in connection with the sale of our remaining equity interest in a partnership that owned naviHealth. (in millions, except per common share amounts) First Second Third Fourth Fiscal 2019 Revenue $ 35,213 $ 37,740 $ 35,228 $ 37,353 Gross margin 1,667 1,730 1,764 1,674 Distribution, selling, general and administrative expenses 1,155 1,064 1,097 1,168 Net earnings/(loss) 594 281 296 194 Less: Net earnings attributable to noncontrolling interests (1 ) (1 ) — — Net earnings/(loss) attributable to Cardinal Health, Inc. 593 280 296 194 Net earnings/(loss) attributable to Cardinal Health, Inc. per common share: Basic $ 1.95 $ 0.94 $ 0.99 $ 0.65 Diluted (3) 1.94 0.93 0.99 0.65 (1) Includes a $508 million gain ( $378 million after tax) related to the naviHealth divestiture. |
Schedule II - Valuations and Qu
Schedule II - Valuations and Qualifying Accounts | 12 Months Ended |
Jun. 30, 2020 | |
Schedule II [Abstract] | |
SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] | Cardinal Health, Inc. and Subsidiaries Schedule II - Valuation and Qualifying Accounts (in millions) Balance at Beginning of Period Charged to Costs and Expenses (1) Charged to Other Accounts (2) Deductions (3) Balance at End of Period Fiscal 2020 Accounts receivable $ 193 $ 139 $ 1 $ (127 ) $ 206 Finance notes receivable 14 15 — (2 ) 27 Sales returns and allowances 479 2,253 — (2,237 ) 495 Other 1 — — — 1 $ 687 $ 2,407 $ 1 $ (2,366 ) $ 729 Fiscal 2019 Accounts receivable $ 139 $ 140 $ 1 $ (87 ) $ 193 Finance notes receivable 7 8 — (1 ) 14 Sales returns and allowances 479 2,205 — (2,205 ) 479 Other 1 — — — 1 $ 626 $ 2,353 $ 1 $ (2,293 ) $ 687 Fiscal 2018 Accounts receivable $ 137 $ 113 $ 1 $ (111 ) $ 139 Finance notes receivable 9 (2 ) — — 7 Sales returns and allowances 347 2,402 — (2,270 ) 479 Other 1 — — — 1 $ 494 $ 2,513 $ 1 $ (2,381 ) $ 626 (1) Fiscal 2020 , 2019 and 2018 include $49 million , $60 million and $37 million , respectively, for reserves related to service charges and customer pricing disputes, excluded from provision for bad debts on the consolidated statements of cash flows and classified as a reduction in revenue in the consolidated statements of earnings/(loss). (2) Recoveries of amounts provided for or written off in prior years was $1 million in each fiscal year 2020 , 2019 and 2018 . (3) Write-off of uncollectible accounts or actual sales returns. |
Basis of Presentation and Sum_2
Basis of Presentation and Summary of Significant Accounting Policies (Policies) | 12 Months Ended |
Jun. 30, 2020 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation Our consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively. |
Use of Estimates | Use of Estimates Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of financial statements in accordance with GAAP requires us to make estimates, judgments and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Estimates, judgments and assumptions are used in the accounting and disclosure related to, among other items, allowance for doubtful accounts, inventory valuation and reserves, goodwill and other intangible asset impairment, loss contingencies (including product liability and self-insurance accruals), and income taxes. Actual amounts could ultimately differ from these estimated amounts. The outbreak of the novel strain of coronavirus (“COVID-19”) has severely impacted, and continues to severely impact the U.S. and global economies, and beginning in the third quarter of fiscal 2020, our businesses have been impacted in a variety of ways. We cannot estimate the length or severity of the COVID-19 pandemic or the related U.S. and global economic consequences on our business and operations, including whether and when historic economic and operating conditions will resume or the extent to which the disruption may impact our business, financial position, results of operations or cash flow. Our e stimates, judgments and assumptions related to COVID-19 could ultimately differ over time . |
Cash Equivalents | Cash Equivalents We consider liquid investments purchased with an initial maturity of three months or less to be cash equivalents. The carrying value of cash equivalents approximates fair value. |
Receivables | Receivables and Allowance for Doubtful Accounts Trade receivables are presented net of an allowance for doubtful accounts of $206 million and $193 million at June 30, 2020 and 2019 , respectively. An account is considered past due on the first day after its due date. In accordance with contract terms, we generally have the ability to charge customers service fees or higher prices if an account is considered past due. We regularly monitor past due accounts and establish appropriate reserves to cover potential losses, which are based primarily on historical collection rates and the credit worthiness of the customer. We write off any amounts deemed uncollectible against the established allowance for doubtful accounts. We provide financing to various customers. Such financing arrangements range from 1 year to 5 years at interest rates that are generally subject to fluctuation. Interest income on these arrangements is recognized as it is earned. The financings may be collateralized, guaranteed by third parties or unsecured. Finance notes, net and related accrued interest were $104 million (current portion $12 million ) and $103 million (current portion $12 million ) at June 30, 2020 and 2019 , respectively, and are included in other assets (current portion is included in prepaid expenses and other) in the consolidated balance sheets. Finance notes receivable allowance for doubtful accounts were $27 million and $14 million at June 30, 2020 and 2019 , respectively. We estimate an allowance for these financing receivables based on historical collection rates and the credit worthiness of the customer. We write off any amounts deemed uncollectible against the established allowance for doubtful accounts. |
Concentrations of Credit Risk | Concentrations of Credit Risk We maintain cash depository accounts with major banks, and we invest in high quality, short-term liquid instruments, and in marketable securities. Our short-term liquid instruments mature within three months and we have not historically incurred any related losses. |
Major Customers | Major Customers CVS Health Corporation ("CVS") and OptumRx, are our only customers that individually account for at least 10 percent of revenue and gross trade receivables. These customers are primarily serviced through our Pharmaceutical segment. The following table summarizes historical percent of revenue and gross trade receivables from CVS and OptumRx: Percent of Revenue Percent of Gross Trade Receivables at June 30 2020 2019 2018 2020 2019 CVS 26 % 26 % 25 % 26 % 24 % OptumRx 14 % 13 % 11 % 6 % 4 % We have entered into agreements with group purchasing organizations (“GPOs”) which act as purchasing agents that negotiate vendor contracts on behalf of their members. Vizient, Inc. and Premier, Inc. are our two largest GPO member relationships in terms of revenue. Sales to members of these two GPOs collectively accounted for 16 percent , 22 percent and 22 percent of revenue for fiscal 2020 , 2019 and 2018 |
Inventories | Inventories A substantial portion of our inventories ( 56 percent at both June 30, 2020 and 2019 ) are valued at the lower of cost, using the last-in, first-out ("LIFO") method, or market. These inventories are included within the core pharmaceutical distribution facilities of our Pharmaceutical segment (“distribution facilities”) and are primarily merchandise inventories. The LIFO method presumes that the most recent inventory purchases are the first items sold, so LIFO helps us better match current costs and revenue. We believe that the average cost method of inventory valuation provides a reasonable approximation of the current cost of replacing inventory within the distribution facilities. As such, the LIFO reserve is the difference between (a) inventory at the lower of LIFO cost or market and (b) inventory at replacement cost determined using the average cost method of inventory valuation. At June 30, 2020 and 2019 , respectively, inventories valued at LIFO cost were $411 million and $230 million higher than the average cost value. We do not record inventories in excess of replacement cost. As such, we did not write-up the value of our inventory from average cost to LIFO cost at June 30, 2020 or 2019 . Our remaining inventory that is not valued at the lower of LIFO cost or market is stated at the lower of cost, using the first-in, first-out method, or net realizable value. Net realizable value is defined as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Inventories presented in the consolidated balance sheets are net of reserves for excess and obsolete inventory which were $155 million and $171 million at June 30, 2020 and 2019 , respectively. We reserve for inventory obsolescence using estimates based on historical experience, historical and projected sales trends, specific categories of inventory, age and expiration dates of on-hand inventory and manufacturer return policies. |
Cash Discounts | Cash Discounts Manufacturer cash discounts are recorded as a component of inventory cost and recognized as a reduction of cost of products sold as inventory is sold. |
Property and Equipment | Property and Equipment Property and equipment are carried at cost less accumulated depreciation. Property and equipment held for sale are recorded at the lower of cost or fair value less cost to sell. When certain events or changes in operating conditions occur, an impairment assessment may be performed on the recoverability of the carrying amounts. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, including finance lease assets which are depreciated over the terms of their respective leases. We generally use the following range of useful lives for our property and equipment categories: buildings and improvements— 3 to 39 years ; machinery and equipment— 3 to 20 years ; and furniture and fixtures— 3 to 7 years . We recorded depreciation and amortization expense of $405 million , $455 million and $446 million for fiscal 2020 , 2019 and 2018 , respectively. The following table presents the components of property and equipment, net at June 30: (in millions) 2020 2019 Land, building and improvements $ 2,185 $ 1,992 Machinery and equipment 3,008 3,038 Furniture and fixtures 138 138 Total property and equipment, at cost 5,331 5,168 Accumulated depreciation and amortization (2,965 ) (2,812 ) Property and equipment, net $ 2,366 $ 2,356 Repairs and maintenance expenditures are expensed as incurred. Interest on long-term projects is capitalized using a rate that approximates the weighted-average interest rate on long-term obligations, which was 3 percent at June 30, 2020 . The amount of capitalized interest was immaterial for all periods presented. |
Goodwill and Other Intangible Assets | Goodwill and Other Intangible Assets Purchased goodwill and intangible assets with indefinite lives are not amortized, but instead are tested for impairment annually or when indicators of impairment exist. Purchased goodwill is tested for impairment at least annually. Qualitative factors are first assessed to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount. There is an option to bypass the qualitative assessment for any reporting unit in any period and proceed directly to performing the quantitative goodwill impairment test. We have elected to bypass the qualitative assessment for our annual goodwill impairment test in the current year. The quantitative goodwill impairment test involves a comparison of the estimated fair value of the reporting unit to the respective carrying amount. Goodwill impairment testing involves judgment, including the identification of reporting units, qualitative evaluation of events and circumstances to determine if it is more likely than not that an impairment exists, and, if necessary, the estimation of the fair value of the applicable reporting unit. We have two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. These operating segments are comprised of divisions (components), for which discrete financial information is available. Components are aggregated into reporting units for purposes of goodwill impairment testing to the extent that they share similar economic characteristics. Our reporting units are: Pharmaceutical operating segment (excluding our Nuclear and Precision Health Solutions division); Nuclear and Precision Health Solutions division; Medical operating segment (excluding our Cardinal Health at-Home Solutions division) (“Medical Unit”); and Cardinal Health at-Home Solutions division. Our Nuclear and Precision Health Solutions division was formerly referred to as our Nuclear Pharmacy Services division and our Cardinal Health at-Home Solutions division was formerly referred to as our Cardinal Health at Home division. Fair value can be determined using market, income or cost-based approaches. Our determination of estimated fair value of the reporting units is based on a combination of the income-based and market-based approaches. Under the income-based approach, we use a discounted cash flow model in which cash flows anticipated over several future periods, plus a terminal value at the end of that time horizon, are discounted to their present value using an appropriate risk-adjusted rate of return. We use our internal forecasts to estimate future cash flows, which we believe are consistent with those of a market participant, and include an estimate of long-term growth rates based on our most recent views of the long-term outlook for each reporting unit. Actual results may differ materially from those used in our forecasts. We use discount rates that are commensurate with the risks and uncertainty inherent in the respective reporting units and in our internally-developed forecasts. Discount rates used in our reporting unit valuations ranged from 8.5 percent to 10.5 percent . Under the market-based guideline public company method, we determine fair value by comparing our reporting units to similar businesses or guideline companies whose securities are actively traded in public markets. We also use the guideline transaction method to determine fair value based on pricing multiples derived from the sale of companies that are similar to our reporting units. To further confirm fair value, we compare the aggregate fair value of our reporting units to our total market capitalization. Estimating the fair value of reporting units requires the use of estimates and significant judgments that are based on a number of factors including forecasted operating results. The use of alternate estimates and assumptions or changes in the industry or peer groups could materially affect the determination of fair value for each reporting unit and potentially result in goodwill impairment. We performed annual impairment testing in fiscal 2020 , 2019 and 2018 and with the exception of our Medical Unit in fiscal 2018 , concluded that there were no impairments of goodwill as the estimated fair value of each reporting unit exceeded its carrying value. In conjunction with the preparation of our consolidated financial statements for fiscal 2018, we completed our annual quantitative goodwill impairment test, which we perform annually in the fourth quarter. Using a combination of income and market-based approaches (using a discount rate of 8.5 percent ), the carrying value exceeded the fair value and resulted in an impairment charge of $1.4 billion related to our Medical Unit, which is included in impairments and loss on disposal of assets in our consolidated statements of earnings/(loss). Our fair value estimates utilize significant unobservable inputs and thus represent Level 3 fair value measurements. The impairment was primarily driven by inventory and cost challenges within our Cordis business which furthered in the fourth quarter of fiscal 2018 . This impairment charge did not impact our liquidity, cash flows from operations, or compliance with debt covenants. There was no tax benefit related to the goodwill impairment charge. The impairment test for indefinite-lived intangibles other than goodwill (primarily IPR&D) involves first assessing qualitative factors to determine if it is more likely than not that the fair value of the indefinite-lived intangible asset is less than its carrying amount. If so, then a quantitative test is performed to compare the estimated fair value of the indefinite-lived intangible asset to the respective asset's carrying amount. Our qualitative evaluation requires the use of estimates and significant judgments and considers the weight of evidence and significance of all identified events and circumstances and most relevant drivers of fair value, both positive and negative, in determining whether it is more likely than not that the fair value of the indefinite-lived intangible asset is less than its carrying amount. Intangible assets with finite lives, primarily customer relationships; trademarks, trade names and patents; and developed technology, are amortized using a combination of straight-line and accelerated methods based on the expected cash flows from the asset over their estimated useful lives. We review intangible assets with finite lives for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable. Determining whether an impairment loss occurred requires a comparison of the carrying amount to the sum of the future forecasted undiscounted cash flows expected to be generated by the asset group. Actual results may differ materially from those used in our forecasts. |
Assets Held for Sale, Policy [Policy Text Block] | Assets Held for Sale We classify assets and liabilities (the “disposal group”) as held for sale when management commits to a plan to sell the disposal group in its present condition and at a price that is reasonable in relation to its current fair value. We also consider whether an active program to locate a buyer has been initiated and if it is probable that the sale will occur within one year without significant changes to the plan to sell. Upon classification of the disposal group as held for sale, we test the assets for impairment and cease related depreciation and amortization. |
Investments | Investments Investments in non-marketable equity securities are accounted for under the fair value, equity or net asset value method of accounting and are included in other assets in the consolidated balance sheets. For equity securities without a readily determinable fair value, we use the fair value measurement alternative and measure the securities at cost less impairment, if any, including adjustments for observable price changes in orderly transactions for an identical or similar investment of the same issuer. For investments in which we can exercise significant influence but do not control, we use the equity method of accounting. Our share of the earnings and losses are recorded in other (income)/expense, net in the consolidated statements of earnings/(loss). We monitor our investments for impairment by considering factors such as the operating performance of the investment and current economic and market conditions. |
Vendor Reserves | Vendor Reserves In the ordinary course of business, our vendors may dispute deductions taken against payments otherwise due to them or assert other disputes. These disputes are researched and resolved based upon the findings of the research performed. At any given time, there are outstanding items in various stages of research and resolution. In determining appropriate reserves for areas of exposure with our vendors, we assess historical experience and current outstanding claims. We have established various levels of reserves based on the type of claim and status of review. Though the claim types are relatively consistent, we periodically refine our methodology by updating the reserve estimate percentages to reflect actual historical experience. The ultimate outcome of certain claims may be different than our original estimate and may require an adjustment. Adjustments to vendor reserves are included in cost of products sold. In addition, the reserve balance will fluctuate due to variations of outstanding claims from period-to-period, timing of settlements and specific vendor issues, such as bankruptcies. Vendor reserves were $77 million and $53 million at June 30, 2020 and 2019 , respectively, excluding third-party returns. See Third-Party Returns section within this Note for a description of third-party returns. |
Distribution Service Agreement and Other Vendor Fees | Distribution Services Agreement and Other Vendor Fees Our Pharmaceutical segment recognizes fees received from distribution services agreements and other fees received from vendors related to the purchase or distribution of the vendors’ inventory when those fees have been earned and we are entitled to payment. Since the benefit provided to a vendor is related to the purchase and distribution of the vendor’s inventory, we recognize the fees as a reduction in the carrying value of the inventory that generated the fees, and as such, a reduction of cost of products sold in our consolidated statements of earnings/(loss) when the inventory is sold. |
Loss Contingencies | Loss Contingencies and Self-Insurance We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. In connection with the opioid litigation as described further in the Note 7 , we recorded a pre-tax charge of $5.63 billion ( $5.14 billion after tax) during fiscal 2020. Definitive terms of a settlement under the Settlement Framework continue to be negotiated, and there is no assurance that the necessary parties will agree to a definitive settlement agreement or that the contingencies to any agreement will be satisfied. We develop and periodically update reserve estimates for the Cordis inferior vena cava ("Cordis IVC") claims, including those received to date and expected to be received in the future and related costs. To project future Cordis IVC claim costs, we use a methodology based largely on recent experience, including claim filing rates, estimated indemnity severity by claim type, sales data, implant and injury to report lag patterns and estimated defense costs. We also self-insure for employee healthcare, general liability, certain product liability matters, auto liability, property and workers' compensation. Self-insurance accruals include an estimate for expected settlements or pending claims, defense costs, administrative fees, claim adjustment costs and an estimate for claims incurred but not reported. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies and other liabilities is highly subjective and requires judgments about future events. We regularly review contingencies and our self-insurance accruals to determine whether our accruals and related disclosures are adequate. Any adjustments for changes in reserves are recorded in the period in which the change in estimate occurs. The amount of ultimate loss may differ materially from these estimates. We recognize these estimated loss contingencies, income from favorable resolution of litigation and certain defense costs in litigation (recoveries)/charges in our consolidated statements of earnings/(loss). See Note 7 for additional information regarding loss contingencies and product liability lawsuits. |
Income Taxes | Income Taxes We account for income taxes using the asset and liability method. Deferred tax assets and liabilities are measured using enacted tax rates in the respective jurisdictions in which we operate . We assess the realizability of deferred tax assets on a quarterly basis and provide a valuation allowance for deferred tax assets when it is more likely than not that at least a portion of the deferred tax assets will not be realized. The realizability of deferred tax assets depends on our ability to generate sufficient taxable income within the carryback or carryforward periods provided for in the tax law for each applicable tax jurisdiction and also considers all available positive and negative evidence. Deferred taxes for non-U.S. liabilities are not provided on the unremitted earnings of subsidiaries outside of the United States when it is expected that these earnings are indefinitely reinvested. We operate in a complex multinational tax environment and are subject to tax treaty arrangements and transfer pricing guidelines for intercompany transactions that are subject to interpretation. Uncertainty in a tax position may arise as tax laws are subject to interpretation. Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination of the technical merits of the position, including resolutions of any related appeals or litigation processes. The amount recognized is measured as the largest amoun t of tax benefit that is greater than 50 percent likely of being realized upon settlement. For tax benefits that do not qualify for recognition, we recognize a liability for unrecognized tax benefits. See Note 8 for additional information regarding income taxes. |
Other Accrued Liabilities, Policy [Policy Text Block] | Other Accrued Liabilities Other accrued liabilities represent various current obligations, including certain accrued operating expenses and taxes payable. |
Noncontrolling Interests and Redeemable Noncontrolling Interests | Noncontrolling Interests Noncontrolling interests represent the portion of net earnings, comprehensive income and net assets that is not attributable to Cardinal Health, Inc. |
Share-Based Compensation | Share-Based Compensation Share-based compensation provided to employees is recognized in the consolidated statements of earnings/(loss) based on the grant date fair value of the awards. The fair value of restricted share units and performance share units is determined by the grant date market price of our common shares. The fair value of stock options is determined on the grant date using a lattice valuation model. The compensation expense associated with nonvested performance share units is dependent on our periodic assessment of the probability of the targets being achieved and our estimate, which may vary over time, of the number of shares that ultimately will be issued. The compensation expense recognized for share-based awards is net of estimated forfeitures and is recognized ratably over the service period of the awards. All income tax effects of share-based awards are recognized in the consolidated statements of earnings/(loss) as awards vest or are settled. We classify share-based compensation expense in distribution, selling, general and administrative ("SG&A") expenses to correspond with the same line item as the majority of the cash compensation paid to employees. If awards are modified in connection with a restructuring activity, the incremental share-based compensation expense is classified in restructuring and employee severance. See Note 14 for additional information regarding share-based compensation. |
Dividends, Policy [Policy Text Block] | Dividends We paid cash dividends per common share of $1.92 , $1.91 and $1.85 in fiscal 2020 , 2019 and 2018 , respectively. |
Revenue Recognition | Revenue Recognition We recognize revenue in an amount that reflects the consideration to which we expect to be entitled in exchange for the transfer of goods or services to customers. Revenue in both segments is primarily related to the distribution of pharmaceutical and medical products, which include both manufactured and sourced products, and we recognize at a point in time when title transfers to customers and we have no further obligation to provide services related to such merchandise. Service revenues are recognized over the period that services are provided to the customer. Revenues derived from services are not material for either segment for all periods presented. We are generally the principal in a transaction, therefore our revenue is primarily recorded on a gross basis. When we are a principal in a transaction, we have determined that we control the ability to direct the use of the product or service prior to transfer to a customer, are primarily responsible for fulfilling the promise to provide the product or service to our customer, have discretion in establishing prices, and ultimately control the transfer of the product or services provided to the customer. |
Sales Returns and Allowances | Sales Returns and Allowances Revenue is recorded net of sales returns and allowances. Revenues are measured based on the amount of consideration that we expect to receive, reduced by estimates for return allowances, discounts, rebates and other variable consideration. Sales returns are recorded based on estimates using historical data. Our customer return policies generally require that the product be physically returned, subject to restocking fees. We only allow customers to return products for credit in a condition suitable to be added back to inventory and resold at full value (“merchantable product”) or returned to vendors for credit. Product returns are generally consistent throughout the year and typically are not specific to any particular product or customer. We accrue for estimated sales returns and allowances at the time of sale based upon historical customer return trends, margin rates and processing costs. Our accrual for sales returns is reflected as a reduction of revenue and cost of products sold for the sales price and cost, respectively. At both June 30, 2020 and 2019 , the accrual for estimated sales returns and allowances was $495 million and $479 million , the impact of which is reflected in trade receivables, net and inventories, net in the consolidated balance sheets. Sales returns and allowances were $2.3 billion , $2.2 billion and $2.4 billion , for fiscal 2020 , 2019 and 2018 , respectively, and the net impact on net earnings/(loss) in the consolidated statements of earnings/(loss) was immaterial in fiscal 2020 , 2019 and 2018 . Third-Party Returns We generally do not accept non-merchantable pharmaceutical product returns from our customers, so many of our customers return non-merchantable pharmaceutical products to the manufacturer through third parties. Since our customers generally do not have a direct relationship with manufacturers, our vendors pass the value of such returns to us (usually in the form of an accounts payable deduction). We, in turn, pass the value received to our customer. In certain instances, we pass the estimated value of the return to our customer prior to our receipt of the value from the vendor. Although we believe we have satisfactory protections, we could be subject to claims from customers or vendors if our administration of this overall process was deficient in some respect or our contractual terms with vendors are in conflict with our contractual terms with our customers. We have maintained reserves for some of these situations based on their nature and our historical experience with their resolution. |
Shipping and Handling | Shipping and Handling Shipping and handling costs are primarily included in SG&A expenses in our consolidated statements of earnings/(loss) and include all delivery expenses as well as all costs to prepare the product for shipment to the end customer. Shipping and handling costs were $620 million , $622 million and $543 million , for fiscal 2020 , 2019 and 2018 , respectively. |
Restructuring and Employee Severance | Restructuring and Employee Severance Restructuring activities are programs that are not part of the ongoing operations of our underlying business, such as closing and consolidating facilities, changing the way we manufacture or distribute our products, moving manufacturing of a product to another location, changes in production or business process outsourcing or insourcing, employee severance (including rationalizing headcount or other significant changes in personnel) and realigning operations (including realignment of the management structure in response to changing market conditions). Also included within restructuring and employee severance are employee severance costs that are not incurred in connection with a restructuring activity. See Note 3 for additional information regarding our restructuring activities. |
Amortization and Other Acquisition-Related Costs | Amortization and Other Acquisition-Related Costs We classify certain costs incurred in connection with acquisitions as amortization and other acquisition-related costs in our consolidated statements of earnings/(loss). These costs consist of amortization of acquisition-related intangible assets, transaction costs, integration costs and changes in the fair value of contingent consideration obligations. Transaction costs are incurred during the initial evaluation of a potential acquisition and primarily relate to costs to analyze, negotiate and consummate the transaction as well as due diligence activities. Integration costs relate to activities required to combine the operations of an acquired enterprise into our operations and, in the case of the Cordis and Patient Recovery businesses, to stand-up the systems and processes needed to support an expanded geographic footprint. We record changes in the fair value of contingent consideration obligations relating to acquisitions as income or expense in amortization and other acquisition-related costs. See Note 4 for additional information regarding amortization of acquisition-related intangible assets. |
Translation of Foreign Currencies | Translation of Foreign Currencies Financial statements of our subsidiaries outside the United States are generally measured using the local currency as the functional currency. Adjustments to translate the assets and liabilities of these foreign subsidiaries into U.S. dollars are accumulated in shareholders’ equity through accumulated and other comprehensive loss ("AOCI") utilizing period-end exchange rates. Revenues and expenses of these foreign subsidiaries are translated using average exchange rates during the year. The foreign currency translation gains/(losses) included in AOCI at June 30, 2020 and 2019 are presented in Note 11 . Foreign currency transaction gains and losses for the period are included in the consolidated statements of earnings/(loss) in the respective financial statement line item. |
Interest Rate, Currency and Commodity Risk | Interest Rate, Currency and Commodity Risk All derivative instruments are recognized at fair value on the consolidated balance sheets and all changes in fair value are recognized in net earnings or shareholders’ equity through AOCI, net of tax. For contracts that qualify for hedge accounting treatment, the hedge contracts must be effective at reducing the risk associated with the exposure being hedged and must be designated as a hedge at the inception of the contract. Hedge effectiveness is assessed periodically. Any contract not designated as a hedge, or so designated but ineffective, is adjusted to fair value and recognized immediately in net earnings. If a fair value or cash flow hedge ceases to qualify for hedge accounting treatment, the contract continues to be carried on the balance sheet at fair value until settled and future adjustments to the contract’s fair value are recognized immediately in net earnings. If a forecasted transaction is probable not to occur, amounts previously deferred in AOCI are recognized immediately in net earnings. Interest payments received from the cross currency swap are excluded from the net investment hedge effectiveness assessment and are recorded in interest expense, net in the consolidated statements of earnings/(loss). See Note 10 for additional information regarding our derivative instruments, including the accounting treatment for instruments designated as fair value, cash flow and economic hedges. |
Fair Value Measurements | Fair Value Measurements Fair value is defined as the price that would be received upon selling an asset or the price paid to transfer a liability on the measurement date. It focuses on the exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between willing market participants. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair values are: Level 1 - Observable prices in active markets for identical assets and liabilities. Level 2 - Observable inputs other than quoted prices in active markets for identical assets and liabilities. Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities. See Note 9 for additional information regarding fair value measurements. |
Recent Financial Accounting Standards | Recently Adopted Financial Accounting Standards Derivatives and Hedging In October 2018, the Financial Accounting Standards Board ("FASB") issued amended accounting guidance related to derivatives and hedging which permits the use of the Secured Overnight Financing Rate ("SOFR") Overnight Index Swap ("OIS") as a benchmark interest rate for hedge accounting purposes. This guidance was effective beginning the first quarter of fiscal 2020. The adoption did not have a material impact on our consolidated financial statements. Leases In February 2016, the FASB issued amended accounting guidance that requires lessees to recognize most leases on the balance sheet as a lease liability and corresponding right-of-use asset. The guidance also requires disclosures that meet the objective of enabling financial statement users to assess the amount, timing and uncertainty of cash flows arising from leases. We adopted this guidance during the first quarter of fiscal 2020 and elected the transition option which allows us to apply the guidance prospectively. The initial adoption in the first quarter of fiscal 2020 resulted in the recognition of lease liabilities in the amount of $422 million and did not have a material impact on our results of operations, liquidity or debt covenant compliance under our current debt agreements. The majority of our lease spend relates to certain real estate with the remaining lease spend primarily related to vehicles and equipment. The adoption required certain changes to our systems and processes. See Note 5 for additional information regarding leases. Recently Issued Financial Accounting Standards Not Yet Adopted Financial Instruments - Credit Losses In June 2016, the FASB issued amended accounting guidance that will require entities to measure credit losses on trade and other receivables, held-to-maturity debt securities, loans and other instruments using an "expected credit loss" model that considers historical experience, current conditions and reasonable supportable forecasts. This guidance also requires that credit losses on available-for-sale debt securities with unrealized losses be recognized as allowances rather than as deductions in the amortized cost of the securities. This guidance will be effective for us in the first quarter of fiscal 2021. The adoption of this guidance will not have a material impact on our consolidated financial statements or disclosures. |
Guarantees, Indemnifications and Warranties Policies [Policy Text Block] | Guarantees In the ordinary course of business, we agree to indemnify certain other parties under acquisition and disposition agreements, customer agreements, intellectual property licensing agreements, and other agreements. Such indemnification obligations vary in scope and, when defined, in duration. In many cases, a maximum obligation is not explicitly stated, and therefore the overall maximum amount of the liability under such indemnification obligations cannot be reasonably estimated. Where appropriate, such indemnification obligations are recorded as a liability. Historically, we have not, individually or in the aggregate, made payments under these indemnification obligations in any material amounts. In certain circumstances, we believe that existing insurance arrangements, subject to the general deduction and exclusion provisions, would cover portions of the liability that may arise from these indemnification obligations. In addition, we believe that the likelihood of a material liability being triggered under these indemnification obligations is not probable. From time to time we enter into agreements that obligate us to make fixed payments upon the occurrence of certain events. Such obligations primarily relate to obligations arising under acquisition transactions, where we have agreed to make payments based upon the achievement of certain financial performance measures by the acquired business. Generally, the obligation is capped at an explicit amount. There were no material obligations at June 30, 2020 |
Leases (Tables)
Leases (Tables) | 12 Months Ended |
Jun. 30, 2020 | |
Leases [Abstract] | |
Schedule of Lease Costs | The following table summarizes the components of lease cost: (in millions) 2020 Operating lease cost $ 134 Finance lease cost 13 Variable lease cost 17 Total lease cost $ 164 |
Leases Supplemental Balance Sheet Information | The following table summarizes supplemental balance sheet information related to leases at June 30: (in millions) 2020 Operating Leases Operating lease right-of-use assets $ 426 Current portion of operating lease liabilities 104 Long-term operating lease liabilities 341 Total operating lease liabilities 445 Finance Leases Finance lease right-of-use assets 33 Current portion of finance lease liabilities 9 Long-term finance lease liabilities 25 Total finance lease liabilities $ 34 |
Leases Supplemental Cash Flow Information | The following tables summarizes supplemental cash flow information related to leases: (in millions) 2020 Cash paid for lease liabilities: Operating cash flows paid for operating leases $ 125 Financing cash flows paid for finance leases 7 Non-cash right-of-use assets obtained in exchange for lease obligations: New operating leases 150 New finance leases 40 Amended lease standard adoption impact as of July 1, 2019 (1) 400 (1) Includes the effect of $22 million |
Schedule of Future Lease Payments | Future lease payments under non-cancellable leases as of June 30, 2020 were as follows: (in millions) Operating Leases Finance Leases Total 2021 $ 117 $ 10 $ 127 2022 96 9 105 2023 72 9 81 2024 51 4 55 2025 44 2 46 Thereafter 123 2 125 Total future lease payments 503 36 539 Less: leases not yet commenced (1) 4 — 4 Less: imputed interest 54 2 56 Total lease liabilities $ 445 $ 34 $ 479 (1) As of June 30, 2020 , we had certain leases that were executed but did not have control of the underlying assets; therefore, the lease liabilities and right-of-use assets are not recorded in the consolidated balance sheet. |
Basis of Presentation and Sum_3
Basis of Presentation and Summary of Significant Accounting Policies (Tables) | 12 Months Ended |
Jun. 30, 2020 | |
Accounting Policies [Abstract] | |
Schedule of Revenue and Gross Trade Receivables Percentage by Major Customers | The following table summarizes historical percent of revenue and gross trade receivables from CVS and OptumRx: Percent of Revenue Percent of Gross Trade Receivables at June 30 2020 2019 2018 2020 2019 CVS 26 % 26 % 25 % 26 % 24 % OptumRx 14 % 13 % 11 % 6 % 4 % |
Components of Property and Equipment | The following table presents the components of property and equipment, net at June 30: (in millions) 2020 2019 Land, building and improvements $ 2,185 $ 1,992 Machinery and equipment 3,008 3,038 Furniture and fixtures 138 138 Total property and equipment, at cost 5,331 5,168 Accumulated depreciation and amortization (2,965 ) (2,812 ) Property and equipment, net $ 2,366 $ 2,356 |
Restructuring and Employee Se_2
Restructuring and Employee Severance (Tables) | 12 Months Ended |
Jun. 30, 2020 | |
Restructuring Charges [Abstract] | |
Summary of Restructuring and Employee Severance | The following tables summarize restructuring and employee severance costs: (in millions) 2020 2019 2018 Employee-related costs $ 66 $ 95 $ 34 Facility exit and other costs 56 30 142 Total restructuring and employee severance $ 122 $ 125 $ 176 Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of product distribution and lease contract termination costs, lease costs associated with vacant facilities, accelerated depreciation, equipment relocation costs, project consulting fees, vendor transition fees, costs associated with restructuring our delivery of information technology infrastructure services and certain other divestiture-related costs. |
Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance | The following table summarizes activity related to liabilities associated with restructuring and employee severance: (in millions) Employee- Related Costs Facility Exit and Other Costs Total Balance at June 30, 2018 $ 24 $ 4 $ 28 Additions 84 8 92 Payments and other adjustments (44 ) (4 ) (48 ) Balance at June 30, 2019 64 8 72 Additions 85 24 109 Payments and other adjustments (81 ) (4 ) (85 ) Balance at June 30, 2020 $ 68 $ 28 $ 96 |
Goodwill and Other Intangible_2
Goodwill and Other Intangible Assets (Tables) | 12 Months Ended |
Jun. 30, 2020 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of Goodwill by Reportable Segment | The following table summarizes the changes in the carrying amount of goodwill by segment and in total: (in millions) Pharmaceutical (1) Medical (2) Total Balance at June 30, 2018 $ 2,621 $ 5,695 $ 8,316 Goodwill acquired, net of purchase price adjustments 45 7 52 Foreign currency translation adjustments and other (3 ) 13 10 Balance at June 30, 2019 2,663 5,715 8,378 Goodwill acquired, net of purchase price adjustments (5 ) — (5 ) Foreign currency translation adjustments and other (1 ) (15 ) (16 ) Balance at June 30, 2020 $ 2,657 $ 5,700 $ 8,357 (1) At June 30, 2020 and 2019 , the Pharmaceutical segment accumulated goodwill impairment loss was $829 million . (2) At June 30, 2020 and 2019 , the Medical segment accumulated goodwill impairment loss was $1.4 billion . |
Schedule of Finite-Lived Intangible Assets | The following tables summarize other intangible assets by class at June 30: 2020 (in millions) Gross Intangible Accumulated Amortization Net Intangible Weighted- Average Remaining Amortization Period (Years) Indefinite-life intangibles: IPR&D, trademarks and other $ 23 $ — $ 23 N/A Total indefinite-life intangibles 23 — 23 N/A Definite-life intangibles: Customer relationships 3,554 1,828 1,726 13 Trademarks, trade names and patents 673 341 332 13 Developed technology and other 1,604 767 837 11 Total definite-life intangibles 5,831 2,936 2,895 12 Total other intangible assets $ 5,854 $ 2,936 $ 2,918 N/A 2019 (in millions) Gross Intangible Accumulated Amortization Net Intangible Indefinite-life intangibles: IPR&D, trademarks and other $ 22 $ — $ 22 Total indefinite-life intangibles 22 — 22 Definite-life intangibles: Customer relationships 3,562 1,517 2,045 Trademarks, trade names and patents 672 295 377 Developed technology and other 1,602 616 986 Total definite-life intangibles 5,836 2,428 3,408 Total other intangible assets $ 5,858 $ 2,428 $ 3,430 |
Schedule of Indefinite-Lived Intangible Assets | The following tables summarize other intangible assets by class at June 30: 2020 (in millions) Gross Intangible Accumulated Amortization Net Intangible Weighted- Average Remaining Amortization Period (Years) Indefinite-life intangibles: IPR&D, trademarks and other $ 23 $ — $ 23 N/A Total indefinite-life intangibles 23 — 23 N/A Definite-life intangibles: Customer relationships 3,554 1,828 1,726 13 Trademarks, trade names and patents 673 341 332 13 Developed technology and other 1,604 767 837 11 Total definite-life intangibles 5,831 2,936 2,895 12 Total other intangible assets $ 5,854 $ 2,936 $ 2,918 N/A 2019 (in millions) Gross Intangible Accumulated Amortization Net Intangible Indefinite-life intangibles: IPR&D, trademarks and other $ 22 $ — $ 22 Total indefinite-life intangibles 22 — 22 Definite-life intangibles: Customer relationships 3,562 1,517 2,045 Trademarks, trade names and patents 672 295 377 Developed technology and other 1,602 616 986 Total definite-life intangibles 5,836 2,428 3,408 Total other intangible assets $ 5,858 $ 2,428 $ 3,430 |
Long-Term Obligations and Oth_2
Long-Term Obligations and Other Short-Term Borrowings (Tables) | 12 Months Ended |
Jun. 30, 2020 | |
Debt Disclosure [Abstract] | |
Schedule of Debt | The following table summarizes long-term obligations and other short-term borrowings at June 30: (in millions) (1) 2020 2019 2.4% Notes due 2019 $ — $ 450 4.625% Notes due 2020 — 508 2.616% Notes due 2022 834 1,079 3.2% Notes due 2022 236 247 Floating Rate Notes due 2022 321 340 3.2% Notes due 2023 576 551 3.079% Notes due 2024 809 781 3.5% Notes due 2024 413 402 3.75% Notes due 2025 529 494 3.41% Notes due 2027 1,215 1,318 4.6% Notes due 2043 340 346 4.5% Notes due 2044 342 342 4.9% Notes due 2045 441 445 4.368% Notes due 2047 560 594 7.0% Debentures due 2026 124 124 Other Obligations 35 10 Total 6,775 8,031 Less: current portion of long-term obligations and other short-term borrowings 10 452 Long-term obligations, less current portion $ 6,765 $ 7,579 (1) Maturities are presented on a calendar year basis. |
Income Taxes (Tables)
Income Taxes (Tables) | 12 Months Ended |
Jun. 30, 2020 | |
Income Tax Disclosure [Abstract] | |
Schedule of Income Before Income Tax, Domestic and Foreign | The following table summarizes earnings/(loss) before income taxes: (in millions) 2020 2019 2018 U.S. operations $ (4,056 ) $ 1,478 $ 391 Non-U.S. operations 284 273 (619 ) Earnings/(loss) before income taxes $ (3,772 ) $ 1,751 $ (228 ) |
Schedule of Components of Income Tax Expense (Benefit), Current and Deferred | The following table summarizes the components of provision for/(benefit from) income taxes: (in millions) 2020 2019 2018 Current: Federal $ 659 $ 295 $ 341 State and local 154 89 41 Non-U.S. 69 85 143 Total current $ 882 $ 469 $ 525 Deferred: Federal $ (822 ) $ (28 ) $ (1,003 ) State and local (127 ) (37 ) 16 Non-U.S. (12 ) (18 ) (25 ) Total deferred (961 ) (83 ) (1,012 ) Provision for/(benefit from) income taxes $ (79 ) $ 386 $ (487 ) |
Schedule of Effective Income Tax Rate Reconciliation | The following table presents a reconciliation of the provision based on the federal statutory income tax rate to our effective income tax rate: 2020 (1) 2019 (2) 2018 (1) Provision at Federal statutory rate 21.0 % 21.0 % 28.1 % State and local income taxes, net of federal benefit 2.5 0.9 (16.0 ) Tax effect of foreign operations — (0.7 ) (48.4 ) Nondeductible/nontaxable items (0.1 ) 2.5 (10.2 ) Goodwill impairment — — (124.7 ) Tax Act 0.1 (0.8 ) 410.9 Change in valuation allowances 1.5 4.5 (76.9 ) Foreign tax credits 0.5 (1.0 ) 27.3 China tax related to divestiture — — (25.8 ) Legal entity reorganization — (3.6 ) 71.4 Opioid litigation (23.2 ) — — Other (0.2 ) (0.7 ) (21.9 ) Effective income tax rate 2.1 % 22.1 % 213.8 % |
Schedule of Deferred Tax Assets and Liabilities | The following table presents the components of the deferred income tax assets and liabilities at June 30: (in millions) 2020 2019 Deferred income tax assets: Receivable basis difference $ 39 $ 35 Accrued liabilities 607 133 Share-based compensation 38 39 Loss and tax credit carryforwards 589 621 Deferred tax assets related to uncertain tax positions 52 30 Other 87 6 Total deferred income tax assets 1,412 864 Valuation allowance for deferred income tax assets (470 ) (542 ) Net deferred income tax assets $ 942 $ 322 Deferred income tax liabilities: Inventory basis differences $ (1,083 ) $ (1,056 ) Property-related (327 ) (171 ) Goodwill and other intangibles (751 ) (808 ) Total deferred income tax liabilities $ (2,161 ) $ (2,035 ) Net deferred income tax liability $ (1,219 ) $ (1,713 ) |
Schedule of Deferred Tax Assets and Liabilities after Netting by Tax Jurisdiction | Deferred income tax assets and liabilities in the preceding table, after netting by taxing jurisdiction and for uncertain tax positions, are in the following captions in the consolidated balance sheets at June 30: (in millions) 2020 2019 Noncurrent deferred income tax asset (1) $ 39 $ 36 Noncurrent deferred income tax liability (2) (1,258 ) (1,749 ) Net deferred income tax liability $ (1,219 ) $ (1,713 ) (1) Included in other assets in the consolidated balance sheets. (2) Included in deferred income taxes and other liabilities in the consolidated balance sheets. |
Schedule of Unrecognized Tax Benefits Roll Forward | sheets. The following table presents a reconciliation of the beginning and ending amounts of unrecognized tax benefits: (in millions) 2020 2019 2018 Balance at beginning of fiscal year $ 456 $ 423 $ 417 Additions for tax positions of the current year 500 24 15 Additions for tax positions of prior years (1) 78 39 141 Reductions for tax positions of prior years (27 ) (5 ) (40 ) Settlements with tax authorities (1) (6 ) (25 ) (99 ) Expiration of the statute of limitations (1) (3 ) — (11 ) Balance at end of fiscal year $ 998 $ 456 $ 423 (1) Included in fiscal 2018 additions for tax positions of prior years is $110 million related to exposures acquired as part of the Patient Recovery Business for which we are fully indemnified. Also for fiscal 2018 are settlements of $81 million related to the Patient Recovery Business as well as $11 million of statute expirations. |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 12 Months Ended |
Jun. 30, 2020 | |
Fair Value Disclosures [Abstract] | |
Fair Value, Assets and Liabilities Measured on Recurring Basis | The following tables present the fair values for assets and (liabilities) measured on a recurring basis at June 30: 2020 (in millions) Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 721 $ — $ — $ 721 Other investments (1) 114 — — 114 Forward contracts (2) — 53 — 53 2019 (in millions) Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 297 $ — $ — $ 297 Other investments (1) 118 — — 118 Forward contracts (2) — 53 — 53 (1) The other investments balance includes investments in mutual funds, which are used to offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high-quality fixed income debt securities. The fair value of these investments is determined using quoted market prices. (2) |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation | The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the consolidated balance sheets. |
Financial Instruments (Tables)
Financial Instruments (Tables) | 12 Months Ended |
Jun. 30, 2020 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Schedule of Fair Value of Assets and Liabilities Related to Derivatives Designated as Hedging Instruments | The following table summarizes the fair value of our assets and liabilities related to derivatives designated as hedging instruments and the respective line items in which they were recorded in the consolidated balance sheets at June 30: (in millions) 2020 2019 Assets: Pay-floating interest rate swaps (1) $ 27 $ 46 Cross-currency swap (1) 47 12 Foreign currency contracts (2) — 6 Total assets $ 74 $ 64 Liabilities: Pay-floating interest rate swaps (3) $ — $ 6 Foreign currency contracts (4) 4 2 Forward interest rate swaps (3) 16 — Commodity contracts (4) 1 3 Total liabilities $ 21 $ 11 (1) Included in other assets in the consolidated balance sheets. (2) Included in prepaid expenses and other in the consolidated balance sheets. (3) Included in deferred income taxes and other liabilities in the consolidated balance sheets. (4) Included in other accrued liabilities in the consolidated balance sheets. |
Derivative [Line Items] | |
Schedule of Gain/(Loss) Included in AOCI for Derivative Instruments | The following table summarizes the pre-tax gain/(loss) included in OCI for derivative instruments designated as cash flow hedges: (in millions) 2020 2019 2018 Forward interest rate swaps $ (16 ) $ — $ — Commodity contracts 1 (5 ) 3 Foreign currency contracts (8 ) 5 (1 ) |
Schedule of Gain/(Loss) Recognized in Earnings for Interest Rate Contracts Designated as Fair Value Hedges | The following table summarizes the gain/(loss) recognized in earnings for interest rate swaps designated as fair value hedges: (in millions) 2020 2019 2018 Pay-floating interest rate swaps (1) $ 106 $ 9 $ 11 Fixed-rate debt (1) (106 ) (9 ) (11 ) (1) Included in interest expense, net in the consolidated statements of earnings/(loss). |
Schedule of Gain/(Loss) Reclassified from AOCI into Earnings for Derivative Instruments Designated as Cash Flow Hedges | The following table summarizes the pre-tax gain/(loss) reclassified from AOCI into earnings for derivative instruments designated as cash flow hedges: (in millions) 2020 2019 2018 Foreign currency contracts (1) $ 7 $ 2 $ 1 Foreign currency contracts (2) 1 — — Foreign currency contracts (3) — 1 (2 ) Forward interest rate swaps (4) 2 2 2 Commodity contracts (3) (5 ) — — (1) Included in revenue in the consolidated statements of earnings/(loss). (2) Included in cost of products sold in the consolidated statements of earnings/(loss). (3) Included in SG&A expenses in the consolidated statements of earnings/(loss). |
Schedule of Gain/(Loss) Recognized in Earnings for Economic (Non-designated) Derivative Instruments | The following table summarizes the gain/(loss) recognized in earnings for economic (non-designated) derivative instruments: (in millions) 2020 2019 2018 Foreign currency contracts (1) $ (11 ) $ (13 ) $ (5 ) (1) Included in other income, net in the consolidated statements of earnings/(loss). |
Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount | The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at June 30: (in millions) 2020 2019 Estimated fair value $ 7,273 $ 8,065 Carrying amount 6,775 8,031 |
Schedule of Fair Value Gain/(Loss) Derivative Instrument | The following table is a summary of the fair value gain/(loss) of our derivative instruments based upon the estimated amount that we would receive (or pay), considering counter-party credit risk, to terminate the contracts at June 30: 2020 2019 (in millions) Notional Fair Value Notional Fair Value Pay-floating interest rate swaps $ 550 $ 27 $ 2,150 $ 40 Foreign currency contracts 653 (4 ) 869 4 Forward interest rate swaps 200 (16 ) — — Cross-currency swap 833 47 233 12 Commodity contracts 16 (1 ) 20 (3 ) |
Not Designated as Hedging Instrument | |
Derivative [Line Items] | |
Schedule of Outstanding Instruments | The following tables summarize the outstanding economic (non-designated) derivative instruments at June 30: 2020 (in millions) Notional Amount Maturity Date Foreign currency contracts $ 325 July 2020 2019 (in millions) Notional Amount Maturity Date Foreign currency contracts $ 488 Jul 2019 |
Fair Value Hedging | |
Derivative [Line Items] | |
Schedule of Outstanding Instruments | The following tables summarize the outstanding interest rate swaps designated as fair value hedges at June 30: 2020 (in millions) Notional Amount Maturity Date Pay-floating interest rate swaps $ 550 Mar 2023 2019 (in millions) Notional Amount Maturity Date Pay-floating interest rate swaps $ 2,150 Nov 2019 - Sep 2025 |
Cash Flow Hedging | |
Derivative [Line Items] | |
Schedule of Outstanding Instruments | The following tables summarize the outstanding cash flow hedges at June 30: 2020 (in millions) Notional Amount Maturity Date Forward interest rate swaps $ 200 Jun 2022 Foreign currency contracts 328 Jul 2020 - Jun 2021 Commodity contracts 16 Jul 2020 - Jun 2021 2019 (in millions) Notional Amount Maturity Date Foreign currency contracts $ 381 Jul 2019 - Jun 2020 Commodity contracts 20 Jul 2019 - Jun 2020 |
Shareholders' Equity (Tables)
Shareholders' Equity (Tables) | 12 Months Ended |
Jun. 30, 2020 | |
Equity [Abstract] | |
Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total | The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total: (in millions) Foreign Currency Translation Adjustments and other Unrealized Gain/(Loss) on Derivatives, net of tax Accumulated Other Comprehensive Loss Balance at June 30, 2018 $ (113 ) $ 21 $ (92 ) Other comprehensive income/(loss), net before reclassifications 18 — 18 Amounts reclassified to earnings — (5 ) (5 ) Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax of $1 million 18 (5 ) 13 Balance at June 30, 2019 (95 ) 16 (79 ) Other comprehensive loss, before reclassifications 3 (23 ) (20 ) Amounts reclassified to earnings — (5 ) (5 ) Total comprehensive income/(loss) attributable to Cardinal Health, Inc., net of tax of $4 million 3 (28 ) (25 ) Balance at June 30, 2020 $ (92 ) $ (12 ) $ (104 ) |
Earnings Per Share Attributab_2
Earnings Per Share Attributable to Cardinal Health, Inc. (Tables) | 12 Months Ended |
Jun. 30, 2020 | |
Earnings Per Share [Abstract] | |
Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share | The following table reconciles the computation of basic and diluted earnings per share attributable to Cardinal Health, Inc.: (in millions, except per share amounts) 2020 2019 2018 Net earnings/(loss) $ (3,693 ) $ 1,365 $ 259 Net earnings attributable to noncontrolling interest (3 ) (2 ) (3 ) Net earnings/(loss) attributable to Cardinal Health, Inc. $ (3,696 ) $ 1,363 $ 256 Weighted-average common shares–basic 293 300 313 Effect of dilutive securities: Employee stock options, restricted share units, and performance share units — 1 2 Weighted-average common shares–diluted 293 301 315 Basic earnings/(loss) per common share attributable to Cardinal Health, Inc.: $ (12.61 ) $ 4.55 $ 0.82 Diluted earnings/(loss) per common share attributable to Cardinal Health, Inc.: (12.61 ) 4.53 0.81 |
Segment Information (Tables)
Segment Information (Tables) | 12 Months Ended |
Jun. 30, 2020 | |
Segment Reporting [Abstract] | |
Schedule of Segment Reporting Information, by Segment [Table Text Block] | The following table presents revenue for each reportable segment and Corporate: (in millions) 2020 2019 2018 Pharmaceutical $ 137,495 $ 129,917 $ 121,241 Medical 15,444 15,633 15,581 Total segment revenue 152,939 145,550 136,822 Corporate (1) (17 ) (16 ) (13 ) Total revenue $ 152,922 $ 145,534 $ 136,809 (1) Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments. |
Revenue by Reportable Segment | The following tables present revenue for each reportable segment and disaggregated revenue within our two reportable segments and Corporate: (in millions) 2020 2019 Pharmaceutical Distribution and Specialty Solutions (1) (2) $ 136,693 $ 129,067 Nuclear and Precision Health Solutions 802 850 Pharmaceutical segment revenue 137,495 129,917 Medical distribution and products (3) 13,429 13,833 Cardinal Health at-Home Solutions 2,015 1,800 Medical segment revenue 15,444 15,633 Total segment revenue 152,939 145,550 Corporate (4) (17 ) (16 ) Total revenue $ 152,922 $ 145,534 (1) Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services" (2) Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division. (3) Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division (4) Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments. |
Disaggregation of Revenue [Table Text Block] | (in millions) 2020 2019 Pharmaceutical Distribution and Specialty Solutions (1) (2) $ 136,693 $ 129,067 Nuclear and Precision Health Solutions 802 850 Pharmaceutical segment revenue 137,495 129,917 Medical distribution and products (3) 13,429 13,833 Cardinal Health at-Home Solutions 2,015 1,800 Medical segment revenue 15,444 15,633 Total segment revenue 152,939 145,550 Corporate (4) (17 ) (16 ) Total revenue $ 152,922 $ 145,534 (1) Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services" (2) Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division. (3) Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division (4) Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments. |
Revenue from External Customers by Geographic Areas [Table Text Block] | The following table presents revenue by geographic area: (in millions) 2020 2019 2018 United States $ 148,707 $ 141,479 $ 132,539 International 4,232 4,071 4,283 Total segment revenue 152,939 145,550 136,822 Corporate (1) (17 ) (16 ) (13 ) Total revenue $ 152,922 $ 145,534 $ 136,809 (1) Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments. |
Segment Profit by Reportable Segment | The following tables present segment profit by reportable segment and Corporate: (in millions) 2020 2019 2018 Pharmaceutical $ 1,753 $ 1,834 $ 1,992 Medical 663 576 662 Total segment profit 2,416 2,410 2,654 Corporate (6,514 ) (350 ) (2,528 ) Total operating earnings $ (4,098 ) $ 2,060 $ 126 |
Depreciation and Amortization and Additions to Property and Equipment by Reportable Segment | The following tables present depreciation and amortization and additions to property and equipment by reportable segment and Corporate: (in millions) 2020 2019 2018 Pharmaceutical $ 135 $ 147 $ 156 Medical 243 288 278 Corporate 535 565 598 Total depreciation and amortization $ 913 $ 1,000 $ 1,032 (in millions) 2020 2019 2018 Pharmaceutical $ 47 $ 35 $ 58 Medical 86 74 127 Corporate 242 219 199 Total additions to property and equipment $ 375 $ 328 $ 384 |
Assets by Reportable Segment | The following table presents total assets for each reportable segment and Corporate at June 30: (in millions) 2020 2019 2018 Pharmaceutical $ 22,398 $ 22,446 $ 21,421 Medical 14,691 15,284 16,066 Corporate 3,677 3,233 2,464 Total assets $ 40,766 $ 40,963 $ 39,951 |
Property and Equipment, Net by Geographic Area | The following tables present property and equipment, net by geographic area: (in millions) 2020 2019 2018 United States $ 1,880 $ 1,846 $ 1,950 International 486 510 537 Property and equipment, net $ 2,366 $ 2,356 $ 2,487 |
Share-Based Compensation (Table
Share-Based Compensation (Tables) | 12 Months Ended |
Jun. 30, 2020 | |
Share-based Payment Arrangement [Abstract] | |
Schedule of Total Share-based Compensation Expense by Type of Award | The following table provides total share-based compensation expense by type of award: (in millions) 2020 2019 2018 Restricted share unit expense $ 70 $ 63 $ 73 Employee stock option expense 3 10 22 Performance share unit expense 17 9 (10 ) Total share-based compensation expense $ 90 $ 82 $ 85 |
Schedule of Stock Option Transactions Under the Plans | The following table summarizes all stock option transactions under the Plans: (in millions, except per share amounts) Stock Options Weighted-Average Exercise Price per Common Share Outstanding at June 30, 2018 7 $ 64.50 Granted — — Exercised — — Canceled and forfeited (1 ) 72.54 Outstanding at June 30, 2019 6 63.78 Granted — — Exercised (1 ) 42.36 Canceled and forfeited — — Outstanding at June 30, 2020 5 $ 65.15 Exercisable at June 30, 2020 5 $ 65.25 |
Schedule of Additional Data Related to Stock Option Activity | The following table provides additional detail related to stock options: (in millions, except per share amounts) 2020 2019 2018 Aggregate intrinsic value of outstanding options at period end $ 12 $ 10 $ 13 Aggregate intrinsic value of exercisable options at period end 12 10 13 Aggregate intrinsic value of exercised options 8 1 14 Net proceeds/(withholding) from share-based compensation 26 3 (3 ) Excess tax benefits from share based compensation 6 7 10 Total compensation cost, net of estimated forfeitures, related to unvested stock options not yet recognized, pre-tax 1 5 17 Total fair value of shares vested during the year 8 20 19 Weighted-average grant date fair value per stock option $ 8.26 $ 8.34 $ 13.50 |
Schedule of Remaining Stock Option Plan Data | (in years) 2020 2019 2018 Weighted-average remaining contractual life of outstanding options 5 5 7 Weighted-average remaining contractual life of exercisable options 5 5 5 Weighted-average period over which stock option compensation cost is expected to be recognized 1 1 2 |
Schedule of Range of Assumptions Used to Estimate Fair Value of Stock Options | The following table provides the range of assumptions used to estimate the fair value of stock options: 2018 Risk-free interest rate 2.1% Expected volatility 25% Dividend yield 2.7% - 2.8% Expected life in years 7 |
Schedule of Transactions Related to Restricted Share Units Under the Plans | The following table summarizes all transactions related to restricted share units under the Plans: (in millions, except per share amounts) Restricted Share Units Weighted-Average Grant Date Fair Value per Share Nonvested at June 30, 2018 2 $ 71.58 Granted 2 50.13 Vested (1 ) 74.52 Canceled and forfeited (1 ) 62.32 Nonvested at June 30, 2019 2 51.65 Granted 2 42.71 Vested (1 ) 60.21 Canceled and forfeited — — Nonvested at June 30, 2020 3 $ 45.92 |
Additional Restricted Shares and Restricted Share Units Activity | The following table provides additional data related to restricted share unit activity: (in millions) 2020 2019 2018 Total compensation cost, net of estimated forfeitures, related to nonvested restricted share and share unit awards not yet recognized, pre-tax $ 77 $ 75 $ 78 Weighted-average period in years over which restricted share and share unit cost is expected to be recognized (in years) 2 2 2 Total fair value of shares vested during the year $ 57 $ 68 $ 65 |
Schedule of Transactions Related to Performance Share Units Under the Plans | The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts): (in millions, except per share amounts) Performance Share Units Weighted-Average Grant Date Fair Value per Share Nonvested at June 30, 2018 0.4 $ 66.13 Granted 0.6 50.96 Vested — — Canceled and forfeited (0.1 ) 52.20 Nonvested at June 30, 2019 0.9 51.45 Granted 0.7 44.03 Vested (0.1 ) 48.40 Canceled and forfeited (0.2 ) 50.92 Nonvested at June 30, 2020 1.3 $ 54.24 |
Additional Data Related to Performance Share Units Activity | The following table provides additional data related to performance share unit activity: (in millions) 2020 2019 2018 Total compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized, pre-tax $ 29 $ 12 $ 1 Weighted-average period over which performance share unit cost is expected to be recognized (in years) 2 2 2 Total fair value of shares vested during the year $ 5 $ — $ 14 |
Selected Quarterly Financial _2
Selected Quarterly Financial Data (Unaudited) (Tables) | 12 Months Ended |
Jun. 30, 2020 | |
Quarterly Financial Information Disclosure [Abstract] | |
Schedule of Selected Quarterly Financial Data | The following is selected quarterly financial data for fiscal 2020 and 2019 . The sum of the quarters may not equal year-to-date due to rounding. (in millions, except per common share amounts) First Second Third Fourth Fiscal 2020 Revenue $ 37,341 $ 39,735 $ 39,157 $ 36,689 Gross margin 1,679 1,714 1,885 1,590 Distribution, selling, general and administrative expenses 1,107 1,163 1,165 1,137 Net earnings/(loss) (4,921 ) 220 351 657 Less: Net earnings attributable to noncontrolling interests (1 ) — (1 ) (1 ) Net earnings/(loss) attributable to Cardinal Health, Inc. (4,922 ) 220 350 656 Net earnings/(loss) attributable to Cardinal Health, Inc. per common share: Basic $ (16.65 ) $ 0.75 $ 1.20 $ 2.25 Diluted (16.65 ) 0.75 1.19 2.23 (1) Includes a $5.63 billion pre-tax charge for the opioid litigation ( $5.14 billion after tax). (2) Includes a $579 million pre-tax gain ( $493 million after tax) in connection with the sale of our remaining equity interest in a partnership that owned naviHealth. (in millions, except per common share amounts) First Second Third Fourth Fiscal 2019 Revenue $ 35,213 $ 37,740 $ 35,228 $ 37,353 Gross margin 1,667 1,730 1,764 1,674 Distribution, selling, general and administrative expenses 1,155 1,064 1,097 1,168 Net earnings/(loss) 594 281 296 194 Less: Net earnings attributable to noncontrolling interests (1 ) (1 ) — — Net earnings/(loss) attributable to Cardinal Health, Inc. 593 280 296 194 Net earnings/(loss) attributable to Cardinal Health, Inc. per common share: Basic $ 1.95 $ 0.94 $ 0.99 $ 0.65 Diluted (3) 1.94 0.93 0.99 0.65 (1) Includes a $508 million gain ( $378 million after tax) related to the naviHealth divestiture. |
Leases (Details)
Leases (Details) - USD ($) $ in Millions | Jul. 01, 2019 | Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2020 |
Operating Leases, Rent Expense | $ 153 | $ 172 | ||
Reclassification of deferred rent in accordance with ASC 842 | $ 22 | |||
Operating Leases, Future Minimum Payments Due, Next Twelve Months | 126 | |||
Future minimum rental payments for operating leases - 2020 | 100 | |||
Future minimum rental payments for operating leases - 2021 | 76 | |||
Operating Leases, Future Minimum Payments, Due in Four Years | 54 | |||
Operating Leases, Future Minimum Payments, Due in Five Years | 33 | |||
Operating Leases, Future Minimum Payments, Due Thereafter | $ 94 | |||
Operating Lease, Weighted Average Remaining Lease Term | 6 years 4 months 24 days | |||
Operating Lease, Weighted Average Discount Rate, Percent | 2.90% | |||
Finance Lease, Weighted Average Remaining Lease Term | 4 years 3 months 18 days | |||
Finance Lease, Weighted Average Discount Rate, Percent | 2.40% | |||
Minimum | ||||
Lessee, Operating Lease, Term of Contract | 1 year | |||
Maximum | ||||
Lessee, Operating Lease, Term of Contract | 22 years |
Basis of Presentation and Sum_4
Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Receivables) (Details) - USD ($) $ in Millions | 12 Months Ended | |||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2017 | |
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||||
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount | $ 729 | $ 687 | $ 626 | $ 494 |
Finance notes and related accrued interest, net, total | 104 | 103 | ||
Finance notes and related accrued interest, net, current | $ 12 | 12 | ||
Minimum | ||||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||||
Receivable financing agreement term | 1 year | |||
Maximum | ||||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||||
Receivable financing agreement term | 5 years | |||
SEC Schedule, 12-09, Allowance, Credit Loss [Member] | ||||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||||
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount | $ 206 | 193 | 139 | 137 |
SEC Schedule, 12-09, Allowance, Loss on Finance Receivable [Member] | ||||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||||
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount | $ 27 | $ 14 | $ 7 | $ 9 |
Leases Schedule of Lease Costs
Leases Schedule of Lease Costs (Details) $ in Millions | 12 Months Ended |
Jun. 30, 2020USD ($) | |
Leases [Abstract] | |
Operating Lease, Cost | $ 134 |
Amortization of right-of-use assets | 13 |
Variable lease cost | 17 |
Total lease cost | $ 164 |
Basis of Presentation and Sum_5
Basis of Presentation and Summary of Significant Accounting Policies (Revenue and Gross Trade Receivables Percentage by Major Customers) (Details) - Pharmaceutical | 12 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | |
CVS Health | |||
Revenue, Major Customer [Line Items] | |||
Percent of Revenue | 26.00% | 26.00% | 25.00% |
Percent of Gross Trade Receivables | 26.00% | 24.00% | |
OptumRx [Member] | |||
Revenue, Major Customer [Line Items] | |||
Percent of Revenue | 14.00% | 13.00% | 11.00% |
Percent of Gross Trade Receivables | 6.00% | 4.00% |
Leases Supplemental Balance She
Leases Supplemental Balance Sheet Information (Details) $ in Millions | Jun. 30, 2020USD ($) |
Leases [Abstract] | |
Operating Lease, Liability, Noncurrent | $ 341 |
Operating Lease, Liability, Current | 104 |
Operating Lease, Right-of-Use Asset | 426 |
Total operating lease liabilities | 445 |
Total finance lease liabilities | 34 |
Finance Lease, Right-of-Use Asset, after Accumulated Amortization | 33 |
Finance Lease, Liability, Current | 9 |
Finance Lease, Liability, Noncurrent | $ 25 |
Basis of Presentation and Sum_6
Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Major Customers) (Details) - organization | 12 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | |
Concentration Risk [Line Items] | |||
Largest group purchasing organizations | 2 | ||
Group Purchasing Organizations | |||
Concentration Risk [Line Items] | |||
Revenue, major customer, percentage | 16.00% | 22.00% | 22.00% |
Leases Supplemental Cash Flow I
Leases Supplemental Cash Flow Information (Details) - USD ($) $ in Millions | Jul. 01, 2019 | Jun. 30, 2020 |
Operating Lease, Payments | $ 125 | |
Finance Lease, Principal Payments | 7 | |
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | 150 | |
Right-of-Use Asset Obtained in Exchange for Finance Lease Liability | $ 40 | |
ASC 842 | ||
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification (Deprecated 2020-01-31) | $ 400 |
Basis of Presentation and Sum_7
Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Inventories) (Details) - USD ($) $ in Millions | Jun. 30, 2020 | Jun. 30, 2019 |
Accounting Policies [Abstract] | ||
Portion of inventories held at LIFO, percentage | 56.00% | 56.00% |
Inventories valued at LIFO amount higher than average cost value | $ 411 | $ 230 |
Reserves for excess and obsolete inventory | $ 155 | $ 171 |
Leases Schedule of Future Lease
Leases Schedule of Future Lease Payments (Details) $ in Millions | Jun. 30, 2020USD ($) |
Remainder of 2020 | $ 127 |
2021 | 105 |
2022 | 81 |
2023 | 55 |
2024 | 46 |
Thereafter | 125 |
Total future lease payments | 539 |
Less: leases not yet commenced (1) | 4 |
Less: imputed interest | 56 |
Total lease liabilities | 445 |
Total lease liabilities | 34 |
Total Lease Liability | 479 |
Operating Leases | |
Remainder of 2020 | 117 |
2021 | 96 |
2022 | 72 |
2023 | 51 |
2024 | 44 |
Thereafter | 123 |
Total future lease payments | 503 |
Less: leases not yet commenced (1) | 4 |
Less: imputed interest | 54 |
Total lease liabilities | 445 |
Finance Leases | |
Remainder of 2020 | 10 |
2021 | 9 |
2022 | 9 |
2023 | 4 |
2024 | 2 |
Thereafter | 2 |
Total future lease payments | 36 |
Less: leases not yet commenced (1) | 0 |
Less: imputed interest | 2 |
Total lease liabilities | $ 34 |
Basis of Presentation and Sum_8
Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Property and Equipment) (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | |
Property, Plant and Equipment [Line Items] | |||
Depreciation | $ 405 | $ 455 | $ 446 |
Interest rate on long-term projects (approximates weighted-average on long-term obligations) | 3.00% | ||
Building and Improvements | Minimum | |||
Property, Plant and Equipment [Line Items] | |||
Useful life of property and equipment | 3 years | ||
Building and Improvements | Maximum | |||
Property, Plant and Equipment [Line Items] | |||
Useful life of property and equipment | 39 years | ||
Machinery and equipment | Minimum | |||
Property, Plant and Equipment [Line Items] | |||
Useful life of property and equipment | 3 years | ||
Machinery and equipment | Maximum | |||
Property, Plant and Equipment [Line Items] | |||
Useful life of property and equipment | 20 years | ||
Furniture and fixtures | Minimum | |||
Property, Plant and Equipment [Line Items] | |||
Useful life of property and equipment | 3 years | ||
Furniture and fixtures | Maximum | |||
Property, Plant and Equipment [Line Items] | |||
Useful life of property and equipment | 7 years |
Basis of Presentation and Sum_9
Basis of Presentation and Summary of Significant Accounting Policies (Components of Property and Equipment) (Details) $ in Millions | 12 Months Ended | ||
Jun. 30, 2020USD ($)segment | Jun. 30, 2019USD ($) | Jun. 30, 2018USD ($) | |
Property, Plant and Equipment [Line Items] | |||
Long-term Debt, Weighted Average Interest Rate, at Point in Time | 3.00% | ||
Number of Operating Segments | segment | 2 | ||
Total property and equipment, at cost | $ 5,331 | $ 5,168 | |
Accumulated depreciation and amortization | (2,965) | (2,812) | |
Property and equipment, net | 2,366 | 2,356 | $ 2,487 |
Land, building and improvements | |||
Property, Plant and Equipment [Line Items] | |||
Total property and equipment, at cost | 2,185 | 1,992 | |
Machinery and equipment | |||
Property, Plant and Equipment [Line Items] | |||
Total property and equipment, at cost | 3,008 | 3,038 | |
Furniture and fixtures | |||
Property, Plant and Equipment [Line Items] | |||
Total property and equipment, at cost | $ 138 | $ 138 | |
Maximum | Building and Improvements | |||
Property, Plant and Equipment [Line Items] | |||
Property, Plant and Equipment, Useful Life | 39 years | ||
Maximum | Machinery and equipment | |||
Property, Plant and Equipment [Line Items] | |||
Property, Plant and Equipment, Useful Life | 20 years | ||
Maximum | Furniture and fixtures | |||
Property, Plant and Equipment [Line Items] | |||
Property, Plant and Equipment, Useful Life | 7 years | ||
Minimum | Building and Improvements | |||
Property, Plant and Equipment [Line Items] | |||
Property, Plant and Equipment, Useful Life | 3 years | ||
Minimum | Machinery and equipment | |||
Property, Plant and Equipment [Line Items] | |||
Property, Plant and Equipment, Useful Life | 3 years | ||
Minimum | Furniture and fixtures | |||
Property, Plant and Equipment [Line Items] | |||
Property, Plant and Equipment, Useful Life | 3 years |
Basis of Presentation and Su_10
Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Goodwill and Other Intangible Assets) (Details) $ in Millions | 12 Months Ended | |||
Jun. 30, 2020USD ($)segment | Jun. 30, 2018USD ($) | Jun. 30, 2019USD ($) | Jun. 30, 2017USD ($) | |
Goodwill and Intangible Assets [Line Items] | ||||
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount | $ 729 | $ 626 | $ 687 | $ 494 |
Goodwill, Impairment Loss | 1,400 | |||
Discount Rate, fair value inputs | 8.50% | |||
Number of Operating Segments | segment | 2 | |||
Minimum | ||||
Goodwill and Intangible Assets [Line Items] | ||||
Discount Rate, fair value inputs | 8.50% | |||
Maximum | ||||
Goodwill and Intangible Assets [Line Items] | ||||
Discount Rate, fair value inputs | 10.50% | |||
SEC Schedule, 12-09, Allowance, Loss on Finance Receivable [Member] | ||||
Goodwill and Intangible Assets [Line Items] | ||||
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount | $ 27 | $ 7 | $ 14 | $ 9 |
Basis of Presentation and Su_11
Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Vendor Reserves) (Details) - USD ($) $ in Millions | Jun. 30, 2020 | Jun. 30, 2019 |
Accounting Policies [Abstract] | ||
Vendor reserves | $ 77 | $ 53 |
Basis of Presentation and Su_12
Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Dividends) (Details) - $ / shares | 12 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | |
Accounting Policies [Abstract] | |||
Cash dividends per common share (in usd per share) | $ 1.92 | $ 1.91 | $ 1.85 |
Basis of Presentation and Su_13
Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Sales Returns and Allowances) (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | |
Accounting Policies [Abstract] | |||
Accrual for estimated sales returns and allowances | $ 495 | $ 479 | |
Revenue Recognition, Sales Returns, Reserve for Sales Returns | $ 2,300 | $ 2,200 | $ 2,400 |
Basis of Presentation and Su_14
Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Shipping and Handling) (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | |
goods and services sold [Line Items] | |||
Cost of Goods and Services Sold | $ 146,054 | $ 138,700 | $ 129,628 |
Shipping and Handling [Member] | |||
goods and services sold [Line Items] | |||
Cost of Goods and Services Sold | $ 620 | $ 622 | $ 543 |
Basis of Presentation and Su_15
Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Recent Financial Accounting Standards) (Details) - USD ($) $ in Millions | Jun. 30, 2020 | Jul. 01, 2019 | Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2017 |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||||
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount | $ 729 | $ 687 | $ 626 | $ 494 | |
Lease Liabilities established as a Result of the adoption of ASC 842 | $ 422 |
Basis of Presentation and Su_16
Basis of Presentation and Summary of Significant Accounting Policies Loss Contingencies (Details) $ in Millions | 3 Months Ended |
Sep. 30, 2019USD ($) | |
Total Opioid Litigation [Member] | |
Loss Contingencies [Line Items] | |
Gain (Loss) Related to Litigation Settlement | $ (5,630) |
Total Opioid Litigation, net of tax [Member] | |
Loss Contingencies [Line Items] | |
Gain (Loss) Related to Litigation Settlement | $ (5,140) |
Divestitures and Acquisitions (
Divestitures and Acquisitions (Narrative) (Details) - USD ($) $ in Millions | Jul. 29, 2017 | Aug. 31, 2018 | Jun. 30, 2020 | Sep. 30, 2018 | Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | May 01, 2020 | Aug. 01, 2018 |
Business Acquisition | |||||||||
Payments to Acquire Businesses, Net of Cash Acquired | $ 0 | $ 82 | $ 6,142 | ||||||
Pre-Tax Gain on Divestiture | 508 | ||||||||
Gain on Sale of Investments | 579 | 0 | 0 | ||||||
Income (Loss) from Equity Method Investments | 2 | 10 | |||||||
Patient Recovery Business [Member] | |||||||||
Business Acquisition | |||||||||
Business Combination, Consideration Transferred | $ 6,100 | ||||||||
Transaction and integration costs | 7 | 75 | 109 | ||||||
China Pharmaceutical and Medical Products Distribution Business [Member] | |||||||||
Business Acquisition | |||||||||
Proceeds from Divestiture of Businesses | 861 | ||||||||
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal | $ 41 | ||||||||
naviHealth [Member] | |||||||||
Business Acquisition | |||||||||
Proceeds from Divestiture of Businesses | $ 737 | ||||||||
Equity Method Investment, Ownership Percentage | 40.00% | ||||||||
Partnership Indirect Ownership | 100.00% | ||||||||
Pre-Tax Gain on Divestiture | $ 508 | $ 508 | |||||||
Equity Method Investments | $ 334 | $ 334 | $ 358 | ||||||
Redeemable Noncontrolling Interest, Equity, Carrying Amount | $ 12 | ||||||||
Provisional tax benefit related to transaction | $ 130 | ||||||||
Gain on Sale of Investments | $ 579 | ||||||||
Navi Ownership Interest Divested [Member] | naviHealth [Member] | |||||||||
Business Acquisition | |||||||||
Noncontrolling Interest, Ownership Percentage by Parent | 98.00% |
Restructuring and Employee Se_3
Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | |
Restructuring Charges [Abstract] | |||
Employee-related costs | $ 66 | $ 95 | $ 34 |
Facility Exit and Other Costs | 56 | 30 | 142 |
Total restructuring and employee severance | $ 122 | $ 125 | $ 176 |
Restructuring and Employee Se_4
Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details) - USD ($) $ in Millions | 12 Months Ended | |
Jun. 30, 2020 | Jun. 30, 2019 | |
Restructuring Reserve [Roll Forward] | ||
Beginning Balance | $ 72 | $ 28 |
Additions | 109 | 92 |
Payments and other adjustments | (85) | (48) |
Ending Balance | 96 | 72 |
Employee- Related Costs | ||
Restructuring Reserve [Roll Forward] | ||
Beginning Balance | 64 | 24 |
Additions | 85 | 84 |
Payments and other adjustments | (81) | (44) |
Ending Balance | 68 | 64 |
Facility Exit and Other Costs | ||
Restructuring Reserve [Roll Forward] | ||
Beginning Balance | 8 | 4 |
Additions | 24 | 8 |
Payments and other adjustments | (4) | (4) |
Ending Balance | $ 28 | $ 8 |
Restructuring and Employee Se_5
Restructuring and Employee Severance Narrative (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | |
Restructuring Cost and Reserve [Line Items] | |||
Restructuring Costs | $ 109 | $ 92 | |
Facility Exit and Other Costs | $ 56 | $ 30 | $ 142 |
Distributor Contract [Member] | |||
Restructuring Cost and Reserve [Line Items] | |||
Facility Exit and Other Costs | $ 125 |
Goodwill and Other Intangible_3
Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | |
Goodwill [Line Items] | |||
Goodwill, Transfers | $ (5) | $ 52 | |
Goodwill [Roll Forward] | |||
Beginning balance | 8,378 | 8,316 | |
Foreign currency translation adjustments and other | 16 | (10) | |
Goodwill, Impairment Loss | $ (1,400) | ||
Ending balance | 8,357 | 8,378 | 8,316 |
Pharmaceutical | |||
Goodwill [Line Items] | |||
Goodwill, Transfers | (5) | 45 | |
Goodwill [Roll Forward] | |||
Beginning balance | 2,663 | 2,621 | |
Foreign currency translation adjustments and other | 1 | 3 | |
Ending balance | 2,657 | 2,663 | 2,621 |
Accumulated goodwill impairment loss | 829 | 829 | |
Medical | |||
Goodwill [Line Items] | |||
Goodwill, Transfers | 0 | 7 | |
Goodwill [Roll Forward] | |||
Beginning balance | 5,715 | 5,695 | |
Foreign currency translation adjustments and other | 15 | (13) | |
Ending balance | 5,700 | 5,715 | $ 5,695 |
Accumulated goodwill impairment loss | $ 1,400 | $ 1,372 |
Goodwill and Other Intangible_4
Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | |
Indefinite-lived Intangible Assets [Line Items] | |||
Net Intangible | $ 23 | $ 22 | |
Finite-Lived Intangible Assets [Line Items] | |||
Amortization of Intangible Assets | 512 | 531 | $ 574 |
Gross Intangible | 5,831 | 5,836 | |
Accumulated Amortization | 2,936 | 2,428 | |
Net Intangible | $ 2,895 | 3,408 | |
Weighted- Average Remaining Amortization Period (Years) | 12 years | ||
Gross Intangible, Total other intangible assets | $ 5,854 | 5,858 | |
Net Intangible, Total other intangible assets | 2,918 | 3,430 | |
IPR&D, trademarks and other | |||
Indefinite-lived Intangible Assets [Line Items] | |||
Net Intangible | 23 | 22 | |
Customer relationships | |||
Finite-Lived Intangible Assets [Line Items] | |||
Gross Intangible | 3,554 | 3,562 | |
Accumulated Amortization | 1,828 | 1,517 | |
Net Intangible | $ 1,726 | 2,045 | |
Weighted- Average Remaining Amortization Period (Years) | 13 years | ||
Trademarks, trade names and patents | |||
Finite-Lived Intangible Assets [Line Items] | |||
Gross Intangible | $ 673 | 672 | |
Accumulated Amortization | 341 | 295 | |
Net Intangible | $ 332 | 377 | |
Weighted- Average Remaining Amortization Period (Years) | 13 years | ||
Developed technology and other | |||
Finite-Lived Intangible Assets [Line Items] | |||
Gross Intangible | $ 1,604 | 1,602 | |
Accumulated Amortization | 767 | 616 | |
Net Intangible | $ 837 | $ 986 | |
Weighted- Average Remaining Amortization Period (Years) | 11 years |
Goodwill and Other Intangible_5
Goodwill and Other Intangible Assets (Narrative) (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | |
Goodwill [Line Items] | |||
Discount Rate, fair value inputs | 8.50% | ||
Goodwill, Impairment Loss | $ 1,400 | ||
Goodwill | $ 8,357 | $ 8,378 | 8,316 |
Amortization of Intangible Assets | 512 | $ 531 | $ 574 |
Estimated annual amortization of intangible assets - 2020 | 442 | ||
Estimated annual amortization of intangible assets - 2021 | 408 | ||
Estimated annual amortization of intangible assets - 2022 | 358 | ||
Estimated annual amortization of intangible assets - 2023 | 329 | ||
Estimated annual amortization of intangible assets - 2024 | $ 277 |
Investments (Details)
Investments (Details) - USD ($) $ in Millions | 1 Months Ended | 3 Months Ended | 12 Months Ended | |||
Aug. 31, 2018 | Sep. 30, 2018 | Jun. 30, 2020 | Jun. 30, 2019 | May 01, 2020 | Aug. 01, 2018 | |
Investments [Line Items] | ||||||
Income (Loss) from Equity Method Investments | $ 2 | $ 10 | ||||
Pre-Tax Gain on Divestiture | 508 | |||||
naviHealth [Member] | ||||||
Investments [Line Items] | ||||||
Proceeds from Divestiture of Businesses | $ 737 | |||||
Equity Method Investment, Ownership Percentage | 40.00% | |||||
Equity Method Investments | $ 334 | $ 358 | ||||
Partnership Indirect Ownership | 100.00% | |||||
Pre-Tax Gain on Divestiture | $ 508 | $ 508 | ||||
Navi Ownership Interest Divested [Member] | naviHealth [Member] | ||||||
Investments [Line Items] | ||||||
Noncontrolling Interest, Ownership Percentage by Parent | 98.00% |
Long-Term Obligations and Oth_3
Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details) - USD ($) $ in Millions | Jun. 30, 2020 | Jun. 30, 2019 |
Debt Instrument [Line Items] | ||
Accounts payable | $ 21,374 | $ 21,535 |
Other obligations | 35 | 10 |
Total | 6,775 | 8,031 |
Less: current portion of long-term obligations and other short-term borrowings | 10 | 452 |
Long-term obligations, less current portion | 6,765 | 7,579 |
2.4% Notes due 2019 | ||
Debt Instrument [Line Items] | ||
Notes Payable | 0 | 450 |
4.625% Notes due 2020 | ||
Debt Instrument [Line Items] | ||
Notes Payable | 0 | 508 |
2.616% Notes due fiscal 2022 | ||
Debt Instrument [Line Items] | ||
Notes Payable | 834 | 1,079 |
3.2% Notes due 2022 | ||
Debt Instrument [Line Items] | ||
Notes Payable | 236 | 247 |
Floating Rate Notes due fiscal 2022 | ||
Debt Instrument [Line Items] | ||
Notes Payable | 321 | 340 |
3.2% Notes due 2023 | ||
Debt Instrument [Line Items] | ||
Notes Payable | 576 | 551 |
3.079% Notes due fiscal 2024 | ||
Debt Instrument [Line Items] | ||
Notes Payable | 809 | 781 |
3.5% Notes due fiscal 2025 | ||
Debt Instrument [Line Items] | ||
Notes Payable | 413 | 402 |
3.75% Notes due 2025 | ||
Debt Instrument [Line Items] | ||
Notes Payable | 529 | 494 |
3.41% Notes due fiscal 2027 | ||
Debt Instrument [Line Items] | ||
Notes Payable | 1,215 | 1,318 |
4.6% Notes due 2043 | ||
Debt Instrument [Line Items] | ||
Notes Payable | 340 | 346 |
4.5% Notes due 2044 | ||
Debt Instrument [Line Items] | ||
Notes Payable | 342 | 342 |
4.9% Notes due 2045 | ||
Debt Instrument [Line Items] | ||
Notes Payable | 441 | 445 |
4.368% Notes due fiscal 2047 | ||
Debt Instrument [Line Items] | ||
Notes Payable | 560 | 594 |
7.0% Debentures due 2026 | ||
Debt Instrument [Line Items] | ||
Notes Payable | $ 124 | $ 124 |
Long-Term Obligations and Oth_4
Long-Term Obligations and Other Short-Term Borrowings Narrative (Details) - USD ($) $ in Millions | 1 Months Ended | 12 Months Ended | ||
Jun. 30, 2018 | Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | |
Line of Credit Facility [Line Items] | ||||
Document Fiscal Year Focus | 2020 | |||
Accounts Payable, Current | $ 21,374 | $ 21,535 | ||
Notes Payable Repurchased | 100 | |||
Other Borrowings | 35 | 10 | ||
Gain (Loss) on Extinguishment of Debt | (16) | 0 | $ (2) | |
Maturities of existing long-term obligations and other short-term borrowings - 2020 | 10 | |||
Maturities of existing long-term obligations and other short-term borrowings-2021 | 1,400 | |||
Maturities of existing long-term obligations and other short-term borrowings-2022 | 585 | |||
Maturities of existing long-term obligations and other short-term borrowings-2023 | 814 | |||
Maturities of existing long-term obligations and other short-term borrowings-2024 | 414 | |||
Maturities of existing long-term obligations and other short-term borrowings-Thereafter | 3,600 | |||
Letter of Credit | ||||
Line of Credit Facility [Line Items] | ||||
Long-term Line of Credit | 1 | 24 | ||
Committed Receivables Sales Facility Program | ||||
Line of Credit Facility [Line Items] | ||||
Line of Credit Facility, Maximum Amount Outstanding During Period | 700 | |||
Line of Credit Facility, Average Outstanding Amount | 12 | |||
Revolving Credit Facility | ||||
Line of Credit Facility [Line Items] | ||||
Line of Credit Facility, Maximum Borrowing Capacity | 2,000 | |||
Commercial paper | ||||
Line of Credit Facility [Line Items] | ||||
Line of Credit Facility, Maximum Amount Outstanding During Period | 1,700 | |||
Line of Credit Facility, Average Outstanding Amount | 183 | |||
Line of Credit Facility, Maximum Borrowing Capacity | 2,000 | |||
Short Term Credit Facilities | ||||
Line of Credit Facility [Line Items] | ||||
Line of Credit Facility, Maximum Borrowing Capacity | 6 | 9 | ||
2.616% Notes due fiscal 2022 | ||||
Line of Credit Facility [Line Items] | ||||
Notes Payable Repurchased | 247 | 67 | ||
3.2% Notes due 2023 | ||||
Line of Credit Facility [Line Items] | ||||
Notes Payable Repurchased | 11 | |||
Floating Rate Notes due fiscal 2022 | ||||
Line of Credit Facility [Line Items] | ||||
Notes Payable Repurchased | 20 | 8 | ||
3.41% Notes due fiscal 2027 | ||||
Line of Credit Facility [Line Items] | ||||
Notes Payable Repurchased | 104 | $ 24 | ||
4.6% Notes due 2043 | ||||
Line of Credit Facility [Line Items] | ||||
Notes Payable Repurchased | 6 | |||
4.9% Notes due 2045 | ||||
Line of Credit Facility [Line Items] | ||||
Notes Payable Repurchased | 5 | |||
4.368% Notes due fiscal 2047 | ||||
Line of Credit Facility [Line Items] | ||||
Notes Payable Repurchased | 35 | |||
1.95% Notes due 2018 | ||||
Line of Credit Facility [Line Items] | ||||
Proceeds from (Repayments of) Notes Payable | $ (550) | |||
2.616% Notes, 3.2% Notes, 3.41% Notes, 4.6% Notes, 4.9% Notes and 4.368% Notes [Member] | ||||
Line of Credit Facility [Line Items] | ||||
Gain (Loss) on Extinguishment of Debt | $ 9 |
Long-Term Obligations and Oth_5
Long-Term Obligations and Other Short-Term Borrowings Long-Term Debt (Details) - USD ($) $ in Millions | 1 Months Ended | 12 Months Ended | |||
Nov. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | |
Debt Instrument [Line Items] | |||||
Accounts payable | $ 21,374 | $ 21,535 | |||
Offer as percentage of principal amount | 101.00% | ||||
Gain (Loss) on Extinguishment of Debt | $ (16) | 0 | $ (2) | ||
Notes Payable Repurchased | 100 | ||||
1.948% Notes due 2019 | |||||
Debt Instrument [Line Items] | |||||
Notes Payable Repurchased | 1,000 | ||||
2.616% Notes due fiscal 2022 | |||||
Debt Instrument [Line Items] | |||||
Notes Payable Repurchased | 247 | 67 | |||
3.41% Notes due fiscal 2027 | |||||
Debt Instrument [Line Items] | |||||
Notes Payable Repurchased | 104 | 24 | |||
4.368% Notes due fiscal 2047 | |||||
Debt Instrument [Line Items] | |||||
Notes Payable Repurchased | 35 | ||||
2.616% Notes, 3.2% Notes, 3.41% Notes, 4.6% Notes, 4.9% Notes and 4.368% Notes [Member] | |||||
Debt Instrument [Line Items] | |||||
Gain (Loss) on Extinguishment of Debt | 9 | ||||
Floating Rate Notes due fiscal 2022 | |||||
Debt Instrument [Line Items] | |||||
Notes Payable Repurchased | 20 | 8 | |||
1.95% Notes due 2018 | |||||
Debt Instrument [Line Items] | |||||
Proceeds from (Repayments of) Notes Payable | $ 550 | ||||
2.4% Notes due 2019 | |||||
Debt Instrument [Line Items] | |||||
Repayments of Notes Payable | $ 450 | ||||
3.2% Notes due 2022 | |||||
Debt Instrument [Line Items] | |||||
Notes Payable Repurchased | $ 1 | ||||
3.2% Notes due 2023 | |||||
Debt Instrument [Line Items] | |||||
Notes Payable Repurchased | 11 | ||||
4.6% Notes due 2043 | |||||
Debt Instrument [Line Items] | |||||
Notes Payable Repurchased | 6 | ||||
4.625% Notes due 2020 | |||||
Debt Instrument [Line Items] | |||||
Gain (Loss) on Extinguishment of Debt | 7 | ||||
Notes Payable Repurchased | 500 | ||||
4.9% Notes due 2045 | |||||
Debt Instrument [Line Items] | |||||
Notes Payable Repurchased | $ 5 | ||||
7.0% Debentures due 2026 | Allegiance Corporation | |||||
Debt Instrument [Line Items] | |||||
Stated interest rate | 7.00% |
Long-Term Obligations and Oth_6
Long-Term Obligations and Other Short-Term Borrowings Other Financing Arrangements (Details) - USD ($) $ in Millions | 12 Months Ended | |
Jun. 30, 2020 | Jun. 30, 2019 | |
Debt Instrument [Line Items] | ||
Other obligations | $ 35 | $ 10 |
Revolving Credit Facility | ||
Debt Instrument [Line Items] | ||
Maximum borrowing capacity | 2,000 | |
Letter of Credit | ||
Debt Instrument [Line Items] | ||
Line of credit | 1 | 24 |
Letter of Credit | Committed Receivables Sales Facility Program | ||
Debt Instrument [Line Items] | ||
Line of credit | 29 | 30 |
Short Term Credit Facilities | ||
Debt Instrument [Line Items] | ||
Maximum borrowing capacity | 6 | $ 9 |
Short Term Credit Facilities | Committed Receivables Sales Facility Program | ||
Debt Instrument [Line Items] | ||
Maximum borrowing capacity | 1,000 | |
Commercial Paper | ||
Debt Instrument [Line Items] | ||
Maximum borrowing capacity | 2,000 | |
Average amount outstanding | $ 183 |
Income Taxes (Schedule of Incom
Income Taxes (Schedule of Income before Income Tax, Domestic and Foreign) (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | |
Income Tax Disclosure [Abstract] | |||
Document Fiscal Year Focus | 2020 | ||
U.S. operations | $ (4,056) | $ 1,478 | $ 391 |
Non-U.S. operations | 284 | 273 | (619) |
Earnings/(loss) before income taxes | $ (3,772) | $ 1,751 | $ (228) |
Income Taxes (Schedule of Compo
Income Taxes (Schedule of Components of Income Tax Expense (Benefit), Current and Deferred) (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | |
Current: | |||
Federal | $ 659 | $ 295 | $ 341 |
State and local | 154 | 89 | 41 |
Non-U.S. | 69 | 85 | 143 |
Total current | 882 | 469 | 525 |
Deferred: | |||
Federal | (822) | (28) | (1,003) |
State and local | (127) | (37) | 16 |
Non-U.S. | (12) | (18) | (25) |
Total deferred | (961) | (83) | (1,012) |
Provision for/(benefit from) income taxes | $ (79) | $ 386 | $ (487) |
Income Taxes (Schedule of Effec
Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details) | 12 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | |
Income Tax Disclosure [Abstract] | |||
Provision at Federal statutory rate | 21.00% | 21.00% | 28.10% |
State and local income taxes, net of federal benefit | 2.50% | 0.90% | (16.00%) |
Tax effect of foreign operations | 0.00% | (0.70%) | (48.40%) |
Nondeductible/nontaxable items | (0.10%) | 2.50% | (10.20%) |
Goodwill impairment | 0.00% | 0.00% | (124.70%) |
Tax Act | (0.10%) | 0.80% | (410.90%) |
Change in valuation allowances | 1.50% | 4.50% | (76.90%) |
Foreign tax credits | 0.50% | (1.00%) | 27.30% |
China tax related to divestiture | 0.00% | 0.00% | (25.80%) |
Effective Income Tax Rate Reconciliation Legal Entity Reorganization Reconciling Items Percent | 0.00% | (3.60%) | 71.40% |
Effective Income Tax Reconciliation, Opioid Litigation | (23.20%) | 0.00% | 0.00% |
Other | (0.20%) | (0.70%) | (21.90%) |
Effective income tax rate | 2.10% | 22.10% | 213.80% |
Income Taxes (Narrative) (Detai
Income Taxes (Narrative) (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | ||||
Jun. 30, 2018 | Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | Mar. 31, 2020 | Jun. 30, 2017 | |
Income Taxes | ||||||
Effective Income Tax Rate Reconciliation, Percent | 2.10% | 22.10% | 213.80% | |||
Income Tax Expense (Benefit) | $ (79) | $ 386 | $ (487) | |||
Effective Tax Rate Impact From Certain Foreign Jurisdictions | $ 17 | |||||
Provision at Federal statutory rate | 21.00% | 21.00% | 28.10% | |||
Federal | $ 822 | $ 28 | $ 1,003 | |||
Deferred tax assets on tax credit carryforwards | (589) | (621) | ||||
Valuation allowance on operating loss carryforwards | 461 | |||||
Unrecognized tax benefits that would impact effective tax rate | $ 262 | 753 | 303 | 262 | ||
Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions | 39 | 78 | 141 | |||
Unrecognized tax benefits | 423 | 998 | 456 | 423 | $ 417 | |
Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities | 25 | 6 | 99 | |||
Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations | 0 | 3 | 11 | |||
Unrecognized tax benefits, interest and penalties accrued | 110 | 146 | 122 | 110 | ||
Unrecognized tax benefits, interest and penalties | $ 8 | 16 | 8 | |||
Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense | 800 | |||||
Minimum | ||||||
Income Taxes | ||||||
Estimated range of decrease in unrecognized tax benefits within the next 12 months | 0 | |||||
Maximum | ||||||
Income Taxes | ||||||
Estimated range of decrease in unrecognized tax benefits within the next 12 months | 370 | |||||
Federal | ||||||
Income Taxes | ||||||
Tax credit carryforwards | 123 | |||||
State and Local | ||||||
Income Taxes | ||||||
Tax credit carryforwards | 2,400 | |||||
Foreign | ||||||
Income Taxes | ||||||
Tax credit carryforwards | 2,200 | |||||
Patient Recovery Business [Member] | ||||||
Income Taxes | ||||||
Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions | 110 | |||||
Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities | 81 | |||||
Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations | $ 11 | |||||
Patient Recovery Business [Member] | ||||||
Income Taxes | ||||||
Amount CareFusion is liable under tax matters agreement in the event amount must be paid to the taxing authority | 19 | 22 | ||||
CareFusion [Member] | ||||||
Income Taxes | ||||||
Amount CareFusion is liable under tax matters agreement in the event amount must be paid to the taxing authority | 176 | $ 165 | ||||
Total Opioid Litigation [Member] | ||||||
Income Taxes | ||||||
Estimated Litigation Liability | $ 5,630 | |||||
Income Tax Expense (Benefit) | (488) | |||||
Unrecognized tax benefits that would impact effective tax rate | $ 469 |
Income Taxes (Schedule of Defer
Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details) - USD ($) $ in Millions | Jun. 30, 2020 | Jun. 30, 2019 |
Deferred income tax assets: | ||
Receivable basis difference | $ 39 | $ 35 |
Accrued liabilities | 607 | 133 |
Share-based compensation | 38 | 39 |
Loss and tax credit carryforwards | 589 | 621 |
Deferred tax assets related to uncertain tax positions | 52 | 30 |
Other | 87 | 6 |
Total deferred income tax assets | 1,412 | 864 |
Valuation allowance for deferred income tax assets | (470) | (542) |
Net deferred income tax assets | 942 | 322 |
Deferred income tax liabilities: | ||
Inventory basis differences | (1,083) | (1,056) |
Property-related | (327) | (171) |
Goodwill and other intangibles | (751) | (808) |
Total deferred income tax liabilities | (2,161) | (2,035) |
Net deferred income tax liability | $ (1,219) | $ (1,713) |
Income Taxes (Schedule of Def_2
Income Taxes (Schedule of Deferred Tax Assets and Liabilities After Netting by Tax Jurisdiction) (Details) - USD ($) $ in Millions | Jun. 30, 2020 | Jun. 30, 2019 |
Income Tax Disclosure [Abstract] | ||
Deferred Income Taxes and Other Assets, Noncurrent | $ 39 | $ 36 |
Deferred Income Taxes and Other Tax Liabilities, Noncurrent | 1,258 | 1,749 |
Net deferred income tax liability | $ (1,219) | $ (1,713) |
Income Taxes (Schedule of Unrec
Income Taxes (Schedule of Unrecognized Tax Benefits Roll Forward) (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | ||
Jun. 30, 2018 | Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | |
Income Tax Contingency [Line Items] | ||||
Current Federal Tax Expense (Benefit) | $ 659 | $ 295 | $ 341 | |
Current State and Local Tax Expense (Benefit) | 154 | 89 | 41 | |
Current Foreign Tax Expense (Benefit) | 69 | 85 | 143 | |
Current Income Tax Expense (Benefit) | 882 | 469 | 525 | |
Deferred Federal Income Tax Expense (Benefit) | (822) | (28) | (1,003) | |
Deferred State and Local Income Tax Expense (Benefit) | (127) | (37) | 16 | |
Deferred Foreign Income Tax Expense (Benefit) | (12) | (18) | (25) | |
Deferred Income Tax Expense (Benefit) | (961) | (83) | (1,012) | |
Income Tax Expense (Benefit) | (79) | 386 | (487) | |
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] | ||||
Balance at beginning of fiscal year | 456 | 423 | 417 | |
Additions for tax positions of the current year | $ 24 | 500 | 15 | |
Additions for tax positions of prior years (1) | 39 | 78 | 141 | |
Reductions for tax positions of prior years | (5) | (27) | (40) | |
Settlements with tax authorities (1) | (25) | (6) | (99) | |
Expiration of the statute of limitations (1) | 0 | (3) | (11) | |
Balance at end of fiscal year | $ 423 | $ 998 | $ 456 | 423 |
Patient Recovery Business [Member] | ||||
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] | ||||
Additions for tax positions of prior years (1) | 110 | |||
Settlements with tax authorities (1) | (81) | |||
Expiration of the statute of limitations (1) | $ (11) |
Commitments, Contingent Liabi_2
Commitments, Contingent Liabilities and Litigation (Details) $ in Millions | Jul. 28, 2020plaintifflawsuit | Jun. 30, 2020USD ($) | Mar. 31, 2020USD ($) | Dec. 31, 2019USD ($) | Sep. 30, 2019USD ($) | Jun. 30, 2019USD ($) | Mar. 31, 2019USD ($) | Dec. 31, 2018USD ($) | Sep. 30, 2018USD ($) | Jun. 30, 2020USD ($) | Jun. 30, 2019USD ($) | Jun. 30, 2018USD ($) | Aug. 11, 2020StateAGlawsuit |
Loss Contingencies [Line Items] | |||||||||||||
Income from Settlements of Class Action Lawsuits | $ 16 | $ 94 | $ 22 | ||||||||||
Cost of Goods and Services Sold | 146,054 | 138,700 | 129,628 | ||||||||||
Distribution, selling, general and administrative expenses | $ 1,137 | $ 1,165 | $ 1,163 | $ 1,107 | $ 1,168 | $ 1,097 | $ 1,064 | $ 1,155 | 4,572 | 4,480 | 4,596 | ||
Opioid Total Settlement, Cuyahoga and Summit Counties | 215 | 215 | |||||||||||
Gain (Loss) Related to Litigation Settlement | $ (5,741) | $ (36) | $ (159) | ||||||||||
Opioid Lawsuits | Subsequent Event | |||||||||||||
Loss Contingencies [Line Items] | |||||||||||||
Loss Contingency, Lawsuits, Number | 3,000 | ||||||||||||
Number of State Attorneys General filing lawsuits | StateAG | 25 | ||||||||||||
Opioid Lawsuits State [Domain] | Subsequent Event | |||||||||||||
Loss Contingencies [Line Items] | |||||||||||||
Loss Contingency, Lawsuits, Number | 2,800 | ||||||||||||
Product Liability Lawsuits | Subsequent Event | |||||||||||||
Loss Contingencies [Line Items] | |||||||||||||
Number of lawsuits filed | lawsuit | 31 | ||||||||||||
Opioid Litigation, less Cuyahoga and Summit Counties [Member] | |||||||||||||
Loss Contingencies [Line Items] | |||||||||||||
Estimated Litigation Liability | 5,560 | ||||||||||||
Cash Component For Settlement Framework, Term | 18 years | ||||||||||||
Opioid Litigation, Cuyahoga and Summit Counties [Member] | |||||||||||||
Loss Contingencies [Line Items] | |||||||||||||
Gain (Loss) Related to Litigation Settlement | $ (66) | ||||||||||||
CVS Health | |||||||||||||
Loss Contingencies [Line Items] | |||||||||||||
Maximum quarterly payment | 45.6 | ||||||||||||
Alameda County [Member] | Product Liability Lawsuits | Subsequent Event | |||||||||||||
Loss Contingencies [Line Items] | |||||||||||||
Number of plaintiffs | plaintiff | 4,280 | ||||||||||||
Other Jurisdictions [Member] | Product Liability Lawsuits | Subsequent Event | |||||||||||||
Loss Contingencies [Line Items] | |||||||||||||
Number of plaintiffs | plaintiff | 36 | ||||||||||||
Product Liability Lawsuits | Subsequent Event | |||||||||||||
Loss Contingencies [Line Items] | |||||||||||||
Number of lawsuits filed | lawsuit | 334 | ||||||||||||
Minimum | |||||||||||||
Loss Contingencies [Line Items] | |||||||||||||
Loss Contingency Accrual | 468 | 468 | |||||||||||
Maximum | |||||||||||||
Loss Contingencies [Line Items] | |||||||||||||
Loss Contingency, Estimate of Possible Loss | $ 919 | 919 | |||||||||||
Sterile Surgical Gown Recall [Member] [Domain] | |||||||||||||
Loss Contingencies [Line Items] | |||||||||||||
Inventory Recall Expense | 85 | ||||||||||||
Cost of Goods and Services Sold | 48 | ||||||||||||
Distribution, selling, general and administrative expenses | $ 37 | ||||||||||||
Total Opioid Litigation, net of tax [Member] | |||||||||||||
Loss Contingencies [Line Items] | |||||||||||||
Gain (Loss) Related to Litigation Settlement | (5,140) | ||||||||||||
Total Opioid Litigation [Member] | |||||||||||||
Loss Contingencies [Line Items] | |||||||||||||
Estimated Litigation Liability | $ 5,630 | ||||||||||||
Gain (Loss) Related to Litigation Settlement | $ (5,630) | ||||||||||||
Private Parties [Member] | Opioid Lawsuits | Subsequent Event | |||||||||||||
Loss Contingencies [Line Items] | |||||||||||||
Loss Contingency, Lawsuits, Number | lawsuit | 400 | ||||||||||||
Class Action Lawsuits [Member] | Private Parties [Member] | Opioid Lawsuits | Subsequent Event | |||||||||||||
Loss Contingencies [Line Items] | |||||||||||||
Loss Contingency, Lawsuits, Number | lawsuit | 106 |
Fair Value Measurements (Fair V
Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Millions | Jun. 30, 2020 | Jun. 30, 2019 |
Assets: | ||
Cash equivalents | $ 721 | $ 297 |
Other investments | 114 | 118 |
Liabilities: | ||
Forward contracts | 53 | 53 |
Level 1 | ||
Assets: | ||
Cash equivalents | 721 | 297 |
Other investments | 114 | 118 |
Liabilities: | ||
Forward contracts | 0 | 0 |
Level 2 | ||
Assets: | ||
Cash equivalents | 0 | 0 |
Other investments | 0 | 0 |
Liabilities: | ||
Forward contracts | 53 | 53 |
Level 3 | ||
Assets: | ||
Cash equivalents | 0 | 0 |
Other investments | 0 | 0 |
Liabilities: | ||
Forward contracts | $ 0 | $ 0 |
Fair Value Measurements (Reconc
Fair Value Measurements (Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis Using Unobservable Inputs (Level 3)) (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Millions | Jun. 30, 2020 | Jun. 30, 2019 |
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | ||
Forward contracts | $ 53 | $ 53 |
Level 1 | ||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | ||
Forward contracts | 0 | 0 |
Level 2 | ||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | ||
Forward contracts | 53 | 53 |
Level 3 | ||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | ||
Forward contracts | $ 0 | $ 0 |
Financial Instruments (Schedule
Financial Instruments (Schedule of the Fair Value of Assets and Liabilities Related to Derivatives Designated as Hedging Instruments) (Details) - USD ($) $ in Millions | Jun. 30, 2020 | Jun. 30, 2019 |
Derivatives, Fair Value [Line Items] | ||
Total assets | $ 74 | $ 64 |
Total liabilities | 21 | 11 |
Designated as Hedging Instrument | Cash Flow Hedging | Foreign Currency Contracts | Prepaid Expenses and Other | ||
Derivatives, Fair Value [Line Items] | ||
Total assets | 0 | 6 |
Designated as Hedging Instrument | Cash Flow Hedging | Foreign Currency Contracts | Other Accrued Liabilities | ||
Derivatives, Fair Value [Line Items] | ||
Total liabilities | 4 | 2 |
Designated as Hedging Instrument | Cash Flow Hedging | Interest Rate Swaps | Deferred Income Taxes and Other Liabilities | ||
Derivatives, Fair Value [Line Items] | ||
Total liabilities | 16 | 0 |
Designated as Hedging Instrument | Cash Flow Hedging | Commodity Contracts | Other Accrued Liabilities | ||
Derivatives, Fair Value [Line Items] | ||
Total liabilities | 1 | 3 |
Designated as Hedging Instrument | Fair Value Hedging | Interest Rate Swaps | Other Assets [Member] | ||
Derivatives, Fair Value [Line Items] | ||
Total assets | 27 | 46 |
Designated as Hedging Instrument | Fair Value Hedging | Interest Rate Swaps | Deferred Income Taxes and Other Liabilities | ||
Derivatives, Fair Value [Line Items] | ||
Total liabilities | 0 | 6 |
Designated as Hedging Instrument | Fair Value Hedging | Cross Currency Interest Rate Contract [Member] | Other Assets [Member] | ||
Derivatives, Fair Value [Line Items] | ||
Total assets | $ 47 | $ 12 |
Financial Instruments (Narrativ
Financial Instruments (Narrative) (Details) € in Millions, ¥ in Millions, $ in Millions | 12 Months Ended | |||||
Jun. 30, 2020USD ($) | Jun. 30, 2019USD ($) | Jun. 30, 2020JPY (¥) | Sep. 30, 2018USD ($) | Sep. 30, 2018EUR (€) | Jun. 30, 2018USD ($) | |
Derivative [Line Items] | ||||||
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments | $ 0 | $ 0 | ||||
Currency Swap [Member] | ||||||
Derivative [Line Items] | ||||||
Derivative Liability, Notional Amount | 600 | ¥ 64,000 | $ 233 | € 200 | ||
Foreign Currency Contracts | ||||||
Derivative [Line Items] | ||||||
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax | 35 | 12 | ||||
Interest Income (Expense), Nonoperating, Net | 17 | 5 | ||||
Fair Value Hedging | Interest Rate Swaps | ||||||
Derivative [Line Items] | ||||||
Derivative, notional amount | 550 | 2,150 | ||||
Cash Flow Hedging | Foreign Currency Contracts | ||||||
Derivative [Line Items] | ||||||
Derivative, notional amount | 328 | 381 | ||||
Designated as Hedging Instrument | Fair Value Hedging | Interest Rate Swaps | ||||||
Derivative [Line Items] | ||||||
Derivative, notional amount | $ 1,100 | |||||
Derivatives, terminated notional amounts | 163 | |||||
Derivatives, matured notional amounts | $ 200 | $ 550 | ||||
Designated as Hedging Instrument | Cash Flow Hedging | Interest Rate Swaps | ||||||
Derivative [Line Items] | ||||||
Derivative, notional amount | $ 200 |
Financial Instruments (Schedu_2
Financial Instruments (Schedule of Outstanding Instruments, Fair Value Hedges) (Details) - Fair Value Hedging - Interest Rate Swaps - USD ($) $ in Millions | Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 |
Derivative [Line Items] | |||
Notional Amount | $ 550 | $ 2,150 | |
Designated as Hedging Instrument | |||
Derivative [Line Items] | |||
Deferred Gain (Loss) on Discontinuation of Interest Rate Fair Value Hedge | 112 | ||
Derivatives, matured notional amounts | $ 200 | $ 550 | |
Notional Amount | $ 1,100 |
Financial Instruments (Schedu_3
Financial Instruments (Schedule of Gain/(Loss) Recognized in Earnings for Interest Rate Contracts Designated as Fair Value Hedges) (Details) - Fair Value Hedging - Interest Expense, Net - USD ($) $ in Millions | 12 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | |
Interest Rate Swaps | |||
Derivative [Line Items] | |||
Gain/(loss) on derivative | $ 106 | $ 9 | $ 11 |
Fixed-Rate Debt | |||
Derivative [Line Items] | |||
Gain/(loss) on derivative | $ (106) | $ (9) | $ (11) |
Financial Instruments (Schedu_4
Financial Instruments (Schedule of Outstanding Instruments, Cash Flow Hedges) (Details) - USD ($) $ in Millions | Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 |
Cash Flow Hedging | |||
Derivative [Line Items] | |||
Derivative Liability, Notional Amount | $ 200 | ||
Fair Value Hedging | Interest Rate Swaps | |||
Derivative [Line Items] | |||
Notional Amount | 550 | $ 2,150 | |
Cash Flow Hedging | Foreign Currency Contracts | |||
Derivative [Line Items] | |||
Notional Amount | 328 | 381 | |
Cash Flow Hedging | Commodity Contracts | |||
Derivative [Line Items] | |||
Notional Amount | $ 16 | 20 | |
Designated as Hedging Instrument | Fair Value Hedging | Interest Rate Swaps | |||
Derivative [Line Items] | |||
Notional Amount | $ 1,100 | ||
Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Amount | 163 | ||
Designated as Hedging Instrument | Cash Flow Hedging | Interest Rate Swaps | |||
Derivative [Line Items] | |||
Notional Amount | $ 200 |
Financial Instruments (Schedu_5
Financial Instruments (Schedule of Gain/(Loss) Included in AOCI for Derivative Instruments Designated as Cash Flow Hedges) (Details) - Cash Flow Hedging - USD ($) $ in Millions | 12 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | |
Forward Contracts [Member] | |||
Derivative [Line Items] | |||
Gain/(loss) included in AOCI for derivative instruments designated as cash flow hedges | $ (16) | $ 0 | $ 0 |
Commodity Contracts | |||
Derivative [Line Items] | |||
Gain/(loss) included in AOCI for derivative instruments designated as cash flow hedges | 1 | (5) | 3 |
Foreign Currency Contracts | |||
Derivative [Line Items] | |||
Gain/(loss) included in AOCI for derivative instruments designated as cash flow hedges | $ (8) | $ 5 | $ (1) |
Financial Instruments (Schedu_6
Financial Instruments (Schedule of Gain/(Loss) Reclassified from AOCI into Earnings for Derivative Instruments Designated as Cash Flow Hedges) (Details) - Cash Flow Hedging - USD ($) $ in Millions | 12 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | |
Foreign Currency Contracts | Revenue | |||
Derivative [Line Items] | |||
Gain/(loss) reclassified from AOCI into earnings for derivative instruments designated as cash flow hedges | $ 7 | $ 2 | $ 1 |
Foreign Currency Contracts | Cost of Products Sold | |||
Derivative [Line Items] | |||
Gain/(loss) reclassified from AOCI into earnings for derivative instruments designated as cash flow hedges | 1 | 0 | 0 |
Foreign Currency Contracts | SG&A Expenses | |||
Derivative [Line Items] | |||
Gain/(loss) reclassified from AOCI into earnings for derivative instruments designated as cash flow hedges | 0 | 1 | (2) |
Forward Contracts [Member] | Interest Expense, Net | |||
Derivative [Line Items] | |||
Gain/(loss) reclassified from AOCI into earnings for derivative instruments designated as cash flow hedges | 2 | 2 | 2 |
Commodity Contracts | SG&A Expenses | |||
Derivative [Line Items] | |||
Gain/(loss) reclassified from AOCI into earnings for derivative instruments designated as cash flow hedges | $ (5) | $ 0 | $ 0 |
Financial Instruments (Schedu_7
Financial Instruments (Schedule of Outstanding Instruments, Economic Hedges) (Details) - USD ($) $ in Millions | Jun. 30, 2020 | Jun. 30, 2019 |
Foreign Currency Contracts | Not Designated as Hedging Instrument | ||
Derivative [Line Items] | ||
Notional Amount | $ 325 | $ 488 |
Financial Instruments (Schedu_8
Financial Instruments (Schedule of Gain/(Loss) Recognized in Earnings for Derivatives Not Designated as Hedging Instrument) (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | |
Not Designated as Hedging Instrument | Foreign Currency Contracts | Other Income, Net | |||
Derivative [Line Items] | |||
Gain/(loss) recognized in earnings for economic (non-designated) derivative instruments | $ (11) | $ (13) | $ (5) |
Financial Instruments (Summary
Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details) - USD ($) $ in Millions | Jun. 30, 2020 | Jun. 30, 2019 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Carrying Amount of Long-Term and other Short-Term Borrowings | $ 6,775 | $ 8,031 |
Carrying amount | 6,775 | 8,031 |
Level 2 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Estimated fair value | $ 7,273 | 8,065 |
Interest Rate Swaps | Designated as Hedging Instrument | Fair Value Hedging | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Amount | $ 163 |
Financial Instruments (Schedu_9
Financial Instruments (Schedule of Fair Value Gain Loss Derivative Instrument) (Details) - USD ($) $ in Millions | Jun. 30, 2020 | Jun. 30, 2019 |
Fair Value Hedging | Interest Rate Swaps | ||
Derivative [Line Items] | ||
Notional Amount | $ 550 | $ 2,150 |
Fair Value Gain/(Loss) | 27 | 40 |
Cash Flow Hedging | Foreign Currency Contracts | ||
Derivative [Line Items] | ||
Notional Amount | 653 | 869 |
Fair Value Gain/(Loss) | (4) | 4 |
Cash Flow Hedging | Forward Contracts [Member] | ||
Derivative [Line Items] | ||
Notional Amount | 200 | 0 |
Fair Value Gain/(Loss) | (16) | 0 |
Cash Flow Hedging | Currency Swap [Member] | ||
Derivative [Line Items] | ||
Notional Amount | 833 | 233 |
Fair Value Gain/(Loss) | 47 | 12 |
Cash Flow Hedging | Commodity Contracts | ||
Derivative [Line Items] | ||
Notional Amount | 16 | 20 |
Fair Value Gain/(Loss) | $ (1) | $ (3) |
Shareholders' Equity (Narrative
Shareholders' Equity (Narrative) (Details) $ / shares in Units, $ in Millions | 1 Months Ended | 12 Months Ended | 36 Months Ended | ||
Mar. 21, 2018USD ($)$ / sharesshares | Jun. 30, 2020USD ($)$ / sharesshares | Jun. 30, 2019USD ($)$ / sharesshares | Jun. 30, 2018USD ($)$ / sharesshares | Jun. 30, 2020USD ($)shares | |
Class of Stock [Line Items] | |||||
Common shares, authorized | 755,000,000 | 755,000,000 | 755,000,000 | ||
Preferred shares, authorized | 500,000 | 500,000 | 500,000 | ||
Treasury shares acquired | $ | $ 350 | $ 600 | $ 550 | ||
Payments for Repurchase of Common Stock | $ | 350 | 600 | 550 | ||
Retained earnings decrease | $ | (1,170) | (5,434) | $ (1,170) | ||
Treasury Shares | |||||
Class of Stock [Line Items] | |||||
Treasury shares acquired | $ | $ 350 | $ 600 | $ 550 | $ 1,500 | |
Treasury Stock, Shares, Acquired | 7,300,000 | 11,000,000 | 8,400,000 | ||
Payments for Repurchase of Common Stock | $ | $ 350 | ||||
Treasury shares acquired, average price per share (in usd per share) | $ / shares | $ 48 | $ 52.32 | $ 65.30 | ||
Treasury Stock Acquired Shares | 11,500,000 | ||||
Common Class A | |||||
Class of Stock [Line Items] | |||||
Common shares, authorized | 750,000,000 | 750,000,000 | 750,000,000 | ||
Common Stock, Voting Rights, Votes | 1 | ||||
Common Class B | |||||
Class of Stock [Line Items] | |||||
Common shares, authorized | 5,000,000 | 5,000,000 | 5,000,000 | ||
Common Stock, Voting Rights, Votes | 0.2 | ||||
Accelerated share repurchase plan | Treasury Shares | |||||
Class of Stock [Line Items] | |||||
Treasury Stock, Shares, Acquired | 4,300,000 | ||||
Payments for Repurchase of Common Stock | $ | $ 300 | ||||
Treasury shares acquired, average price per share (in usd per share) | $ / shares | $ 69.26 |
Shareholders' Equity (Changes i
Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | |
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | |||
Other Comprehensive Income (Loss), Tax | $ (4) | $ (1) | |
AOCI Attributable to Parent, Net of Tax [Roll Forward] | |||
Balance at beginning of period | 6,330 | 6,059 | $ 6,828 |
Amounts reclassified to earnings | 0 | 0 | (23) |
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent | (25) | 13 | 33 |
Balance at end of period | 1,792 | 6,330 | 6,059 |
Foreign Currency Translation Adjustments and other | |||
AOCI Attributable to Parent, Net of Tax [Roll Forward] | |||
Balance at beginning of period | (95) | (113) | |
Other comprehensive income/(loss), net before reclassifications | 3 | 18 | |
Amounts reclassified to earnings | 0 | 0 | |
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent | 3 | 18 | |
Balance at end of period | (92) | (95) | (113) |
Unrealized Gain/(Loss) on Derivatives, net of tax | |||
AOCI Attributable to Parent, Net of Tax [Roll Forward] | |||
Balance at beginning of period | 16 | 21 | |
Other comprehensive income/(loss), net before reclassifications | (23) | 0 | |
Amounts reclassified to earnings | (5) | (5) | |
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent | (28) | (5) | |
Balance at end of period | (12) | 16 | 21 |
AOCI Including Portion Attributable to Noncontrolling Interest [Member] | |||
AOCI Attributable to Parent, Net of Tax [Roll Forward] | |||
Balance at beginning of period | (79) | ||
Balance at end of period | (104) | (79) | |
Accumulated Other Comprehensive Loss | |||
AOCI Attributable to Parent, Net of Tax [Roll Forward] | |||
Balance at beginning of period | (79) | (92) | (125) |
Other comprehensive income/(loss), net before reclassifications | (20) | 18 | |
Amounts reclassified to earnings | (5) | (5) | |
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent | (25) | 13 | 33 |
Balance at end of period | $ (104) | $ (79) | $ (92) |
Earnings Per Share Attributab_3
Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions | 3 Months Ended | 12 Months Ended | |||||||||
Jun. 30, 2020 | Mar. 31, 2020 | Dec. 31, 2019 | Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | Dec. 31, 2018 | Sep. 30, 2018 | Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | |
Earnings Per Share [Abstract] | |||||||||||
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | $ 657 | $ 351 | $ 220 | $ (4,921) | $ 194 | $ 296 | $ 281 | $ 594 | $ (3,693) | $ 1,365 | $ 259 |
Net earnings attributable to noncontrolling interest | (1) | 1 | 0 | 1 | 0 | 0 | 1 | 1 | (3) | (2) | (3) |
Net Income (Loss) Attributable to Parent | $ 656 | $ 350 | $ 220 | $ (4,922) | $ 194 | $ 296 | $ 280 | $ 593 | $ (3,696) | $ 1,363 | $ 256 |
Weighted-average common shares–basic (in shares) | 293 | 300 | 313 | ||||||||
Effect of dilutive securities: | |||||||||||
Employee stock options, restricted share units, and performance share units (in shares) | 0 | 1 | 2 | ||||||||
Weighted-average common shares–diluted (in shares) | 293 | 301 | 315 | ||||||||
Diluted earnings per common share attributable to Cardinal Health, Inc.: | |||||||||||
Earnings Per Share, Basic | $ (12.61) | $ 4.55 | $ 0.82 | ||||||||
Earnings Per Share, Diluted | $ (12.61) | $ 4.53 | $ 0.81 |
Earnings Per Share Attributab_4
Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details) - shares shares in Millions | 12 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | |
Earnings Per Share [Abstract] | |||
Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares) | 6 | 7 | 6 |
shares that would be antidilutive as a result of net loss | 2 |
Segment Information (Narrative)
Segment Information (Narrative) (Details) $ in Millions | 3 Months Ended | 12 Months Ended | ||||
Jun. 30, 2020USD ($) | Sep. 30, 2019USD ($) | Sep. 30, 2018USD ($) | Jun. 30, 2020USD ($)segment | Jun. 30, 2019USD ($) | Jun. 30, 2018USD ($) | |
Segment Reporting Information [Line Items] | ||||||
Number of Reportable Segments | segment | 2 | |||||
Number of Operating Segments | segment | 2 | |||||
Pre-Tax Gain on Divestiture | $ 508 | |||||
Gain (Loss) Related to Litigation Settlement | (5,741) | $ (36) | $ (159) | |||
Project costs on investment and other spending | 69 | 55 | $ 43 | |||
naviHealth [Member] | ||||||
Segment Reporting Information [Line Items] | ||||||
Gain on Divestiture After Tax | $ 493 | $ 378 | ||||
Pre-Tax Gain on Divestiture | $ 508 | $ 508 | ||||
Sterile Surgical Gown Recall [Member] | ||||||
Segment Reporting Information [Line Items] | ||||||
Inventory Recall Expense | $ 85 | |||||
Total Opioid Litigation [Member] | ||||||
Segment Reporting Information [Line Items] | ||||||
Gain (Loss) Related to Litigation Settlement | $ (5,630) |
Segment Information (Revenue by
Segment Information (Revenue by Reportable Segment) (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | |||||||||
Jun. 30, 2020 | Mar. 31, 2020 | Dec. 31, 2019 | Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | Dec. 31, 2018 | Sep. 30, 2018 | Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | |
Segment Reporting Information [Line Items] | |||||||||||
Revenue | $ 36,689 | $ 39,157 | $ 39,735 | $ 37,341 | $ 37,353 | $ 35,228 | $ 37,740 | $ 35,213 | $ 152,922 | $ 145,534 | $ 136,809 |
Non-US [Member] | |||||||||||
Segment Reporting Information [Line Items] | |||||||||||
Revenue | 4,232 | 4,071 | 4,283 | ||||||||
United States | |||||||||||
Segment Reporting Information [Line Items] | |||||||||||
Revenue | 148,707 | 141,479 | 132,539 | ||||||||
Operating Segments | |||||||||||
Segment Reporting Information [Line Items] | |||||||||||
Revenue | 152,939 | 145,550 | 136,822 | ||||||||
Operating Segments | Pharmaceutical | |||||||||||
Segment Reporting Information [Line Items] | |||||||||||
Revenue | 137,495 | 129,917 | 121,241 | ||||||||
Operating Segments | Pharmaceutical | Pharmaceutical Distribution and Specialty [Member] | |||||||||||
Segment Reporting Information [Line Items] | |||||||||||
Revenue | 136,693 | 129,067 | |||||||||
Operating Segments | Pharmaceutical | Nuclear Precision Health Services [Member] | |||||||||||
Segment Reporting Information [Line Items] | |||||||||||
Revenue | 802 | 850 | |||||||||
Operating Segments | Medical | |||||||||||
Segment Reporting Information [Line Items] | |||||||||||
Revenue | 15,444 | 15,633 | 15,581 | ||||||||
Operating Segments | Medical | Medical distribution and products [Member] | |||||||||||
Segment Reporting Information [Line Items] | |||||||||||
Revenue | 13,429 | 13,833 | |||||||||
Operating Segments | Medical | Cardinal Health At Home Solutions [Member] | |||||||||||
Segment Reporting Information [Line Items] | |||||||||||
Revenue | 2,015 | 1,800 | |||||||||
Corporate | |||||||||||
Segment Reporting Information [Line Items] | |||||||||||
Revenue | $ (17) | $ (16) | $ (13) |
Segment Information (Segment Pr
Segment Information (Segment Profit by Reportable Segment) (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | |
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] | |||
Total operating earnings | $ (4,098) | $ 2,060 | $ 126 |
Operating Segments | |||
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] | |||
Total operating earnings | 2,416 | 2,410 | 2,654 |
Operating Segments | Pharmaceutical | |||
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] | |||
Total operating earnings | 1,753 | 1,834 | 1,992 |
Operating Segments | Medical | |||
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] | |||
Total operating earnings | 663 | 576 | 662 |
Corporate | |||
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] | |||
Total operating earnings | $ (6,514) | $ (350) | $ (2,528) |
Segment Information (Depreciati
Segment Information (Depreciation and Amortization and Additions to Property and Equipment by Reportable Segment) (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | |
Segment Reporting Information [Line Items] | |||
Total depreciation and amortization | $ 913 | $ 1,000 | $ 1,032 |
Total additions to property and equipment | 375 | 328 | 384 |
Operating Segments | Pharmaceutical | |||
Segment Reporting Information [Line Items] | |||
Total depreciation and amortization | 135 | 147 | 156 |
Total additions to property and equipment | 47 | 35 | 58 |
Operating Segments | Medical | |||
Segment Reporting Information [Line Items] | |||
Total depreciation and amortization | 243 | 288 | 278 |
Total additions to property and equipment | 86 | 74 | 127 |
Corporate | |||
Segment Reporting Information [Line Items] | |||
Total depreciation and amortization | 535 | 565 | 598 |
Total additions to property and equipment | $ 242 | $ 219 | $ 199 |
Segment Information (Assets by
Segment Information (Assets by Reportable Segment) (Details) - USD ($) $ in Millions | Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 |
Segment Reporting Information [Line Items] | |||
Total assets | $ 40,766 | $ 40,963 | $ 39,951 |
Operating Segments | Pharmaceutical | |||
Segment Reporting Information [Line Items] | |||
Total assets | 22,398 | 22,446 | 21,421 |
Operating Segments | Medical | |||
Segment Reporting Information [Line Items] | |||
Total assets | 14,691 | 15,284 | 16,066 |
Corporate | |||
Segment Reporting Information [Line Items] | |||
Total assets | $ 3,677 | $ 3,233 | $ 2,464 |
Segment Information Property a
Segment Information Property and Equipment, net by Geographic Area) (Details) - USD ($) $ in Millions | Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 |
Long-Lived Assets [Line Items] | |||
Property and equipment, net | $ 2,366 | $ 2,356 | $ 2,487 |
United States | |||
Long-Lived Assets [Line Items] | |||
Property and equipment, net | 1,880 | 1,846 | 1,950 |
International | |||
Long-Lived Assets [Line Items] | |||
Property and equipment, net | $ 486 | $ 510 | $ 537 |
Share-Based Compensation (Narra
Share-Based Compensation (Narrative) (Details) - USD ($) shares in Millions, $ in Millions | 12 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Tax benefit related to share-based compensation | $ 16 | $ 16 | $ 23 |
Total expense on employee retirement savings plans | $ 66 | $ 99 | $ 129 |
Stock Options | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Award vesting period (in years) | 3 years | ||
Exercisable period of plans (in years) | 10 years | ||
Stock Options | Maximum | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Exercisable period of plans (in years) | 10 years | ||
Restricted Share Units | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Award vesting period (in years) | 3 years | ||
Performance Share Units | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Vesting Period in years for Shares | 3 years | ||
Performance Share Units | Minimum | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Target performance goal (as a percent) | 0.00% | ||
Performance Share Units | Maximum | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Target performance goal (as a percent) | 240.00% | ||
2011 LTIP | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Number of shares available for grant | 12 | ||
2011 LTIP | Awards Other than Stock Options | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Number of shares available for grant | 5 | ||
2011 LTIP | Stock Options | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Number of shares available for grant | 12 |
Share-Based Compensation (Sched
Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total share-based compensation expense | $ 90 | $ 82 | $ 85 |
Restricted Share Unit | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total share-based compensation expense | 70 | 63 | 73 |
Stock Options | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total share-based compensation expense | 3 | 10 | 22 |
Performance Share Units | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total share-based compensation expense | $ 17 | $ 9 | $ (10) |
Share-Based Compensation (Sch_2
Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details) - $ / shares shares in Millions | 12 Months Ended | |
Jun. 30, 2020 | Jun. 30, 2019 | |
Stock Options | ||
Outstanding at beginning of period (in shares) | 6 | 7 |
Granted (in shares) | 0 | 0 |
Exercised (in shares) | (1) | 0 |
Canceled and forfeited (in shares) | 0 | (1) |
Outstanding at end of period (in shares) | 5 | 6 |
Exercisable at end of period (in shares) | 5 | |
Weighted-Average Exercise Price per Common Share | ||
Outstanding at beginning of period (in usd per share) | $ 63.78 | $ 64.50 |
Granted (in usd per share) | 0 | 0 |
Exercised (in usd per share) | 42.36 | 0 |
Canceled and forfeited (in usd per share) | 0 | 72.54 |
Outstanding at end of period (in usd per share) | 65.15 | $ 63.78 |
Exercisable at end of period (in usd per share) | $ 65.25 |
Share-Based Compensation (Sch_3
Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details) - USD ($) $ / shares in Units, $ in Millions | 12 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Net proceeds/(withholding) from share-based compensation | $ 8 | $ (14) | $ (3) |
Stock Options | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Aggregate intrinsic value of outstanding options at period end | 12 | 10 | 13 |
Aggregate intrinsic value of exercisable options at period end | 12 | 10 | 13 |
Aggregate intrinsic value of exercised options | 8 | 1 | 14 |
Net proceeds/(withholding) from share-based compensation | 26 | 3 | (3) |
Excess tax benefits from share based compensation | 6 | 7 | 10 |
Total compensation cost, net of estimated forfeitures, related to unvested stock options not yet recognized, pre-tax | 1 | 5 | 17 |
Total fair value of shares vested during the year | $ 8 | $ 20 | $ 19 |
Weighted-average grant date fair value per stock option (in usd per share) | $ 8.26 | $ 8.34 | $ 13.50 |
Share-Based Compensation Schedu
Share-Based Compensation Schedule of Remaining Stock Option Plan Data (Details) - Stock Options | 12 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Weighted-average remaining contractual life of outstanding options | 5 years | 5 years | 7 years |
Weighted-average remaining contractual life of exercisable options | 5 years | 5 years | 5 years |
Weighted-average period over which stock option compensation cost is expected to be recognized | 1 year | 1 year | 2 years |
Share-Based Compensation (Sch_4
Share-Based Compensation (Schedule of the Range of Assumptions Used to Estimate the Fair Value of Stock Options) (Details) - Stock Options | 12 Months Ended |
Jun. 30, 2020 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Risk-free interest rate (minimum) | 2.10% |
Expected volatility | 25.00% |
Expected life in years | 7 years |
Minimum | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Dividend yield | 2.70% |
Maximum | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Dividend yield | 2.80% |
Share-Based Compensation (Sch_5
Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details) - Restricted Share Units - $ / shares shares in Millions | 12 Months Ended | |
Jun. 30, 2020 | Jun. 30, 2019 | |
Restricted Share Units | ||
Nonvested at beginning of period (in shares) | 2 | 2 |
Granted (in shares) | 2 | 2 |
Vested (in shares) | (1) | (1) |
Canceled and forfeited (in shares) | 0 | (1) |
Nonvested at end of period (in shares) | 3 | 2 |
Weighted-Average Grant Date Fair Value per Share | ||
Nonvested at beginning of period (in usd per share) | $ 51.65 | $ 71.58 |
Granted (in usd per share) | 42.71 | 50.13 |
Vested (in usd per share) | 60.21 | 74.52 |
Canceled and forfeited (in usd per share) | 0 | 62.32 |
Nonvested at end of period (in usd per share) | $ 45.92 | $ 51.65 |
Share-Based Compensation (Addit
Share-Based Compensation (Additional Data Related to Restricted Share Unit Activity) (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | |
Restricted Share Units | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total compensation cost, net of estimated forfeitures, related to nonvested restricted share and share unit awards not yet recognized, pre-tax | $ 77 | $ 75 | $ 78 |
Weighted-average period in years over which restricted share and share unit cost is expected to be recognized (in years) | 2 years | 2 years | 2 years |
Total fair value of shares vested during the year | $ 57 | $ 68 | $ 65 |
Performance Share Units | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total compensation cost, net of estimated forfeitures, related to nonvested restricted share and share unit awards not yet recognized, pre-tax | $ 29 | $ 12 | $ 1 |
Weighted-average period in years over which restricted share and share unit cost is expected to be recognized (in years) | 2 years | 2 years | 2 years |
Total fair value of shares vested during the year | $ 5 | $ 0 | $ 14 |
Share-Based Compensation (Sch_6
Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) - Performance Share Units - $ / shares shares in Millions | 12 Months Ended | |
Jun. 30, 2020 | Jun. 30, 2019 | |
Performance Share Units | ||
Nonvested at beginning of period (in shares) | 0.9 | 0.4 |
Granted (in shares) | 0.7 | 0.6 |
Vested (in shares) | (0.1) | 0 |
Canceled and forfeited (in shares) | (0.2) | (0.1) |
Nonvested at end of period (in shares) | 1.3 | 0.9 |
Weighted-Average Grant Date Fair Value per Share | ||
Nonvested at beginning of period (in usd per share) | $ 51.45 | $ 66.13 |
Granted (in usd per share) | 44.03 | 50.96 |
Vested (in usd per share) | 48.40 | 0 |
Canceled and forfeited (in usd per share) | 50.92 | 52.20 |
Nonvested at end of period (in usd per share) | $ 54.24 | $ 51.45 |
Share-Based Compensation (Add_2
Share-Based Compensation (Additional Data Related to Performance Share Unit Activity) (Details) - Performance Share Units - USD ($) $ in Millions | 12 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized, pre-tax | $ 29 | $ 12 | $ 1 |
Weighted-average period over which performance share unit cost is expected to be recognized (in years) | 2 years | 2 years | 2 years |
Total fair value of shares vested during the year | $ 5 | $ 0 | $ 14 |
Selected Quarterly Financial _3
Selected Quarterly Financial Data (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Millions | 3 Months Ended | 12 Months Ended | |||||||||
Jun. 30, 2020 | Mar. 31, 2020 | Dec. 31, 2019 | Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | Dec. 31, 2018 | Sep. 30, 2018 | Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | |
Quarterly Financial Information Disclosure [Abstract] | |||||||||||
Revenue | $ 36,689 | $ 39,157 | $ 39,735 | $ 37,341 | $ 37,353 | $ 35,228 | $ 37,740 | $ 35,213 | $ 152,922 | $ 145,534 | $ 136,809 |
Gross margin | 1,590 | 1,885 | 1,714 | 1,679 | 1,674 | 1,764 | 1,730 | 1,667 | 6,868 | 6,834 | 7,181 |
Distribution, selling, general and administrative expenses | 1,137 | 1,165 | 1,163 | 1,107 | 1,168 | 1,097 | 1,064 | 1,155 | 4,572 | 4,480 | 4,596 |
Net earnings | 657 | 351 | 220 | (4,921) | 194 | 296 | 281 | 594 | (3,693) | 1,365 | 259 |
Less: Net earnings attributable to noncontrolling interests | (1) | 1 | 0 | 1 | 0 | 0 | 1 | 1 | (3) | (2) | (3) |
Net earnings attributable to Cardinal Health, Inc. | $ 656 | $ 350 | $ 220 | $ (4,922) | $ 194 | $ 296 | $ 280 | $ 593 | (3,696) | 1,363 | 256 |
Net earnings/(loss) attributable to Cardinal Health, Inc. per common share: | |||||||||||
Basic (in usd per share) | $ 2.25 | $ 1.20 | $ 0.75 | $ (16.65) | $ 0.65 | $ 0.99 | $ 0.94 | $ 1.95 | |||
Diluted (in usd per share) | $ 2.23 | $ 1.19 | $ 0.75 | $ (16.65) | $ 0.65 | $ 0.99 | $ 0.93 | $ 1.94 | |||
Goodwill and Intangible Assets [Line Items] | |||||||||||
Gain (Loss) Related to Litigation Settlement | (5,741) | (36) | (159) | ||||||||
Gain on Sale of Investments | 579 | 0 | 0 | ||||||||
Pre-Tax Gain on Divestiture | $ 508 | ||||||||||
Goodwill, Impairment Loss | $ 1,400 | ||||||||||
naviHealth [Member] | |||||||||||
Goodwill and Intangible Assets [Line Items] | |||||||||||
Gain on Sale of Investments | $ 579 | ||||||||||
Pre-Tax Gain on Divestiture | $ 508 | $ 508 | |||||||||
Gain on Divestiture After Tax | $ 493 | $ 378 | |||||||||
Total Opioid Litigation [Member] | |||||||||||
Goodwill and Intangible Assets [Line Items] | |||||||||||
Gain (Loss) Related to Litigation Settlement | $ (5,630) | ||||||||||
Total Opioid Litigation, net of tax [Member] | |||||||||||
Goodwill and Intangible Assets [Line Items] | |||||||||||
Gain (Loss) Related to Litigation Settlement | $ (5,140) |
Schedule II - Valuations and _2
Schedule II - Valuations and Qualifying Accounts (Details) - USD ($) $ in Millions | 12 Months Ended | |||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2017 | |
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] | ||||
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount | $ 729 | $ 687 | $ 626 | $ 494 |
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] | ||||
SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense | 2,407 | 2,353 | 2,513 | |
SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account | 1 | 1 | 1 | |
SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction | 2,366 | 2,293 | 2,381 | |
Pricing Disputes [Member] | ||||
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] | ||||
SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense | 49 | 60 | 37 | |
SEC Schedule, 12-09, Allowance, Credit Loss [Member] | ||||
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] | ||||
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount | 206 | 193 | 139 | 137 |
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] | ||||
SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense | 139 | 140 | 113 | |
SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account | 1 | 1 | 1 | |
SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction | 127 | 87 | 111 | |
Prior Year Recoveries | ||||
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] | ||||
SEC Schedule, 12-09, Valuation Allowances and Reserves, Addition, Recovery | 1 | 1 | 1 | |
SEC Schedule, 12-09, Allowance, Loss on Finance Receivable [Member] | ||||
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] | ||||
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount | 27 | 14 | 7 | 9 |
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] | ||||
SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense | 15 | 8 | (2) | |
SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account | 0 | 0 | 0 | |
SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction | 2 | 1 | 0 | |
Sales Returns and Allowances [Member] | ||||
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] | ||||
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount | 495 | 479 | 479 | 347 |
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] | ||||
SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense | 2,253 | 2,205 | 2,402 | |
SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account | 0 | 0 | 0 | |
SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction | 2,237 | 2,205 | 2,270 | |
SEC Schedule, 12-09, Allowance, Loan and Lease Loss [Member] | ||||
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] | ||||
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount | 1 | 1 | 1 | $ 1 |
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] | ||||
SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense | 0 | 0 | 0 | |
SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account | 0 | 0 | 0 | |
SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction | $ 0 | $ 0 | $ 0 |